



NON-INTERVENTIONAL (NI) FINAL STUDY REPORT

Title	Survey of Pharmacists to Evaluate the Effectiveness of the Viagra Connect National Additional Risk Minimisation Measures (aRMMs) in the United Kingdom (UK)
Protocol number	A1481334
Version identifier of the final study report	Final 1.0
Date	23 July 2019
EU Post Authorisation Study (PAS) register number	EUPAS27346
Active substance	Sildenafil citrate
Medicinal product	Viagra Connect Anatomical therapeutic chemical (ATC) Code: G04B E03
Product reference	Viagra Connect 50 mg Film Coated Tablets PL 00165/0392
Procedure number	NO/H/0307/001/DC
Marketing Authorisation Holder (MAH)	Pfizer Consumer Healthcare Ltd.
Joint PASS	No
Research question and objectives	To evaluate the effectiveness of the Viagra Connect national aRMM by assessing: <ul style="list-style-type: none">• The pharmacists' knowledge of the key risk messages contained in the Viagra Connect training materials;• The pharmacists' participation in the Viagra Connect pharmacist training;

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

	<ul style="list-style-type: none">The pharmacists' utilisation of the optional <i>Viagra Connect Pharmacy Checklist</i> at the point of dispensing.
Country(-ies) of study	UK
Authors	Joanna (Asia) Lem, MPH Director Pfizer, Inc. 235 East 42nd Street 219/09/01 New York, NY 10017 Dr Janine Collins Executive Director UBC Chemin des Coquelicots 16 1214 Vernier Switzerland

This document contains confidential information belonging to Pfizer. Except as otherwise agreed to in writing, by accepting or reviewing this document, you agree to hold this information in confidence and not copy or disclose it to others (except where required by applicable law) or use it for unauthorised purposes. In the event of any actual or suspected breach of this obligation, Pfizer must be promptly notified.

TABLE OF CONTENTS

TITLE PAGE	1
TABLE OF CONTENTS.....	3
LIST OF IN-TEXT TABLES AND FIGURES.....	4
1. ABSTRACT (STAND-ALONE DOCUMENT)	12
2. LIST OF ABBREVIATIONS.....	12
3. RESPONSIBLE PARTIES.....	13
4. OTHER RESPONSIBLE PARTIES.....	14
5. MILESTONES.....	15
6. RATIONALE AND BACKGROUND.....	16
7. RESEARCH QUESTION AND OBJECTIVES	17
8. AMENDMENTS AND UPDATES.....	17
9. RESEARCH METHODS	17
9.1. Study design	17
9.2. Setting.....	17
9.2.1. Recruitment	18
9.2.2. Inclusion criteria.....	18
9.2.3. Exclusion criteria	19
9.3. Data collection and variables.....	19
9.3.1. Reporting of safety events.....	19
9.4. Study size.....	20
9.5. Data analysis.....	20
9.5.1. Demographic and administration statistics	20
9.5.2. Key risk message analysis.....	22
9.6. Data management	25
9.7. Limitations of the research methods.....	25
10. RESULTS	26
10.1. Survey administration statistics	26
10.2. Time to complete survey and demographic data	29
10.3. Outcome data	31
10.4. Pharmacist knowledge of key risk messages, part I.....	31
10.4.1. Pharmacist knowledge of other important key risk messages, part II.....	36

10.4.2. Main sources of pharmacists knowledge about Viagra Connect key risk messages	41
10.4.3. Pharmacist experience toward patient counseling	42
10.4.4. Awareness and utilization of the Viagra Connect pharmacist checklist	44
10.4.5. Participation in pharmacist training	46
10.4.6. Utilization and reading of the Essential Information for the Supply of Viagra Connect guide	47
10.4.7. Responses to knowledge questions by subgroup	48
10.4.8. Pharmacists awareness, utilization of aRMMs by subgroups	51
10.4.9. Attitudes toward the aRMM materials	54
10.5. Other analyses	56
10.6. Adverse events / adverse reactions	56
11. DISCUSSION	56
12. CONCLUSIONS	60
13. REFERENCES	60
14. LIST OF SOURCE TABLES AND LISTINGS	61

LIST OF TABLES

Table 1 Precision of Estimated Comprehension Rate with a Sample Size of 200 (2-sided 95% CI) (Clopper Pearson Exact Method).....	20
Table 2 Number of Questions Pertaining to Each of the Key Risk Message Questions	23
Table 3 Survey Administration Statistics	27
Table 4 Survey Participant Eligibility Results - Screened Respondents	27
Table 5 Time to Complete Survey - Completed Surveys	29
Table 6 Description of Survey Participants - Completed Surveys	30
Table 7 Responses to all Questions about Pharmacist Knowledge of Part I Key Risk Messages for Pharmacists to Consider when Determining the Suitability of a Patient for Viagra Connect - Completed Surveys	32
Table 8 Responses to all Questions about Pharmacist Knowledge of Part II Other Important Key Messages for Pharmacists to Consider During Consultation - Completed Surveys.....	37
Table 9 Responses to all Questions Regarding the Source of Pharmacist Knowledge of Key Risk Messages Pertaining to Viagra Connect and Other OTC Products - Completed Surveys.....	42
Table 10 Responses to All Questions about Pharmacist Experience Toward Patient Counseling - Completed Surveys	43

Table 11 Responses to all Questions about the Pharmacist Awareness and Utilization of the Viagra Connect Pharmacist Checklist and Tear-off Slip at the Point of Dispensing - Completed Surveys	44
Table 12 Responses to all Questions about Pharmacists Participating in Viagra Connect Pharmacist Training - Completed Surveys.....	46
Table 13 Responses to all Questions about Pharmacist Utilization/Reading of the Essential Information for the Supply of Viagra Connect Guide for Pharmacists - Completed Surveys.....	48
Table 14 Responses to all Questions about the Pharmacist Attitude Toward Viagra Connect Pharmacist Training and Patient Counselling - Completed Surveys	55

LIST OF SOURCE TABLES AND LISTINGS.....	62
Source Table 1.1 Survey Administration Statistics.....	62
Source Table 1.1b: Time to Complete Survey - Completed Surveys.....	63
Source Table 1.2 Survey Participant Eligibility Results - Screened Respondents.....	64
Source Table 2 Description of Survey Participants - Completed Surveys.....	66
Source Table 3 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect - Completed surveys.....	68
Source Table 3.1 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by participation in the Viagra Connect pharmacist training - Completed surveys.....	73
Source Table 3.2 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys.....	79
Source Table 3.3 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by place of pharmacy - Completed surveys.....	85
Source Table 3.4 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by type of pharmacy - Completed surveys.....	91
Source Table 3.5 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by time dispensing medications as pharmacist - Completed surveys.....	97
Source Table 3.6 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by age group - Completed surveys.....	107
Source Table 3.7 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by gender - Completed surveys.....	113
Source Table 3.8 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists" - Completed surveys.....	119
Source Table 3.9 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by using the optional Viagra Connect Pharmacy Checklist at the point of supply - Completed surveys.....	125

Source Table 3.10 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys.....	131
Source Table 4 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation - Completed surveys	141
Source Table 4.1 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by participation in the Viagra Connect pharmacist training - Completed surveys	145
Source Table 4.2 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys.....	150
Source Table 4.3 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by place of pharmacy - Completed surveys.....	155
Source Table 4.4 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by type of pharmacy - Completed surveys	160
Source Table 4.5 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by time dispensing medications as pharmacist - Completed surveys	165
Source Table 4.6 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by age group - Completed surveys.....	173
Source Table 4.7 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by gender - Completed surveys.....	178
Source Table 4.8 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists" - Completed surveys.....	183
Source Table 4.9 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by using the optional Viagra Connect Pharmacy Checklist at the point of supply - Completed surveys.....	188
Source Table 4.10 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys.....	193
Source Table 5 Responses to all questions regarding the source of pharmacist knowledge of key risk messages pertaining to Viagra Connect and other OTC products - Completed surveys	202

Source Table 6 Responses to all questions about pharmacist experience toward patient counseling - Completed surveys.....	203
Source Table 7 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing - Completed surveys	204
Source Table 7.1 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by participation in the Viagra Connect pharmacist training - Completed surveys.....	206
Source Table 7.2 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys	208
Source Table 7.3 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by place of pharmacy - Completed surveys	210
Source Table 7.4 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by type of pharmacy - Completed surveys.....	212
Source Table 7.5 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by time dispensing medications as pharmacist - Completed surveys	214
Table 7.6 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by age group - Completed surveys	217
Source Table 7.7 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by gender - Completed surveys.....	219
Source Table 7.8 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists" - Completed surveys.....	221
Source Table 7.9 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys	223
Source Table 8 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training - Completed surveys.....	227
Source Table 8.1 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys.....	228
Source Table 8.2 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by place of pharmacy - Completed surveys.....	230

Source Table 8.3 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by type of pharmacy - Completed surveys	231
Source Table 8.4 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by time dispensing medications as pharmacist - Completed surveys	233
Source Table 8.5 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by age group - Completed surveys	235
Source Table 8.6 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by gender - Completed surveys	237
Source Table 8.7 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys	239
Source Table 9 Responses to all questions about pharmacist utilization/reading of the "Essential Information For The Supply of Viagra Connect" guide for pharmacists - Completed surveys	241
Source Table 9.1 Responses to all questions about pharmacist utilization/reading of the "Essential Information For The Supply of Viagra Connect" guide for pharmacists by participation in the Viagra Connect pharmacist training - Completed surveys	242
Source Table 9.2 Responses to all questions about pharmacist utilization/reading of the "Essential Information For The Supply of Viagra Connect" guide for pharmacists by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys	243
Source Table 9.3 Responses to all questions about pharmacist utilization/reading of the "Essential Information For The Supply of Viagra Connect" guide for pharmacists by place of pharmacy - Completed surveys	244
Source Table 9.4 Responses to all questions about pharmacist utilization/reading of the "Essential Information For The Supply of Viagra Connect" guide for pharmacists by type of pharmacy - Completed surveys	245
Source Table 9.5 Responses to all questions about pharmacist utilization/reading of the "Essential Information For The Supply of Viagra Connect" guide for pharmacists by time dispensing medications as pharmacist - Completed surveys ..	246
Source Table 9.6 Responses to all questions about pharmacist utilization/reading of the "Essential Information For The Supply of Viagra Connect" guide for pharmacists by age group - Completed surveys	247
Source Table 9.7 Responses to all questions about pharmacist utilization/reading of the "Essential Information For The Supply of Viagra Connect" guide for pharmacists by gender - Completed surveys	248
Source Table 9.8 Responses to all questions about pharmacist utilization/reading of the "Essential Information For The Supply of Viagra Connect" guide for pharmacists by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys	249
Source Table 10 Responses to all questions about the pharmacist attitude toward Viagra Connect pharmacist training and patient counselling - Completed surveys	250

Source Listing 1 Last question answered and time spend on the survey for eligible respondents who did not complete the survey..... 251

Annex 1. List of stand-alone documents

[Appendix 1. SIGNATURES](#)

[Appendix 2. FINAL QUESTIONNAIRE](#)

[Appendix 3. STUDY PROTOCOL](#)

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

1. ABSTRACT (STAND-ALONE DOCUMENT)

2. LIST OF ABBREVIATIONS

Abbreviation	Definition
AE	Adverse Event
aRMMs	Additional Risk Minimisation Measures
ATC	Anatomical Therapeutic Chemical
BNF	British National Formulary
CI	Confidence interval
CYP3A4	Cytochrome P450 3A4
ED	Erectile Dysfunction
EDC	Electronic Data Capture
EMA	European Medicines Agency
KRM	Key Risk Message
MAH	Marketing Authorisation Holder
MHRA	Medicines and Health Products Regulatory Agency
NIS	Non-Interventional Study
OTC	Over the Counter
PAS	Post-Authorisation Study
PASS	Post-Authorisation Safety Study
PDE-5is	phosphodiesterase type 5 inhibitors
PGD	Patient Group Direction
PMG	Precision Marketing Group
PPI	Proton Pump Inhibitor
RPS	Royal Pharmaceutical Society
SJS	Stevens-Johnson Syndrome
SmPC	Summary of Product Characteristics
UK	United Kingdom

3. RESPONSIBLE PARTIES

Name, degree(s)	Title	Affiliation	Address
Joanna (Asia) Lem, MPH	Director	Epidemiology Worldwide Safety and Regulatory Pfizer Inc.	235 East 42nd Street 219/09/01 New York, NY 10017
Janine Collins, MBBS, LLM	Executive Director	Safety, Epidemiology, Registries and Risk Management UBC	Chemin des Coquelicots 16 1214 Vernier Switzerland
Klaus W. Freivogel, Dr. rer. nat	Principal Statistician	Biostatistics UBC	UBC (Germany) GmbH
Paul Crossley, BSc	Associate Project Director	Clinical Operations UBC	26-28 Hammersmith Grove London, W6 7HA UK
Milena Toncheva, MSc	Project Manager	Clinical Operations UBC	26-28 Hammersmith Grove London, W6 7HA UK

4. OTHER RESPONSIBLE PARTIES

Not Applicable.

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

5. MILESTONES

Milestone	Planned date	Actual date
Viagra Connect Approval in UK	28 November 2017	28 November 2017
Roll out of pharmacist training Start Date	February 2018	February 2018
Viagra Connect availability in UK pharmacies	April 2018	April 2018
Protocol Approval	July 2018	June 2018
Start of data collection for the pilot survey	July 2018	July 2018
End of data collection for the pilot survey	August 2018	August 2018
Pilot results report and updated survey protocol (if warranted) submitted to the Agency	October 2018	October 2018
Feedback from the MHRA on the pilot results (anticipated)	December 2018	December 2018
Registration in the EU PAS register	December 2018	28 December 2018
Start of data collection for full survey (estimated)	January 2019	January 2019
End of data collection for full survey (estimated)	March 2019	March 2019
Final study report	July 2019	23 July 2019

6. RATIONALE AND BACKGROUND

On 28th November 2017 the Medicines and Health Products Regulatory Agency (MHRA) granted a licence for an over-the-counter (OTC) sildenafil 50 mg pharmacy medicine (Viagra Connect 50 mg film-coated tablets) in the United Kingdom (UK), for the treatment of erectile dysfunction (ED).

Pharmacists were identified as having an important role in facilitating discussions and counselling male patients seeking to purchase Viagra Connect to determine their suitability for use, and for directing these patients to their doctors. Accordingly, Pfizer developed a training programme in the UK for pharmacists, consisting of a training guide with essential information, regarding the safe supply of Viagra Connect to the ED patient and a checklist which pharmacists can choose to use when a patient requests to purchase Viagra Connect. It is worth noting that the use of the Viagra Connect checklist is not mandatory, and some pharmacy chain retailers have developed their own modified versions using the Pfizer checklist as guidance. The training guide and the checklist are considered UK national additional risk minimisation measures (aRMMs), which with agreement of the MHRA, were put in place to minimise the risk of Viagra Connect being sold to patients who may be unsuitable to take the product without prior consultation with their doctor.

The pharmacist training was offered in a variety of modalities to ensure the widest opportunity for learning. This included online resources, regional meetings, printed materials and in-store face-to-face training. The pharmacist training started at the end of February 2018 prior to launch of Viagra Connect in April 2018 and continues to be available as a resource to all pharmacists.

Pfizer committed to conducting a post-authorisation safety study (PASS) in the form of a survey of pharmacists to evaluate the effectiveness of the national aRMMs in the pharmacy setting in the UK.

Prior to the implementation of this full survey, user-testing of the survey instrument was performed with a sample of pharmacists to assess the clarity of the survey questions as they were presented to pharmacists, the interest and acceptance of the surveys among all prospective respondents, as well as the flow and ease of completing the surveys. Findings and recommendations from survey pre-testing were incorporated into the final survey instrument.

Additionally, a pilot survey was performed to ensure that the implementation approach was optimal, that the survey questions performed as intended and also to give insight into the recruitment methodology. The pilot survey took place between July 2018 and August 2018, approximately 3 months after the launch of Viagra Connect and no operational obstacles were identified. The recruitment methodology confirmed that both the invitation and respondent pool were representative of the distribution of the various types of pharmacies across the UK (large multiple, small multiple, and independent pharmacies). The survey instrument performed as intended, requiring an amendment to only one question (for Question 29, "I am Patient Group Direction (PGD)-trained (or equivalent) for

phosphodiesterase type 5 inhibitors (PDE-5i's)" was included as a response option).* As a result of the pilot, no changes were required to the protocol for the full survey, which is presented in Annex 1, [Appendix 3](#), of this report with the original survey. The amended survey with update to Question 29 is presented in Annex 1, [Appendix 2](#) of this report.

This full pharmacist survey was conducted from 28 January 2019 through 31 March 2019.

*It should be noted that the term "Patient Group Direction (PGD)-trained" was presented in the survey as "Pharmacy Group Direction (PGD)-trained" in error. As "PGD" is a commonly used term among pharmacists, it was not expected to have affected pharmacist understanding of the selection or the survey results. The corrected term is used for consistency throughout the report.

7. RESEARCH QUESTION AND OBJECTIVES

The overall objective of the study was to evaluate the effectiveness of the Viagra Connect national aRMMs by assessing:

- The pharmacists' knowledge of key risk messages contained in the Viagra Connect Training materials.
- The pharmacists' participation in Viagra Connect pharmacist training.
- The pharmacists' utilisation of the optional *Viagra Connect Pharmacy Checklist* at the point of dispensing.

8. AMENDMENTS AND UPDATES

None.

9. RESEARCH METHODS

9.1. Study design

The study was a cross-sectional, non-interventional web-based survey that was conducted in the UK. All survey aspects were conducted anonymously among pharmacists who had received at least one patient request to supply Viagra Connect within the six months preceding the survey administration.

The pharmacist survey was hosted on line and was expected to take approximately 20 to 30 minutes to complete. The survey questions can be found in Annex 1, Appendix 2 of this report.

9.2. Setting

This survey was conducted in the UK from 28 January 2019 through 31 March 2019 in a population of pharmacists who had received at least one patient request for the supply of Viagra Connect. The survey took place approximately nine months after the availability of Viagra Connect on the UK market to allow sufficient time for pharmacists to complete

training, gain experience with dispensing the product over the counter and to counsel patients.

9.2.1. Recruitment

The pharmacists in this study were recruited via a third party vendor, Precision Marketing Group (PMG).

PMG owns and maintains the National Pharmacy Database, which contains over 14,000 pharmacy records. The database is representative of the UK pharmacy population with national/large, regional/small and independent pharmacies represented. To generate the quantity of pharmacies required per group, PMG selected a proportionate sample to represent the overall pharmacy population from their full pool of data (ie, 49.2% of large multiple pharmacies, 12.4% of small multiple pharmacies, and 38.4% of independent pharmacies). They then selected a random sample of pharmacies within each group for the purpose of creating an unbiased invitation sample as far as possible. The random sample of pharmacists were eligible to be invited in the survey regardless of whether they had already completed the training or not.

The initial invitation letter included a link to the electronic survey and described the purpose of the survey, how the data would be reported and to whom and the measures taken to preserve the participant's confidentiality. The invitation was sent by PMG by mail to the branch postal address of 4000 pharmacies with the expected response rate of 5%. A week later, all 4000 pharmacies were sent an email invitation (same content as the paper one) to their branch business email address, which was counted as a reminder. One additional reminder was issued via email one month later excluding those who had not already responded or whose email contacts were not viable. Each pharmacy branch received 1 unique code that was used for tracking purposes and was included in the invitations and reminder emails. This code could only be used once, which excluded any possibility for duplicate entries by more than one person at the same branch. If more than one pharmacist at a given branch wanted to complete the survey they were able to contact PMG to request an additional code. A single compensation of £75 was offered to participating pharmacists for a completed survey based on fair market value assessment of the expected time to complete the instrument.

Prior to contacting any pharmacists, it was verified that all applicable data protection requirements had been complied with.

9.2.2. Inclusion criteria

Pharmacists who met all of the following inclusion criteria were eligible for the study:

- Willing/consent to participate in this self-administered survey (Answered "Yes" to a survey question asking "Do you agree to proceed with this survey?");
- A practicing pharmacist in the UK;

- Received at least one patient face-to-face request to supply Viagra Connect in the past six months.

9.2.3. Exclusion criteria

Pharmacists who met the following criteria were excluded from the study:

- Pharmacists who answer affirmatively to a question asking if they or their immediate family members currently work for Pfizer, another pharmaceutical company, or the survey vendor (UBC), the European Medicines Agency (EMA) or the MHRA.
- Pharmacists who work only as on-line pharmacists and who do not participate in face-to-face consultations

9.3. Data collection and variables

A structured self-administered questionnaire comprised of closed-ended questions or statements with multiple response choices (ie, questions or statements asking the pharmacists to choose from a defined list of responses) was used to collect the survey data. The survey instrument designed for the study is presented in Annex 1, [Appendix 2](#) of this report).

The questionnaire included questions/statements that assessed how effectively the pharmacist training was implemented, including but not limited to whether training had been completed, use of the checklist and knowledge of the key risk messages. Specifically, the variables collected included:

- a. Screening questions;*
- b. Pharmacist's characteristics;*
- c. Pharmacist's experience with Viagra Connect;*
- d. Pharmacist's knowledge of key risk messages;*
- e. Source of knowledge of the key risk messages pertaining to Viagra Connect;*
- f. Pharmacists' participation in Viagra Connect pharmacist training;*
- g. Utilisation of pharmacist checklist at the point of dispensing;*
- h. Utilisation of patient record tear-off slip;*
- i. Attitude towards Viagra Connect pharmacist training material and patient counselling.*

9.3.1. Reporting of safety events

It is possible that a study participant provided information that constituted a safety event (eg, serious and non-serious adverse events (AEs) and/or scenarios involving exposure during pregnancy, exposure during breast feeding, medication error, overdose, misuse, extravasation, lack of efficacy and occupational exposure) to Programme staff or the study vendor while in conversation about the survey for any other reason (eg, seeking information

about the purpose of the study). In the event that a study participant in this study reported a safety event associated with the use of the Pfizer product, the Programme staff or the study vendor would complete a NIS AE monitoring report form and submitted the form to Pfizer within 24 hours of becoming aware of the safety event.

9.4. Study size

The goal for this survey was a sample size of 200 completed surveys from pharmacists who had received at least one patient request for the supply of Viagra Connect. This sample size of 200 was based on statistical and practical considerations of participation in this type of survey.

Table 1 shows the precision of the estimated level of understanding key risk messages with 95% confidence intervals (CIs) for a fixed sample size of 200 completed surveys. Two-sided CIs are used to indicate that for an estimated comprehension level, the true population level of comprehension is at least as high as the lower limit of the 95% CI, and may be as high as the upper limit of the 95% CI.

Table 1 Precision of Estimated Comprehension Rate with a Sample Size of 200 (2-sided 95% CI) (Clopper Pearson Exact Method)

Estimated Rate of Understanding	Estimated CI		Precision
	Low	High	
50%	42.9%	57.1%	-7.1%; +7.1%
55%	47.8%	62.0%	-7.2%; +7.0%
60%	52.9%	66.8%	-7.1%; +6.8%
65%	58.0%	71.6%	-7.0%; +6.6%
70%	63.1%	76.3%	-6.9%; +6.3%
75%	68.4%	80.8%	-6.6%; +5.8%
80%	73.8%	85.3%	-6.2%; +5.3%
85%	79.3%	89.6%	-5.7%; +4.6%
90%	85.0%	93.8%	-5.0%; +3.8%
95%	91.0%	97.6%	-4.0%; +2.6%

CI = Confidence interval.

9.5. Data analysis

9.5.1. Demographic and administration statistics

Data collected from the study were reported as descriptive statistics. No statistical inferences were made. Frequency distributions with 95% CIs were calculated for pharmacists' responses to all questions that addressed the survey objectives listed in the full study protocol (Annex 1, [Appendix 3](#)).

The following were reported as part of the analysis:

- Survey administration statistics:
 - Number of pharmacists to whom at least one invitation has been sent;
 - Total number of invitations sent;
 - Contact rate: number of invitations sent as a proportion of total pharmacist pool;
 - Number of pharmacists screened for participation (pharmacists who respond to the survey invitation and provide the unique code);
 - Response rate: number of pharmacists screened for participation as a proportion of number of pharmacists who received at least one invitation;
 - Number of pharmacists eligible for participation following screening;
 - Number of pharmacists ineligible for participation and reason for being ineligible;
 - Eligibility rate: number of pharmacists eligible for participation as a proportion of those screened;
 - Number of pharmacists completing the survey;
 - Completion rate: number of pharmacists completing the survey as a proportion of those eligible following screening;
 - Refusal rate: number of pharmacists invited less the number of pharmacists screened for participation.
 - Demographic and other pharmacist characteristics of the survey completers:
 - Gender;
 - Age;
 - Time practicing as pharmacist;
 - Location of pharmacy (urban or rural);
 - Type of pharmacy (pharmacy chain or independent);
 - Experience with requests for Viagra Connect in the preceding six months.
 - Responses to the questions pertaining to the knowledge about the key risk messages associated with Viagra Connect.

- Distribution of the number of correct responses by key risk message and by key risk message group, ie, the number of respondents who answered 0, 1, 2, etc. questions correctly). Confidence intervals (CI, 95%) were calculated for the percentages of respondents who answered the targeted 70% of the questions correctly in each KRM group individually and who reached the target in both KRM groups.
- Response to questions on the source of knowledge of the key risk messages.
- Responses to questions pertaining to participation in the Viagra Connect pharmacist training.
- Responses to questions pertaining to the use of the Viagra Connect pharmacist's checklist.
- Responses to questions pertaining to the use of the Viagra Connect patient record tear-off slip.
- Responses to questions pertaining to attitude towards patient counselling.
- Responses to questions pertaining to attitude towards Viagra Connect pharmacist's training.

9.5.2. Key risk message analysis

The table below shows the number of questions pertaining to each of the Key Risk Message Questions.

Table 2 Number of Questions Pertaining to Each of the Key Risk Message Questions

Key Risk Message	Question Number	Number of Questions/Response Options within the
Part I: Key risk messages for pharmacists to consider when determining the suitability of a patient for Viagra Connect		
Supply criteria	13	4
Patient's cardiovascular health should be considered	14	3
	15	9
Patients' concomitant medication use should be assessed	16	8
Pharmacists should ask patients about concomitant conditions	17	4
Total number of questions pertaining to Key Risk Message Part I	5	28
Part II: Other important key messages for pharmacists to consider during consultation		
Causes of ED	18	8
Undiagnosed depression, anxiety or alcohol abuse	19	2
Advise patients to consult doctor	20	4
Advise patients when to stop taking Viagra Connect	21	9
Total number of questions pertaining to Key Risk Message Part II	4	23

Survey data were stratified by training participation, reading the *Essential Information for the Supply of Viagra Connect* guide for pharmacist, use of the optional *Viagra Connect Pharmacy Checklist*, and by other key pharmacist's characteristics. However, the sub-group analyses have only been presented where sample sizes were at least 25.

Responses to key risk message knowledge questions in Parts I and II (ie, questions 13-21) were summarized within the following categories:

Attended the pharmacist training

- Yes
- No
- Don't recall

Reading the *Essential Information for the Supply of Viagra Connect* guide for pharmacists:

- Yes
- No

Using the optional *Viagra Connect Pharmacy Checklist* at the point of supply:

- Yes
- No

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

- I do not recall

Number of patients who requested to purchase Viagra Connect in the last 6 months:

- 1-10
- 11-30
- 31-50
- More than 51
- I don't know

Location of pharmacy

- Urban
- Rural

Type of pharmacy

- Chain pharmacy (more than 100 stores)
- Small chain pharmacy (6-99 stores)
- Independent pharmacy (1-5 stores)

Time dispensing medications as a pharmacist?

- Less than 2 years
- 2-5 years
- 6-10 years
- 11-20 years
- Greater than 20 years

Age group:

- 22-30 years
- 31-40 years
- 41-60 years
- Greater than 61 years

Gender:

- Male
- Female
- Prefer not to answer

Main reference about the safe dispensing practices of Viagra Connect

- Due to a large number of response options (ie, 10), categories were combined for subgroups as follows:

New Response Option Category	Survey Question Response Option
Viagra Connect SmPC / Box Label	The Viagra Connect Summary of Product Characteristics (SmPC)
	The Viagra Connect Box Label
Viagra Connect Training/aRMM tools/ Pfizer sales professional	The Viagra Connect Pharmacist Training <i>Essential Information for the Supply of Viagra Connect</i>
	The Viagra Connect Pharmacist Checklist
	Viagra Connect website
	Pfizer sales professional
Medication reference (BNF)	My pharmacy's medication reference eg, British National Formulary (BNF)
Pharmacy Journals / Colleagues	Pharmacy journals (eg, The Pharmaceutical Journal, Pharmacy, The Clinical Pharmacist)
	Colleagues
Other	Other

9.6. Data management

UBC's proprietary electronic data capture (EDC) System was used for this programme and was designed to collect survey data for evaluation and analysis. This system was validated and EudraLex Annex 11 compliant.

All data collected during the survey were held confidentially by UBC. The EDC system used for data collection encrypted all respondent-identifying information, and respondent identifiers were stored separately from the survey responses. The survey was programmed to ensure respondents could not skip ahead and could not go back to modify answers and only allowed for missing data when caused by skip patterns built into the programming. In instances where respondents stopped and did not complete the survey, the respondent was not considered in the analysis. A completed survey was defined as a survey in which all relevant questions based on skip logic were answered.

9.7. Limitations of the research methods

The Sponsor had limited ability to measure the extent to which pharmacist knowledge or behaviours could be attributed to the pharmacist training, given that the training was put in place at the time of initial marketing authorisation, and therefore no baseline measures of knowledge or behaviour among pharmacists in the absence of the training were available.

There were 2 pharmacist respondent groups:

- 1) Those who took the Viagra Connect training
- 2) Those who did not take the Viagra Connect

Furthermore, some pharmacists would have been already familiar with phosphodiesterase type 5 inhibitors (PDE-5is) supply via the PGD protocol, while others would have had no other relevant training.

Given the level of training a pharmacist needs for supply via PGD, this could potentially explain the pharmacists' choice not to participate in Viagra Connect-specific training. Alternatively, the extent of knowledge of those who were trained in Viagra Connect could also be greater among those who were also PGD-trained. In view of the fact that the product has been available for 20 years in the UK, pharmacists who are already familiar with the product and already have some knowledge of the key risk messages may be less likely to undertake the training than those who have less knowledge of the product and other ED treatments. The rationale for not participating in the pharmacist training was explored through the survey, including being PGD-trained for PDE-5i's.

The pharmacists were asked if they recalled having received the Viagra-Connect-specific training and to recall key information from the training. The survey was conducted approximately 9-11 months after initiation of Viagra-Connect-specific pharmacy training, thus some pharmacists might not recall having taken the training or the training content. The pharmacists were asked to recall their encounters with patients requesting Viagra Connect. Since pharmacists interact with many patients during their working days and discuss a variety of medications, there was the possibility of inaccurate recall of these interactions.

There is an inherent potential for limited generalizability of the study results based on a select group of pharmacists who volunteered to participate in the survey. Those pharmacists who participated may differ in an important way from those who chose not to participate; however, no data are available to compare characteristics of those who did and did not participate. To avoid limiting the participants to only pharmacists who had supplied Viagra Connect, all pharmacists who had received at least one patient request for Viagra Connect to participate.

10. RESULTS

10.1. Survey administration statistics

Of the 4000 pharmacists invited to participate in the survey, 387 were screened for participation (ie, started the survey and were either determined to be eligible based on the screening questions or were discontinued from the survey based on a disqualifying response to a screening question), for a response rate of 9.7% (Table 3). Of those 387 who were screened, 357 were eligible for participation for an eligibility rate of 92.2%; 345 eligible respondents completed the survey for a completion rate of 96.6%.

Overall, 6,865 email reminder letters were sent in two waves with the email invitation sent to the same pharmacies that were initially mailed the paper invitation (therefore, counting the email invitation as a reminder). Of note, the total number of reminders was lower than the number of the original postal invitation letters sent due to unavailability of email addresses for all the invited pharmacies.

Table 3 Survey Administration Statistics

Parameter	Pharmacies n (%)
The number of paper invitations issued to pharmacies ^[1]	4,000
The number of email letters sent in wave 1 ^[2]	3,507
The number of email reminder letters sent in wave 2 ^[2]	3,358
The number of waves of email reminders sent	2
The number of screened respondents (Response rate) ^[3]	387 (9.7)
The number of respondents eligible for participation (Eligibility rate) ^[4]	357 (92.2)
The number and percentages of eligible respondents who completed the survey; "Completers" (Completion rate) ^[5]	345 (96.6)

Source: Section 14: [Table 1.1](#)

^[1] Of the 4000 pharmacies invited to participate, there were 3 instances where more than one pharmacist was invited from a single pharmacy, and identified by the respondent's unique code.

^[2] Total of 6,865 emails were sent in two separate waves. In the first email wave sent 01 February 2019, if a single pharmacy was invited by a paper invitation and by email, the email invitation was counted as a reminder. The second wave sent on 14 February 2019, was an actual email reminder, but excluded those who had already responded and those whose email contacts were not viable.

^[3] The screened respondents consist of all respondents who have accessed the survey using the unique code regardless of whether or not they answered any survey questions. Response rate is calculated as those who were screened as a percentage of those invited.

^[4] Eligibility rate is calculated as those that were eligible as a percentage of the screened respondents.

^[5] The completion rate is calculated as those that completed the survey as a percentage of the eligible pharmacies.

Note: Paper and email invitations are not mutually exclusive.

Of the 387 screened pharmacists, 4 were ineligible because they were not practicing pharmacists in the UK, 2 were ineligible to participate in the survey as they did not have at least one patient face-to-face request for Viagra Connect in the past 6 months, 3 were ineligible because they did not know if an immediate family member was currently employed by Pfizer, another pharmaceutical company, UBC, or contracted by regulatory bodies (EMA or MHRA), and 21 screened pharmacists, who did not complete the eligibility questions, were considered ineligible and counted as discontinued in the survey (Table 4).

Table 4 Survey Participant Eligibility Results - Screened Respondents

Question	Pharmacists (N=387) n (%)
Question 1: Do you agree to participate in this survey?	
Yes	366 (94.6)
No ^[1]	0
<i>Discontinued</i> ^[3]	21 (5.4)

Table 4 Survey Participant Eligibility Results - Screened Respondents

Question	Pharmacists (N=387) n (%)
Question 2: Are you a practicing pharmacist in the UK?	
Yes	362 (93.5)
No ^[1]	4 (1.0)
Question not asked ^[2]	0
Discontinued ^[3]	21 (5.4)
Question 3: Have you received at least one patient face-to-face request for Viagra Connect in the past 6 months?	
Yes	360 (93.0)
No ^[1]	2 (0.5)
Question not asked ^[2]	4 (1.0)
Discontinued ^[3]	21 (5.4)
Question 4: Are you or any of your immediate family members currently employed by Pfizer, another pharmaceutical company, United BioSource Corporation (UBC) or contracted by regulatory bodies (eg, European Medicines Agency (EMA) or Medicines and Healthcare Products Regulatory Agency (MHRA)?	
Yes ^[1]	0
No	357 (92.2)
I don't know ^[1]	3 (0.8)
Question not asked ^[2]	6 (1.6)
Discontinued ^[3]	21 (5.4)
Question 5: Which best describe the type of pharmacy setting you primarily work in? Select ONE option.	
Face-to-face	349 (90.2)
Face-to-face and online	8 (2.1)
Online only ^[1]	0
Question not asked ^[2]	9 (2.3)
Discontinued ^[3]	21 (5.4)

Source: Section 14: [Table 1.2](#)

^[1] Ineligible to participate in the survey.

^[2] Question not asked due to previous question elimination.

^[3] Respondents who discontinued the survey before completing all eligibility questions without being identified as ineligible are counted as discontinued. Once a respondent is counted as discontinued, they will count as discontinued in all subsequent eligibility questions.

Note: The screened respondents consists all respondents who have accessed the survey using the unique code regardless of whether or not they answered any survey questions. The number of screened respondents are used for the calculation of all percentages in this table.

10.2. Time to complete survey and demographic data

Twelve (3.5%) of the 357 eligible pharmacists who accessed the survey, did not complete the survey. The 345 pharmacists who completed the online survey took an average of 19.6 minutes to complete the survey (Table 5). All but 52 (15.1%) completers took the survey in under 30 minutes.

Table 5 Time to Complete Survey - Completed Surveys

Summary Statistic (minutes)	
N	345
Mean (SD)	19.6 (10.09)
Minimum	5
Median	16.6
Maximum	61
Category, n (%)	
0 to <5 Minutes	2 (0.6)
5 to <10 Minutes	46 (13.3)
10 to <15 Minutes	90 (26.1)
15 to <20 Minutes	79 (22.9)
20 to <25 Minutes	49 (14.2)
25 to <30 Minutes	27 (7.8)
30 Minutes or more	52 (15.1)

Source: Section 14: [Table 1.1b](#)
 SD = Standard Deviation

The majority of pharmacists were male (n=241, 69.9%) ([Table 6](#)) and ranged from 31 to 60 years of age (n=256, 74.2%).

There was a wide variation in the estimated number of patients requesting to purchase Viagra Connect from the pharmacists in the previous 6 months with 23 (6.7%) pharmacists having only 1-2 patients and 58 (16.8%) having more than 31. Eighty-two (23.8%) pharmacists had received 6-10 requests.

The majority of pharmacists (n=276, 80.0%) responded that of the patients who requested to purchase Viagra Connect, up to 10% were not suitable to be supplied the product.

Pharmacists were well distributed in terms of place of pharmacy (ie, urban vs. rural setting), type of pharmacy (ie, large multiple chain, small multiple chain, independent), and duration of dispensing practice.

Table 6 Description of Survey Participants - Completed Surveys

Question	Pharmacists (N=345) n (%)
Question 6: How many patients do you estimate have requested to purchase Viagra Connect from you in the past 6 months?	
1 – 2	23 (6.7)
3 – 5	65 (18.8)
6 – 10	82 (23.8)
11 – 20	73 (21.2)
21 – 30	44 (12.8)
More than 31	58 (16.8)
I don't know	0
Question 7: Of those patients who requested to purchase Viagra Connect from you, what percentage do you estimate were not suitable to be supplied the product?	
Up to 10%	276 (80.0)
11-50%	37 (10.7)
51-90%	12 (3.5)
More than 90%	9 (2.6)
I don't know	11 (3.2)
Question 8: Which best describes the place of your pharmacy?	
Urban (city, large town or suburban area)	255 (73.9)
Rural (small town, village, countryside)	90 (26.1)
Question 9: What type of pharmacy setting do you primarily work in? Select ONE option.	
Large multiple pharmacy chain (more than 100 stores)	157 (45.5)
Small multiple pharmacy chain (6 to 99 stores)	61 (17.7)
Independent Pharmacy (1 to 5 stores)	127 (36.8)
Question 10: How long have you been dispensing medications as a pharmacist?	
Less than 2 years	24 (7.0)
2-5 years	39 (11.3)
6-10 years	64 (18.6)
11-20 years	99 (28.7)
Greater than 20 years	119 (34.5)
Question 11: Which best represents your age group?	
22-30 years	68 (19.7)
31-40 years	117 (33.9)

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

Table 6 Description of Survey Participants - Completed Surveys

Question	Pharmacists (N=345) n (%)
41-60 years	139 (40.3)
More than 61 years old	21 (6.1)
Question 12: Which gender are you?	
Male	241 (69.9)
Female	102 (29.6)
Prefer not to answer	2 (0.6)

Source: Section 14: [Table 2](#)

10.3. Outcome data

Not applicable.

10.4. Pharmacist knowledge of key risk messages, part I

[Table 7](#) presents responses to all questions about the pharmacist knowledge of Part I Key Risk Messages for pharmacists to consider when determining the suitability of a patient for Viagra Connect. In the following discussion of key risk message results, the data presentation of equal to or greater than 80% is an arbitrary measure of pharmacist understanding, and was not based on any prior knowledge or a predetermined threshold.

A high proportion of pharmacists (ie, $\geq 80\%$) provided correct responses to 3 of 4 items of Question 13: pharmacists understood that Viagra Connect is intended for use by men over 18 years of age who have experienced ED (n=319, 92.5%), that Viagra Connect must not be supplied to men who do not have ED (n=316, 91.6%), and that men currently prescribed 50 mg sildenafil can be supplied Viagra Connect if a) they meet the criteria for pharmacy supply and b) they do not take more than 50 mg daily (n=309, 89.6%). A lower proportion (<80%) of pharmacists (n=262, 75.9%) correctly identified that men who are using a different dose of sildenafil or another ED treatment cannot also be supplied with Viagra Connect.

A high proportion of pharmacists (ie, $\geq 80\%$) provided correct responses to 2 of 3 items of Question 14: pharmacists understood that patients should not be supplied Viagra Connect, but should be referred to their doctor when they had been advised by their doctor that they are not fit enough for physical or sexual activity (n=341, 98.8%), or when they experience breathlessness or chest pain with light or moderate physical activity (n=340, 98.6%). A lower proportion of pharmacists (n=194, 56.2%) understood that those who had a heart attack or stroke more than 6 months ago could be supplied Viagra Connect.

A high proportion of pharmacists (ie, $\geq 80\%$) provided correct responses to all 9 items of Question 15 in which pharmacists were asked about concomitant cardiovascular conditions and in the presence of which of those conditions Viagra Connect could be supplied. Pharmacists understood that patients with controlled hypertension (n=296, 85.8%) MAY be supplied with Viagra connect. Pharmacists understood that patients with the following cardiovascular conditions MAY NOT be supplied with Viagra Connect: uncontrolled hypertension (n=330, 95.7%), unstable angina (n=333, 96.5%), cardiomyopathy (n=298, 86.4%), left ventricular outflow obstruction or aortic narrowing (n=292, 84.6%), severe cardiac failure (n=338, 98.0%), arrhythmia (n=283, 82.0%), valvular heart disease (n=284, 82.3%), and low blood pressure (n=276, 80.0%).

A high proportion of pharmacists (ie, $\geq 80\%$) provided correct responses to 6 of 8 items of Question 16 which asked which drugs may or may not be used with Viagra Connect. A lower proportion ($< 80\%$) answered correctly that riociguat could not be used with Viagra Connect (71.9%) and that beta blockers could be used (76.5%).

A high proportion of pharmacists (ie, $\geq 80\%$) provided correct responses to all 4 items of Question 17 in relation to concomitant diseases where Viagra Connect should not be supplied.

Table 7 Responses to all Questions about Pharmacist Knowledge of Part I Key Risk Messages for Pharmacists to Consider when Determining the Suitability of a Patient for Viagra Connect - Completed Surveys

Question	Pharmacists (N=345) n (%), [95% CI] ^[1]
Question 13: Please answer True/False/Don't know for the following statements:	
Viagra Connect is only intended for use by men over 45 years of age who are experiencing Erectile Dysfunction (ED).	
True	18 (5.2)
False ^[2]	319 (92.5) [89.2 - 95.0]
Don't know	8 (2.3)
Viagra Connect must not be supplied to men who do not have Erectile Dysfunction (ED).	
True ^[2]	316 (91.6) [88.2 - 94.3]
False	25 (7.2)
Don't know	4 (1.2)
Men currently prescribed 50 mg sildenafil can be supplied Viagra Connect if a) they meet the criteria for pharmacy supply and b) they do not take more than 50 mg daily.	
True ^[2]	309 (89.6) [85.8 - 92.6]
False	28 (8.1)
Don't know	8 (2.3)

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

Table 7 Responses to all Questions about Pharmacist Knowledge of Part I Key Risk Messages for Pharmacists to Consider when Determining the Suitability of a Patient for Viagra Connect - Completed Surveys

Question	Pharmacists (N=345) n (%), [95% CI] ^[1]
Men who are using a different dose of sildenafil or another Erectile Dysfunction (ED) treatment can also be supplied with Viagra Connect.	
True	63 (18.3)
False ^[2]	262 (75.9) [71.1 - 80.4]
Don't know	20 (5.8)
Question 14: The following patients should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.	
Those who have been advised by their doctor that they are not fit enough for physical or sexual activity.	
True ^[2]	341 (98.8) [97.1 - 99.7]
False	3 (0.9)
Don't know	1 (0.3)
B. Those who experience breathlessness or chest pain with light or moderate physical activity (eg walking briskly for 20 mins or climbing two flights of stairs).	
True ^[2]	340 (98.6) [96.7 - 99.5]
False	4 (1.2)
Don't know	1 (0.3)
Those who have had a heart attack or stroke more than 6 months ago.	
True	194 (56.2)
False ^[2]	143 (41.4) [36.2 - 46.8]
Don't know	8 (2.3)
Question 15: A patient with which of the following cardiovascular conditions MAY be supplied with Viagra Connect? Complete Yes/No/Don't know.	
Low blood pressure	
Yes	53 (15.4)
No ^[2]	276 (80.0) [75.4 - 84.1]
Don't know	16 (4.6)
Uncontrolled hypertension	
Yes	7 (2.0)
No ^[2]	330 (95.7) [92.9 - 97.5]
Don't know	8 (2.3)

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

Table 7 Responses to all Questions about Pharmacist Knowledge of Part I Key Risk Messages for Pharmacists to Consider when Determining the Suitability of a Patient for Viagra Connect - Completed Surveys

Question	Pharmacists (N=345) n (%), [95% CI]^[1]
Controlled hypertension	
Yes ^[2]	296 (85.8) [81.7 - 89.3]
No	42 (12.2)
Don't know	7 (2.0)
Unstable angina	
Yes	4 (1.2)
No ^[2]	333 (96.5) [94.0 - 98.2]
Don't know	8 (2.3)
Arrhythmia	
Yes	38 (11.0)
No ^[2]	283 (82.0) [77.6 - 85.9]
Don't know	24 (7.0)
Valvular heart disease	
Yes	27 (7.8)
No ^[2]	284 (82.3) [77.9 - 86.2]
Don't know	34 (9.9)
Cardiomyopathy	
Yes	17 (4.9)
No ^[2]	298 (86.4) [82.3 - 89.8]
Don't know	30 (8.7)
Left Ventricular outflow obstruction or aortic narrowing	
Yes	8 (2.3)
No ^[2]	292 (84.6) [80.4 - 88.3]
Don't know	45 (13.0)
Severe cardiac failure	
Yes	3 (0.9)
No ^[2]	338 (98.0) [95.9 - 99.2]
Don't know	4 (1.2)

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

Table 7 Responses to all Questions about Pharmacist Knowledge of Part I Key Risk Messages for Pharmacists to Consider when Determining the Suitability of a Patient for Viagra Connect - Completed Surveys

Question	Pharmacists (N=345) n (%), [95% CI] ^[1]
Question 16: Look at the list of drugs below and select whether or not they can be used with Viagra Connect. Complete Yes/No/Don't know.	
Nitrates for chest pain	
Yes	10 (2.9)
No ^[2]	333 (96.5) [94.0 - 98.2]
Don't know	2 (0.6)
Riociguat for lung problems	
Yes	18 (5.2)
No ^[2]	248 (71.9) [66.8 - 76.6]
Don't know	79 (22.9)
Ritonavir for HIV infection	
Yes	26 (7.5)
No ^[2]	290 (84.1) [79.8 - 87.8]
Don't know	29 (8.4)
Omeprazole or other proton pump inhibitors (PPIs)	
Yes ^[2]	321 (93.0) [89.8 - 95.5]
No	16 (4.6)
Don't know	8 (2.3)
CYP3A4 inhibitors (eg, saquinavir, cimetidine, itraconazole, ketoconazole, erythromycin or rifampicin, diltiazem)	
Yes	32 (9.3)
No ^[2]	289 (83.8) [79.4 - 87.5]
Don't know	24 (7.0)
Alpha blockers (eg, alfuzosin, doxazosin or tamsulosin)	
Yes	50 (14.5)
No ^[2]	290 (84.1) [79.8 - 87.8]
Don't know	5 (1.4)
Beta-blockers	
Yes ^[2]	264 (76.5) [71.7 - 80.9]
No	66 (19.1)

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

Table 7 Responses to all Questions about Pharmacist Knowledge of Part I Key Risk Messages for Pharmacists to Consider when Determining the Suitability of a Patient for Viagra Connect - Completed Surveys

Question	Pharmacists (N=345) n (%), [95% CI] ^[1]
Don't know	15 (4.3)
Recreational drugs called “poppers” (eg, amyl nitrite)	
Yes	5 (1.4)
No ^[2]	329 (95.4) [92.6 - 97.3]
Don't know	11 (3.2)
Question 17: Patients with the following concomitant diseases should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.	
Hepatic disease	
True ^[2]	284 (82.3) [77.9 - 86.2]
False	36 (10.4)
Don't know	25 (7.2)
Severe renal impairment	
True ^[2]	291 (84.3) [80.1 - 88.0]
False	36 (10.4)
Don't know	18 (5.2)
Osteoarthritis or other musculoskeletal disorders	
True	23 (6.7)
False ^[2]	310 (89.9) [86.2 - 92.8]
Don't know	12 (3.5)
Loss of vision due to optic nerve damage or inherited eye disease (such as retinitis pigmentosa)	
True ^[2]	296 (85.8) [81.7 - 89.3]
False	30 (8.7)
Don't know	19 (5.5)

Source: Section 14: [Table 3](#)

CI = Confidence interval; CYP3A4 = Cytochrome P450 3A4

^[1] 95% exact two-sided CIs are calculated using the Clopper-Pearson method.

^[2] Correct response.

10.4.1. Pharmacist knowledge of other important key risk messages, part II

[Table 8](#) presents the pharmacist responses to the knowledge questions about other important Key Messages (Part II) for pharmacists to consider during consultation (ie, 1) Pharmacists

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

should consider possible causes of ED; 2) Pharmacists should advise Patients to STOP TAKING Viagra Connect and seek medical attention immediately if they experience any serious side effects; 3) Pharmacist should advise all men who seek to purchase Viagra Connect to consult their doctor within 6 months of their first behind the counter purchase; 4) Pharmacists should advise men who have not been supplied the product to consult their doctor).

A high proportion of pharmacists (ie, $\geq 80\%$) provided correct responses to 6 of 8 items of Question 18 which asked which conditions may cause ED and should be considered when assessing the patient for suitability. A lower proportion of pharmacists ($< 80\%$) correctly indicated that hypertension may cause ED (70.1%) and correctly indicated that hypercholesterolaemia may cause ED (56.8%).

A high proportion of pharmacists (ie, $\geq 80\%$) provided correct responses to both items of Question 19. Pharmacists understood that if a patient requests Viagra Connect, but shows evidence of undiagnosed depression, anxiety, or excessive alcohol use, they should provide lifestyle advice (n=336, 97.4%) and recommend follow up with his doctor (n=340, 98.6%).

A high proportion of pharmacists (ie, $\geq 80\%$) provided correct responses to all 4 knowledge items of Question 20 pertaining to lifestyle advice and the requirement that all patients supplied with Viagra Connect should be advised to consult their doctor within 6 months from the first supply (87.2%) and all patients who are refused Viagra Connect should be advised to contact their doctor (90.4%).

A high proportion of pharmacists (ie, $\geq 80\%$) provided correct responses to 7 of the 9 items of Question 21 which asked the question as to when patients should be advised to stop taking Viagra Connect and seek immediate medical attention. 76.2% and 79.4% of pharmacists correctly responded that headache and nausea, respectively, did not require Viagra Connect to be stopped and immediate medical attention to be sought.

Table 8 Responses to all Questions about Pharmacist Knowledge of Part II Other Important Key Messages for Pharmacists to Consider During Consultation - Completed Surveys

Question	Pharmacists (N=345) n (%) [95% CI] ^[1]
Question 18: Which of the following MAY be a cause of Erectile Dysfunction (ED) and should be considered when assessing a patient for suitability for Viagra Connect. Please select True/False/Don't Know.	
Undiagnosed depression	
True ^[2]	308 (89.3) [85.5 - 92.3]
False	27 (7.8)
Don't know	10 (2.9)

Table 8 Responses to all Questions about Pharmacist Knowledge of Part II Other Important Key Messages for Pharmacists to Consider During Consultation - Completed Surveys

Question	Pharmacists (N=345) n (%) [95% CI]^[1]
Anxiety	
True ^[2]	324 (93.9) [90.8 - 96.2]
False	13 (3.8)
Don't know	8 (2.3)
Excessive alcohol use	
True ^[2]	335 (97.1) [94.7 - 98.6]
False	8 (2.3)
Don't know	2 (0.6)
Hypertension	
True ^[2]	242 (70.1) [65.0 - 74.9]
False	83 (24.1)
Don't know	20 (5.8)
Diabetes mellitus	
True ^[2]	322 (93.3) [90.2 - 95.7]
False	15 (4.3)
Don't know	8 (2.3)
Hypercholesterolemia	
True ^[2]	196 (56.8) [51.4 - 62.1]
False	109 (31.6)
Don't know	40 (11.6)
Cardiovascular disease	
True ^[2]	311 (90.1) [86.5 - 93.1]
False	28 (8.1)
Don't know	6 (1.7)
Osteoarthritis	
True	20 (5.8)
False ^[2]	290 (84.1) [79.8 - 87.8]
Don't know	35 (10.1)

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

Table 8 Responses to all Questions about Pharmacist Knowledge of Part II Other Important Key Messages for Pharmacists to Consider During Consultation - Completed Surveys

Question	Pharmacists (N=345) n (%) [95% CI] ^[1]
Question 19: If a patient requests Viagra Connect but shows evidence of undiagnosed depression, anxiety or excessive alcohol use, which action should you take? Please select True/False/Don't Know.	
Provide lifestyle advice	
True ^[2]	336 (97.4) [95.1 - 98.8]
False	9 (2.6)
Don't know	0
Recommend follow up with his doctor	
True ^[2]	340 (98.6) [96.7 - 99.5]
False	4 (1.2)
Don't know	1 (0.3)
Question 20: Please select True/False/Don't Know for the following statements.	
Pharmacists should provide lifestyle advice to all men with Erectile Dysfunction (ED) who request Viagra Connect.	
True ^[2]	299 (86.7) [82.6 - 90.1]
False	36 (10.4)
Don't know	10 (2.9)
Lifestyle advice includes losing weight, stopping smoking, cutting back on alcohol and recreational drugs, exercising regularly and reducing stress.	
True ^[2]	344 (99.7) [98.4 - 100.0]
False	1 (0.3)
Don't know	0
All patients supplied with Viagra Connect should be advised to consult their doctor within 6 months from the first supply.	
True ^[2]	301 (87.2) [83.3 - 90.6]
False	32 (9.3)
Don't know	12 (3.5)
All patients who are refused Viagra Connect should be advised to contact their doctor.	
True ^[2]	312 (90.4) [86.8 - 93.3]
False	30 (8.7)
Don't know	3 (0.9)

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

Table 8 Responses to all Questions about Pharmacist Knowledge of Part II Other Important Key Messages for Pharmacists to Consider During Consultation - Completed Surveys

Question	Pharmacists (N=345) n (%) [95% CI] ^[1]
Question 21: Complete True/False/Don't know for the following statement: Patients should be advised to STOP TAKING Viagra Connect and seek medical attention immediately if they experience the following symptoms.	
Chest pains	
True ^[2]	344 (99.7) [98.4 - 100.0]
False	0
Don't know	1 (0.3)
Persistent and sometimes painful erection lasting longer than 4 hours	
True ^[2]	340 (98.6) [96.7 - 99.5]
False	1 (0.3)
Don't know	4 (1.2)
Dyspepsia	
True	43 (12.5)
False ^[2]	291 (84.3) [80.1 - 88.0]
Don't know	11 (3.2)
Sudden decrease or loss of vision	
True ^[2]	344 (99.7) [98.4 - 100.0]
False	0
Don't know	1 (0.3)
Headache	
True	72 (20.9)
False ^[2]	263 (76.2) [71.4 - 80.6]
Don't know	10 (2.9)
Allergic reaction (with symptoms of wheeziness, difficulty breathing or dizziness)	
True ^[2]	345 (100.0) [98.9 - 100.0]
False	0
Don't know	0
Nausea	
True	53 (15.4)
False ^[2]	274 (79.4) [74.8 - 83.6]

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

Table 8 Responses to all Questions about Pharmacist Knowledge of Part II Other Important Key Messages for Pharmacists to Consider During Consultation - Completed Surveys

Question	Pharmacists (N=345) n (%) [95% CI] ^[1]
Don't know	18 (5.2)
Serious skin reactions (eg, Stevens-Johnson Syndrome [SJS])	
True ^[2]	340 (98.6) [96.7 - 99.5]
False	2 (0.6)
Don't know	3 (0.9)
Seizures or fits	
True ^[2]	339 (98.3) [96.3 - 99.4]
False	1 (0.3)
Don't know	5 (1.4)

Source: Section 14: [Table 4](#)

CI = Confidence interval

^[1] 95% exact two-sided CIs are calculated using the Clopper-Pearson method.

^[2] Correct response.

10.4.2. Main sources of pharmacists knowledge about Viagra Connect key risk messages

[Table 9](#) presents the responses to all questions regarding the source of knowledge of key risk messages pertaining to Viagra Connect.

The majority of pharmacists indicated that their main reference about the safe dispensing practices of Viagra Connect was either the Viagra Connect pharmacist training *Essential Information for the Supply of Viagra Connect* (n=161, 46.7%) or the *Viagra Connect Pharmacist Checklist* (n=115, 33.3%) (Question 22).

Table 9 Responses to all Questions Regarding the Source of Pharmacist Knowledge of Key Risk Messages Pertaining to Viagra Connect and Other OTC Products - Completed Surveys

Question	Pharmacists (N=345) n (%)
Question 22: Which of the following sources is your main reference about the safe dispensing practices of Viagra Connect? Please select ONE only:	
The Viagra Connect Summary of Product Characteristics (SmPC)	52 (15.1)
The Viagra Connect Box Label	2 (0.6)
The Viagra Connect Pharmacist Training <i>Essential Information for the Supply of Viagra Connect</i>	161 (46.7)
The Viagra Connect Pharmacist Checklist	115 (33.3)
My pharmacy's medication reference eg, British National Formulary (BNF)	8 (2.3)
Viagra Connect website	5 (1.4)
Pharmacy journals (eg, The Pharmaceutical Journal, Pharmacy, The Clinical Pharmacist)	1 (0.3)
Colleagues	0
Pfizer sales professional	1 (0.3)
Other	0

Source: Section 14: [Table 5](#)
 OTC = Over the counter

10.4.3. Pharmacist experience toward patient counseling

[Table 10](#) presents the responses to all questions about experience toward patient counselling.

Pharmacists were asked about the counselling of patients seeking to purchase Viagra Connect (Question 23). Overall, the results suggest that the counselling was perceived as a positive exercise with 91.3% of pharmacists saying they were comfortable counselling the patients each time they requested Viagra Connect, 94.8% saying it did not make them feel uncomfortable and 95.9% indicated that there was no difficulty in counselling due to lack of privacy. 67.5% said they would be less likely to repeat the counselling if they had covered it at a previous purchase.

The pharmacists' perception of patients was that 72.2% thought that patients were interested in learning and open to discussing their health and only 28.4% had patients say they did not want to go through counselling. Only 10.1% of pharmacists had patients who expressed dissatisfaction with counselling. However, it was noticeable that 53% of pharmacists thought that discussions made some patients uncomfortable and unwilling to divulge information.

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

Table 10 Responses to All Questions about Pharmacist Experience Toward Patient Counseling - Completed Surveys

Question	Pharmacists (N=345) n (%)
Question 23: Regarding the counselling of patients seeking to purchase Viagra Connect:	
I am comfortable counselling the patient each time they request Viagra Connect	
Yes	315 (91.3)
No	30 (8.7)
My experience is that patients are interested in learning and open to discussing their health	
Yes	249 (72.2)
No	96 (27.8)
Patients often tell me that they do not want to go through counselling	
Yes	98 (28.4)
No	247 (71.6)
If I have covered some of the issues with the patient during a previous purchase I am less likely to discuss it again	
Yes	233 (67.5)
No	112 (32.5)
I think that these discussions (ie, Viagra Connect supply counselling) make some patients uncomfortable and unwilling to divulge information	
Yes	183 (53.0)
No	162 (47.0)
The counselling about Viagra Connect makes me uncomfortable	
Yes	18 (5.2)
No	327 (94.8)
It is difficult to counsel patients because there is no private space to do so in my pharmacy	
Yes	14 (4.1)
No	331 (95.9)
Patients have expressed dissatisfaction with counselling	
Yes	35 (10.1)
No	310 (89.9)

Source: Section 14: [Table 6](#)

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

10.4.4. Awareness and utilization of the Viagra Connect pharmacist checklist

Table 11 presents the responses to all questions about the awareness and utilization of the *Viagra Connect Pharmacy Checklist* at the point of dispensing.

The majority of pharmacists (n=317, 91.9%) responded that they used the optional *Viagra Connect Pharmacy Checklist* at the point of supply (Question 24). Of the remaining 28 pharmacists who either did not use or did not recall using the checklist, only 6 (21.4%) gave the reason that they were not aware of the checklist.

When asked the frequency with which they used the optional *Viagra Connect Pharmacy Checklist*, the majority used it all the time for new requests for all customers presenting (n=308, 97.2%). For patients returning for repeat supplies of Viagra Connect, more than one-third used the checklist all the time for all customers presenting (n=111, 35.0%) or only used the checklist after first trained and no longer required as a prompt (n=122, 38.5%), and a quarter (n=84, 26.5%) of pharmacists never used the checklist (Question 26).

Most pharmacists always provided the patient with the tear-off slip contained on the bottom of the checklist if they have supplied Viagra Connect (n=315, 91.3%). However, this contrasts with 219 (63.5%) of pharmacists when they denied the patient Viagra Connect (Question 27).

The majority of pharmacists stated that before the day of the survey, they were aware of the *Viagra Connect Pharmacy Checklist* (n=341, 98.8%) (Question 32).

Table 11 Responses to all Questions about the Pharmacist Awareness and Utilization of the Viagra Connect Pharmacist Checklist and Tear-off Slip at the Point of Dispensing - Completed Surveys

Question	Pharmacists (N=345) n (%)
Question 24: Do you use the optional <i>Viagra Connect Pharmacy Checklist</i> at the point of supply?	
Yes	317 (91.9)
No	18 (5.2)
I do not recall	10 (2.9)
Question 25: From the list below please select reason(s) for NOT utilizing the optional <i>Viagra Connect Pharmacy Checklist</i>. Select ALL that apply:^{[1], [2]}	
I was not aware of the checklist	6 (21.4)
I used it for a while after the training but did not think I needed to continue to use it as it was no longer required as a prompt.	8 (28.6)
I am PGD (patient group direction)-trained (or equivalent) for PDE-5i's ^[3]	4 (14.3)
I am familiar with the information and I do not think I need the checklist to consult the patient	10 (35.7)

Table 11 Responses to all Questions about the Pharmacist Awareness and Utilization of the Viagra Connect Pharmacist Checklist and Tear-off Slip at the Point of Dispensing - Completed Surveys

Question	Pharmacists (N=345) n (%)
I use it only with new patients but not with returning patients	10 (35.7)
Other	1 (3.6)
N/A (Answered "Yes" to Question 24)	317
Question 26: How frequently do you use the optional <i>Viagra Connect Pharmacy Checklist</i>?	
For new requests for Viagra Connect¹¹	
All the time for all customers presenting	308 (97.2)
Only used after first trained and no longer required as a prompt	8 (2.5)
Never	1 (0.3)
N/A (Answered "No" or "I do not recall" to Question 24)	28
For patients returning for repeat supplies of Viagra Connect¹¹	
All the time for all customers presenting	111 (35.0)
Only used after first trained and no longer required as a prompt	122 (38.5)
Never	84 (26.5)
N/A (Answered "No" or "I do not recall" to Question 24)	28
Question 27: How frequently do you provide the patient with the tear-off slip contained on the bottom of the checklist?	
If I have supplied Viagra Connect	
Always	315 (91.3)
Sometimes	23 (6.7)
Never	7 (2.0)
If I have denied the patient's request for Viagra Connect	
Always	219 (63.5)
Sometimes	59 (17.1)
Never	67 (19.4)

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

Table 11 Responses to all Questions about the Pharmacist Awareness and Utilization of the Viagra Connect Pharmacist Checklist and Tear-off Slip at the Point of Dispensing - Completed Surveys

Question	Pharmacists (N=345) n (%)
Question 32: Before today, were you aware of the <i>Viagra Connect Pharmacy Checklist</i>?	
Yes	341 (98.8)
No	4 (1.2)

Source: Section 14: [Table 7](#)

^[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

^[2] More than one response can be selected, so percentages may not sum up to 100%.

^[3] It should be noted that the term “Patient Group Direction (PGD)-trained” was presented in the survey as “Pharmacy Group Direction (PGD)-trained” in error. As “PGD” is a commonly used term among pharmacists, it was not expected to have affected pharmacist understanding of the selection or the survey results. The corrected term is used for consistency throughout the report.

10.4.5. Participation in pharmacist training

Table 12 presents the responses to all questions about participating in Viagra Connect pharmacist training.

The majority of pharmacists indicated that they participated in the Viagra Connect pharmacist training (n=238, 69.0%) (Question 28). There was a wide variation in the format of the training that they participated in with the most popular format being printed training materials in the mail (n=129, 54.2%).

Of the 107 pharmacists who either did not, or could not recall participating in the training, 35 (32.7%) gave the reason that they did not know about it.

Table 12 Responses to all Questions about Pharmacists Participating in Viagra Connect Pharmacist Training - Completed Surveys

Question	Pharmacists (N=345) n (%)
Question 28: Did you participate in the Viagra Connect pharmacist training?	
Yes	238 (69.0)
No	60 (17.4)
I don't recall	47 (13.6)
Question 29: What was your main reason for NOT accessing the training? Select ONE only.^[1]	
I did not know about it	35 (32.7)

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

Table 12 Responses to all Questions about Pharmacists Participating in Viagra Connect Pharmacist Training - Completed Surveys

Question	Pharmacists (N=345) n (%)
I have not had time	19 (17.8)
I had difficulty accessing the materials electronically	6 (5.6)
I am PGD (patient group direction)-trained (or equivalent) for phosphodiesterase type 5 inhibitors (PDE-5i's) ^[3]	21 (19.6)
Other	26 (24.3)
N/A (Answered "Yes" to Question 28)	238
Question 30: What format of the Viagra Connect pharmacist training did you participate in? Select ALL that apply.^{[1], [2]}	
Online training through a website for pharmacists accredited by the Royal Pharmaceutical Society (RPS)	40 (16.8)
During a regional pharmacist meeting	53 (22.3)
Online training via the Viagra Connect Website	67 (28.2)
Online training provided by company eg, Boots own training	86 (36.1)
I received printed training materials in the mail	129 (54.2)
During a face-to-face training in my pharmacy	44 (18.5)
Other	4 (1.7)
N/A (Answered "No" or "I don't recall" to Question 28)	107

Source: Section 14: [Table 8](#)

^[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

^[2] More than one response can be selected, so percentages may not sum up to 100%.

^[3] It should be noted that the term "Patient Group Direction (PGD)-trained" was presented in the survey as "Pharmacy Group Direction (PGD)-trained" in error. As "PGD" is a commonly used term among pharmacists, it was not expected to have affected pharmacist understanding of the selection or the survey results. The corrected term is used for consistency throughout the report.

10.4.6. Utilization and reading of the *Essential Information for the Supply of Viagra Connect guide*

[Table 13](#) presents the responses to all questions about utilization/reading of the *Essential Information for the Supply of Viagra Connect guide* for pharmacists. The majority of pharmacists (n=334, 96.8%) read the guide for pharmacists (Question 31).

Table 13 Responses to all Questions about Pharmacist Utilization/Reading of the *Essential Information for the Supply of Viagra Connect* Guide for Pharmacists - Completed Surveys

Question	Pharmacists (N=345) n (%)
Question 31: Did you read the <i>Essential Information for the Supply of Viagra Connect</i> guide for pharmacists?	
Yes	334 (96.8)
No	11 (3.2)

Source: Section 14: [Table 9](#)

10.4.7. Responses to knowledge questions by subgroup

Responses to knowledge questions were stratified by the following subgroups, and an overview of subgroup results by Question(s) is presented below:

- Participation in the Viagra Connect Pharmacist Training
- Number of patients who requested to purchase Viagra Connect in the last 6 months
- Place of pharmacy (Urban vs. Rural)
- Type of pharmacy (Large multiple chain (more than 100 stores) vs. Small multiple pharmacy chain (6 to 99 stores) vs. Independent pharmacy (1 to 5 stores))
- Time dispensing medications as a pharmacist
- Age groups
- Gender
- Reading of the *Essential Information for the Supply of Viagra Connect* for pharmacists
- Using the optional *Viagra Connect Pharmacy Checklist* at the point of supply
- Main sources of knowledge about safe dispensing practices of Viagra Connect.

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

The following subgroups in the stratified analyses were too small to permit meaningful comparisons (ie, $n \leq 25$):

- **Time dispensing medications as a pharmacist:** One of the sub-groups consisted of less than 25 pharmacists (ie, $n=24$) making meaningful comparison across subgroups difficult.
- **Reading of the *Essential Information for the Supply of Viagra Connect* guide for pharmacists:** Very few pharmacists ($n=11$, 3.2%) reported not reading the *Essential Information for the Supply of Viagra Connect* guide for pharmacists and thus no meaningful comparisons can be made among those pharmacists who read or did not read the guide.
- **Using the optional *Viagra Connect Pharmacy Checklist* at the point of supply:** Very few pharmacists reported not using the checklist at the point of supply ($n=18$, 5.2%) or not recalling using the checklist ($n=10$, 2.9%), thus, no meaningful comparisons can be made among those who do and don't use the checklist.
- **Main sources of knowledge about safe dispensing practices of Viagra Connect:** No meaningful comparisons of knowledge among people who used different primary sources of knowledge about safe dispensing of Viagra connect can be made because the majority of pharmacists used aRMM tools/training ($n=282$, 81.7%).
- In general, no major or consistent differences were observed for any of the stratification variables. Small differences are noted below but should be interpreted with caution due to overlapping CIs:

Knowledge of Key Risk Messages Part I (Questions 13 through 17) by Subgroups

Results for Key Risk Messages Part I subgroup analyses are presented in source [Tables 3.1](#) through 3.10. The following results are presented as n/N (% [95% CI%]).

- **Participation in the Viagra Connect Pharmacist Training:** Although no consistent patterns of improved knowledge of Key Risk messages Part I were observed among those who went through training compared with those who either did not or did not recall participating in training, some minor differences in knowledge are highlighted below (source Table 3.1):
 - Of those who reported participating in training, 224/238 (94.1% [90.3-96.7%]) correctly answered False that Viagra Connect is only intended for use by men over 45 years of age who are experiencing ED compared with 53/60 (88.3% [77.4-95.2%]) of those who reported not participating in training and 42/47 (89.4% [76.9-96.5%]) of those who did not recall whether they participated.
 - A minor difference was noted in pharmacist's knowledge of the fact that Viagra Connect must not be supplied to men who do not have Erectile Dysfunction (ED):

216/238 (90.8% [86.3-94.1%]) of those who participated in training correctly answered this question compared with 53/60 (88.3% [77.4-95.2]) of those who did not participate and 47/47 (100% [92.5-100.0%]) of those who did not recall whether they participated.

- A slightly higher proportion of trained pharmacists correctly answered as False that patients who had a heart attack or stroke more than 6 months ago should not be supplied with Viagra Connect but should be referred to their doctor: 104/238 (43.7% [37.3 – 50.3%]) of trained pharmacists answered this question correctly compared with 22/60 (36.7% [24.6 – 50.1%]) of those who did not participate in training and 17/47 (36.2% [22.7-51.5%]) of those who did not recall whether they participated.
- A slight difference was noted in those pharmacists who correctly answered “no” to alpha blockers being a medication that can be used with Viagra Connect: 201/238 (84.5% [79.2-88.8%]) of those who participated in training compared with 47/60 78.3% [65.8-87.9%]) of those who did not participate and 42/47 (89.4% [76.9-96.5%]) of those who did not recall whether they participated.
- Similarly, 186/238 (78.2% [72.4 – 83.2]) of those who participated in training compared with 43/60 (71.7% [58.6 – 82.5%]) of those who did not participate and 35/47 (74.5% [59.7-86.1%]) of those who did not recall whether they participated correctly answered beta-blockers being a medication that can be used with Viagra Connect.
- No consistent patterns of improved knowledge were observed among pharmacists with the highest number of patients who requested to purchase Viagra Connect in the last 6 months, by place of pharmacy (rural vs. urban), by type of pharmacy (large chain, small chain, independent), with greater number of years of dispensing drugs as pharmacist, with increasing age of pharmacists, or with gender of pharmacist.

Knowledge of Key Risk Messages Part II (Questions 18, 19, 20, and 21) by subgroups

Results for Key Risk Messages Part II subgroup analyses are presented in source [Tables 4.1](#) through 4.10. The following results are presented as n/N (% [95% CI%]).

- Participation in the Viagra Connect Pharmacist Training: No consistent pattern of improved knowledge of key risk messages part II among those who participated in pharmacist training compared with those who did not participate was observed. There were few questions, however, which received a higher proportion of correct answers among those who did participate in training compared with those who did not (source Table 4.1):
 - With regards to possible causes of ED that should be considered when assessing a patient for suitability for Viagra Connect, 225/238 (94.5% [90.8 – 97.1%]) of those

who participated in training knew that diabetes mellitus may be a potential cause of ED compared with 55/60 (91.7% [81.6-97.2]) of those who did not participate. Similarly, 143/238 (60.1% [53.6-66.4%]) of those who participated in training knew that hypercholesterolemia may be a potential cause of ED compared with 29/60 (48.3% [35.2-61.6]) who did not participate. With regards to cardiovascular disease, 219/238 (92.0% [87.8-95.1]) of those who participated in training knew that it may be a potential cause of ED compared with 48/60 (80% [67.7-89.2]) of those who did not participate.

- Slightly higher proportion of pharmacists who participated in training (234/238 (98.3% [95.8-99.5]) compared with those who did not participate in training (57/60 (95% [86.1-99.0]) knew that if a patient requests Viagra Connect but shows evidence of undiagnosed depression, anxiety or excessive alcohol use they should provide a lifestyle advice to the patient. One notable difference was found: 215/238 (90.3% [85.9-93.8%]) of those who participated in training compared with 48/60 (80.0% [67.7-89.2%]) of those who did not participate knew that, “All patients supplied with Viagra Connect should be advised to consult their doctor within 6 months from the first supply.”
- No consistent pattern of improved knowledge was observed among pharmacists with the highest numbers of patients seeking to purchase Viagra Connect within the first 6 months, by pharmacy setting (rural vs. urban), by type of pharmacy (large chain, small chain, independent), with a greater number of years of dispensing drugs as pharmacist, with increasing age, or by gender.

10.4.8. Pharmacists awareness, utilization of aRMMs by subgroups

Questions 24 through 27: Pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear-off slip at the point of dispensing

The subgroup analysis results for pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear-off slip are presented in source [Tables 7.1](#) through 7.9.

- Similar proportions of those who participated in the pharmacist training and those who did not participate reported utilizing the optional *Viagra Connect Pharmacy Checklist* at the point of supply (219/238, 92.0% vs. 55/60, 91.7%), respectively (source Table 7.1).
- Slight differences were noted among those who participated in the pharmacist training vs. those who did not participate with regards to:
 - How frequently they use the optional checklist for all new requests of Viagra Connect (214/238, 97.7% vs. 52/60, 94.5% of those trained vs. not trained, respectively)
 - How frequently they use the optimal checklist for the repeat supplies of Viagra Connect: here the pattern was reversed with slightly higher proportions of those who did NOT participate in the pharmacist training using the checklist “all the time for all

customers presenting” (23/60, 41.8%) compared with those who did participate in the training (71/238, 32.4%).

- A noteworthy difference was observed with regards to providing patients with the tear-off slip. If they had supplied Viagra Connect, 94.5% (225/238) of those pharmacists who participated in training, reported always handing out the tear-off slip compared with 80.0% (48/60) of those who did not participate in training. If they had denied the patient’s request for Viagra Connect, a smaller proportion of pharmacists in general reported providing patients with the tear-off slip. However, the proportion was higher among the pharmacists who participated in the training (159/238, 66.8%) compared with those pharmacists who reported not participating in the training (32/60, 53.3%) (source [Table 7.1](#)).
- There was a slight difference observed in terms of proportion of pharmacists using the Viagra Connect Checklist at the point of supply: 86.2% (50/58) of pharmacists who had supplied Viagra to most patients (ie, >30) reported using the checklist compared with 95.9% (163/170) of those who supplied Viagra to 1-10 patients in the last 6 months (source [Table 7.2](#)).
- There was a slight difference in utilization of checklist by type of pharmacy. A slightly greater proportion of pharmacists from small multiple chains (60/61, 98.4%) reported utilizing the checklist at the point of sale compared with pharmacists from large multiple chains (143/157, 91.1%) or independent pharmacists (114/127, 89.8%) (source [Table 7.4](#)).
- Regarding frequency of utilizing the Viagra Connect Checklist, for new requests of Viagra Connect, a great majority of pharmacists in all pharmacy types reported using the checklist always (between 95.0% of small chain pharmacists to 98.2% of independent pharmacists). The frequency of use was smaller for returning patients and repeat supplies of Viagra Connect for all types of pharmacies, however slight differences were found. Independent pharmacies reported using the checklists “all the time for all customers presenting” at the highest rate (55/127, 48.2%) compared with 35/157, 24.5% among large multiple chain pharmacists and 21/61 (35.0%) among small multiple chain pharmacists (source [Table 7.4](#)).
- There was a notable difference in the proportions of pharmacists in the 3 types of pharmacies in terms of their reported supply of tear-off slips to patients. The reported provision of tear of slips was higher in general for patients that were supplied Viagra Connect compared with patients who were denied. The large multiple chain pharmacists reported providing the tear-off slip “always” 97.5% (153/157) of the time, compared with 93.4% (57/61) reported by small multiple chain pharmacists and 82.7% (105/127) reported by independent pharmacist. In instances when Viagra Connect was denied, 67.5% (106/157) of large multiple chain pharmacists reported “always” providing the tear of slip compared with 62.3% (38/61) of small multiple chain pharmacists and 59.1% (75/127) of independent pharmacists (source [Table 7.4](#)).

- More female pharmacists reported “always” distributing the tear-off slip to patients than male pharmacists. In the instances when they had supplied Viagra Connect, 97.1% (99/102) of female pharmacists reported supplying the tear-off slip “always” compared with 88.8% (214/241) of male pharmacists. In the instances when Viagra Connect was denied, 68.6% (70/102) of female pharmacists reported always providing the tear-off slip compared with 61.4% (148/241) of males pharmacists (source [Table 7.7](#)).

Questions 28, 29, and 30: Pharmacists participating in Viagra Connect pharmacist training

The subgroup analysis results for pharmacists participating in Viagra Connect pharmacist training are presented in source [Tables 8.1](#) through 8.7.

- A greater proportion of pharmacists who reported a greater number of patients seeking to purchase Viagra Connect reported participating in training compared with those who reported less patients seeking to purchase Viagra. The proportions of those participating in training were 66.5% (113/170) among those who reported 1-10 patients, 70.1% (82/117) among those who reported 11-30 patients, and 74.1% (43/58) among those who reported more than 30 patients (source [Table 8.1](#)).
- The proportion of the types of trainings was different in the different number of patients seeking to purchase Viagra Connect subgroups. The most frequently used form of training was printed material received in the mail and the proportions of those who used this training were 59.3% (67/170) among those who reported 1-10 patients, 43.9% (36/117) among those who reported 11-30 patients, and 60.5% (26/58) among those who reported more than 30 patients. For online training provided by the company the proportions were 31.0% (35/170) among those who reported 1-10 patients, 37.8% (31/117) among those who reported 11-30 patients, and 46.5% (20/58) among those who reported more than 30 patients. For training during a regional pharmacist meeting, the proportions were 24.8% (28/170) among those who reported 1-10 patients, 14.6% (12/117) among those who reported 11-30 patients, and 30.2% (13/58) among those who reported more than 30 patients (source [Table 8.1](#)).
- A higher proportion of rural pharmacists (75.6%, 68/90) compared with urban pharmacists (66.7%, 170/255) participated in training (source [Table 8.2](#))
- The proportions of various types of training were slightly different between urban and rural pharmacy setting. The most frequently used form of training was printed material received in the mail and the proportions of urban vs rural pharmacy settings was 57.1% (97/255) vs 47.1% (32/90), respectively. For online training provided by the company, the proportions were 34.1% (58/255) and 41.2% (28/90), respectively. For online training via the Viagra Connect Website, the proportions were 27.6% (47/255) vs 29.4% (20/90) and during a regional pharmacist meeting 23.5% (40/255) vs 19.1% (13/90), respectively (source [Table 8.2](#)).

- There was a substantial difference in the proportion of pharmacists that participated in training among the different types of pharmacies. A higher proportion of large multiple chain pharmacies (80.9%, 127/157) reported participating in training compared with small multiple chains (67.2%, 41/61) or independent pharmacies (55.1%, 70/127) (source [Table 8.3](#)).
- The proportions of the various types of training in which pharmacists participated differed slightly by pharmacy type. It is important to note that pharmacists could select all training options presented that applied to them. The most frequently used form of training was printed material received in the mail and the proportions of those who used this training were 46.5% (59/157) among large multiple chain pharmacies, 65.9% (27/61) among small multiple chains, and 61.4% (43/127) among independent pharmacies. For online training provided by the company, the proportions were 63.8% (81/157), 2.4% (1/61), and 5.7% (4/127), respectively. For online training via the Viagra Connect Website, the proportions were 30.7% (39/157), 36.6% (15/61), and 18.6% (13/127), respectively. For training during a regional pharmacist meeting, the proportions were 21.3% (27/157), 17.1% (7/61), and 27.1% (19/127), respectively (source [Table 8.3](#)).
- No notable consistent pattern was observed in training participation by time dispensing medications as a pharmacist (source [Table 8.4](#)).
- There was an indication that the older the pharmacists, the more likely they were to participate in training up to 41-60 years of age. The subgroup “greater than 61 years” was too small to permit meaningful analysis (source [Table 8.5](#)).
- A greater proportion of female pharmacists (73.5%, 75/102) than male pharmacists (66.8%, 161/241) reported having participated in the pharmacist training (source [Table 8.6](#)).

Question 31: Pharmacist utilization/reading of the *Essential Information for the Supply of Viagra Connect* guide for pharmacists

As stated above, no meaningful comparisons of knowledge were observed among pharmacists who use different primary sources of knowledge about safe dispensing of Viagra connect because the majority used aRMM tools/training (N=282).

The subgroup analysis results for pharmacist utilization/reading of the *Essential Information for the Supply of Viagra Connect* guide for pharmacists’ are presented in source [Tables 9.1 through 9.8](#).

10.4.9. Attitudes toward the aRMM materials

[Table 14](#) presents the responses to all questions about the attitude toward Viagra Connect pharmacist training and patient counselling.

The majority of pharmacists found the *Viagra Connect Training Guide to Pharmacists* to be either very useful (n=106, 30.7%) or extremely useful (n=205, 59.4%) in their practice; the *Viagra Connect Pharmacist Checklist* to be either very useful (n=70, 20.3%) or extremely useful (n=264, 76.5%); and the tear-off slip at the bottom of the pharmacist checklist to be either very useful (n=110, 31.9%) or extremely useful (n=176, 51.0%).

Table 14 Responses to all Questions about the Pharmacist Attitude Toward Viagra Connect Pharmacist Training and Patient Counselling - Completed Surveys

Question	Pharmacists (N=345) n (%)
Question 33: Did you find the Viagra Connect pharmacist training/reference tools to be of use in your practice? Please select only ONE response for each tool listed below:	
<i>Viagra Connect Training Guide to Pharmacists</i>	
Not useful	2 (0.6)
Somewhat useful	10 (2.9)
No opinion/not sure	13 (3.8)
Very useful	106 (30.7)
Extremely useful	205 (59.4)
Not applicable	9 (2.6)
<i>Viagra Connect Pharmacist Checklist</i>	
Not useful	2 (0.6)
Somewhat useful	5 (1.4)
No opinion/not sure	0
Very useful	70 (20.3)
Extremely useful	264 (76.5)
Not applicable	4 (1.2)
Tear-off slip at the bottom of the pharmacist checklist	
Not useful	8 (2.3)
Somewhat useful	34 (9.9)
No opinion/not sure	13 (3.8)
Very useful	110 (31.9)
Extremely useful	176 (51.0)
Not applicable	4 (1.2)

Source: Section 14: [Table 10](#)

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

10.5. Other analyses

Not Applicable.

10.6. Adverse events / adverse reactions

No safety events were reported during this study.

11. DISCUSSION

Of the 4000 pharmacists invited to participate in the survey, 345 pharmacists completed the survey, thus surpassing the target of 200 completed surveys targeted. The time taken to complete the survey was overall within the 30 minutes expected.

The sample of pharmacists showed a mix of urban and rural pharmacists (73.9% vs. 26.1%). Whilst 73.9% stated they worked in an urban pharmacy, this is likely to reflect the higher number of pharmacies in urban areas compared with rural ones. A study by Todd et al¹ found that 89% of the population in England has access to a community pharmacy within a 20-minute walk. Populations in urban areas of England have better access to a community pharmacy compared with populations in town and fringe and rural areas, which indicates dominance of the urban pharmacy compared with rural.

The survey respondents also worked in a type of pharmacy setting (large multiple, small multiple, or independent) that was similar to the distribution among all pharmacies in the UK² (45.5%, 17.7%, and 36.8% in the survey compared with 49.2%, 12.4%, and 38.4% in the UK, respectively). The sample also showed a good mix of pharmacists according to ages, and years of experience in dispensing medicines.

According to the General Pharmaceutical Register in August 2017, the gender distribution of pharmacists in the UK was 61% female and 39% male. It is possible that the gender distribution seen in this study reflects the preference of men to consult a male pharmacist to request Viagra Connect rather than a female.

In the following discussion of results, the data presentation of 80.0% is an arbitrary measure of pharmacist understanding, and was not based on any prior knowledge or predetermined threshold.

Part I: Key risk messages for the pharmacists to consider when determining the suitability of a patient for Viagra Connect.

The knowledge level among the pharmacists of the Key Risk Messages Part I was generally high. Five survey questions with 28 items pertained to these Key Risk Messages, and at least 80.0% of pharmacists selected correct responses to 24 of the 28 items of Questions 13 through 17.

There were four questions where less than 80% of pharmacists gave the correct response. Three-fourths (75.9%) of the pharmacists understood that men who are using a different dose

of sildenafil or another ED treatment MAY NOT also be supplied with Viagra Connect. This is an area that will be highlighted for the pharmacists in training moving forward.

Only 56.2% of pharmacists understood that those patients who had a heart attack or stroke more than 6 months ago MAY be supplied Viagra Connect and 76.5% knew that beta-blockers could be used with Viagra Connect. However, although pharmacists scored lower for these questions, this may actually reflect an over-cautious approach on the part of pharmacists. The incorrect response will result in denying the patient Viagra Connect and will not put that patient at any additional risk.

Only 71.9% knew that riociguat for lung problems could not be used with Viagra Connect. This may reflect the fact that riociguat is not as frequently dispensed as many other medications and hence pharmacists may have been less familiar with this product.

Part II: Other important key risk messages for the pharmacists to consider during consultation.

Four survey questions with 23 items pertained to other important key risk messages, and 80.0% of pharmacists selected correct responses to 19 of the 23 items of Questions 18 through 21.

Less than 80.0% of pharmacists provided correct responses to the following questions when assessing patient considerations during consultation: that hypertension (70.1%), and hypercholesterolemia (56.8%) MAY be a cause of ED and should be considered when assessing a patient for suitability for Viagra Connect. However, although the knowledge level was lower for these questions, these questions are not questions that determine whether or not Viagra Connect will be supplied to a patient and so do not directly impact patient safety. A potential explanation for lower knowledge could be that these are common conditions and the ED is associated with the most severe, long standing and /or poorly controlled disease. Another potential explanation is that there may still be a perception among some pharmacists that ED is associated with psychological conditions more than physical. Pfizer would prefer knowledge of these underlying health conditions to be greater among the pharmacists. This point will be highlighted in the pharmacists training going forward.

A high proportion of pharmacists understood the requirements that all patients supplied with Viagra Connect should be advised to consult their doctor within 6 months from the first supply (87.2%) and all patients who are refused Viagra Connect should be advised to contact their doctor (90.4%). Although most pharmacists always provided the patient with the tear-off slip contained on the bottom of the checklist if they have supplied Viagra Connect (91.3%), those patients who were denied the product were supplied with the tear-off slip at lower frequency (63.5%). This finding is not entirely surprising. Reasons for not supplying the tear-off slip for patients not receiving treatment may include that they were a healthy non-sufferer, they were under the age of 18, or they were a woman. Often these patients will need advice about who can have the product, but this would not necessarily need to be followed up with a visit to the doctor.

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

At least 76.2% and 79.4% of pharmacists answered correctly that if a patient experiences headache or nausea, respectively, there is no requirement to stop Viagra Connect and seek medical advice immediately. However, again this result may reflect a conservative approach by the pharmacists and does not impact patient safety.

The majority of pharmacists (n=276, 80.0%) indicated that their main reference about the safe dispensing practices of Viagra Connect was either the *Viagra Connect Pharmacist Checklist* (33.3%) or the Viagra Connect pharmacist training guide *Essential Information for the Supply of Viagra Connect* (46.7%) indicating that there is high awareness and utilization of aRMM tools.

Overall, the results suggest that the patient counselling was perceived by the pharmacists as a positive exercise, which they were able to undertake comfortably. The majority of pharmacists' perception of patients was that they thought patients were interested in learning and open to discussing their health (72.2%). Only 10.1% of pharmacists had patients who expressed dissatisfaction with counselling. However, it was notable that 53.0% of pharmacists thought that discussions made some patients uncomfortable and unwilling to divulge information. Despite this perception by pharmacists, it is encouraging that they themselves were comfortable with counselling and did not see this as a deterrent.

The majority (98.8%) of pharmacists stated that they were aware of the *Viagra Connect Pharmacy Checklist* and 91.9% responded that they used the optional *Viagra Connect Pharmacy Checklist* at the point of supply.

As noted above, most pharmacists always provided the patient with the tear-off slip contained on the bottom of the checklist if they have supplied Viagra Connect (n=315, 91.3%) compared with only 219 (63.5%) pharmacists when they denied the patient Viagra Connect. When analyzed by subgroup, a slightly greater proportion of pharmacists who were trained provided the patient with the tear-off slip when they denied the patient Viagra Connect (66.8%) compared with pharmacists who were not trained (53.3%).

More than two-thirds (n=238, 69.0%) of pharmacists took part in the Viagra Connect pharmacist training, 17.4% did not take part in training, and 13.6% did not recall if they had participated in training. Of the 107 pharmacists who either did not, or could not recall participating in the training, 32.7% gave the reason that they did not know about it, 19.6% reported being PGD-trained for PDE-5 is, 17.8% reported not having had time to complete the training, 5.6% reported having had difficulty accessing the materials electronically and 24.3% answered that they had "Other" reasons for not accessing the training. A potential "other" reason for not participating in training could be a perception among the pharmacists of being knowledgeable about the product and thus not needing any further training given that Viagra has been on the market for a long time. Training was provided in a variety of formats in order to maximize the opportunity for uptake. Use of printed material by mail appeared to be the most popular with 54.2% of the 238 pharmacists using this form of training. Online training organized by Pfizer was the next most popular with 36.1% of

pharmacists participating. Other modalities were used by at least 18.5% demonstrating that a multimodal approach is beneficial in achieving maximal uptake.

The *Viagra Connect Training Guide to Pharmacists*, the *Viagra Connect Pharmacy Checklist* and the tear-off slip were well received by pharmacists with 90.1%, 96.8%, and 82.9% stating that these were either extremely useful or very useful.

In general, no consistent patterns of improved knowledge of key risk messages part I or part II were observed among those who went through training compared with those who either did not or did not recall participating in training. For Part I, pharmacists who were trained had slightly higher knowledge scores than those who were not trained for the following key risk messages: Viagra Connect is not just for use by men over 45 years of age who are experienced ED (94.1% vs 88.3%); Viagra Connect must not be supplied to men who do not have ED (90.8% vs 88.3%); it is a false statement that patients who had a heart attack or stroke more than 6 months ago should not be supplied with Viagra Connect but should be referred to their doctor (43.7% vs 36.7%); alpha blockers are not a medication that can be used with Viagra Connect (84.5% vs 78.3%); and beta blockers are a medication that can be used with Viagra Connect (78.2% vs 71.7%). It is noteworthy that the pharmacists who did not recall taking training performed nearly as well as those who were trained.

For Part II, pharmacists who were trained had slightly higher knowledge scores compared with those who were not trained for the following key risk messages: diabetes mellitus may be a potential cause of ED (94.5% vs 91.7%); hypercholesterolemia may be a potential cause of ED (60.1% vs 48.3%); if a patient requests Viagra Connect but shows evidence of undiagnosed depression, anxiety, or excessive alcohol use they should provide life style advise to the patient (98.3% vs 95.0%); all patients supplied with Viagra Connect should be advised to consult their doctor within 6 months of the first supply (90.3% vs 80.0%).

Similar proportions of those who participated in the pharmacist training and those who did not participate reported utilizing the optional *Viagra Connect Pharmacy Checklist* at the point of supply (92.0% vs. 91.7%, respectively). Slight differences were noted among those who participated in the pharmacist training vs. those who did not participate with regards to how frequently they use the optional checklist for all new requests of Viagra Connect (97.7% vs. 94.5%, respectively). In addition, there was a difference noted in how frequently they use the optimal checklist for the repeat supplies of Viagra Connect, here the pattern was reversed with slightly higher proportions of those who did NOT participate in the pharmacist training using the checklist “all the time for all customers presenting” compared with those who did participate in the training (41.8% vs 32.4%, respectively).

A greater proportion of pharmacists who reported a greater number of patients seeking to purchase Viagra Connect reported participating in training compared with those who reported less patients seeking to purchase Viagra. The proportions of those participating in training were 66.5% among those who reported 1-10 patients, 70.1% among those who reported 11-30 patients, and 74.1% among those who reported more than 30 patients. A higher proportion of rural pharmacists (75.6%) compared with urban pharmacists (66.7%)

participated in training. There was a substantial difference in the proportion of pharmacists that participated in training among the different types of pharmacies. A higher proportion of large multiple chain pharmacies (80.9%) reported participating in training compared with small multiple chains (67.2%) or independent pharmacies (55.1%)

12. CONCLUSIONS

In this sample of pharmacists who supply Viagra Connect, there was generally a high level of knowledge and awareness of the Key Risk Messages. There are some areas that could benefit from more emphasis in the training modalities provided to pharmacists, including improved knowledge of the underlying health conditions of patients with ED, contraindicated medications, and that men using a different dose of sildenafil or other ED treatment may not also be supplied Viagra Connect. Pfizer is committed to a continuous improvement of the aRMM program. The company will be reviewing the checklists and identifying areas for potential formatting changes as well as areas requiring additional emphasis within the pharmacist training package. Pfizer will also take the opportunity to consult with outside pharmacy and medical practitioners in order to review the data generated with a view to improving outcomes in key areas.

Utilisation and satisfaction with the Viagra Connect Pharmacy Training and the voluntary pharmacist checklist was high. The stratified analyses indicate that participation in pharmacist training was associated with slightly higher rate of utilization of the voluntary checklist and tear-off slips and a greater proportion of pharmacists advising the patients to see their doctor within 6 months of supply. This along with the high proportion of pharmacists indicating that the aRMMs materials are their main source of knowledge coupled with the overall high rate of correct responses to knowledge questions suggest that the aRMMs have been effective in ensuring patients are supplied Viagra Connect safely by pharmacists. Study data provide reasonable assurance that the pharmacist participants are representative of the wider pharmacist population in the UK with respect to type of pharmacy.

13. REFERENCES

1. Todd A, Copeland A, Husband A, et al. The positive pharmacy care law: an area-level analysis of the relationship between community pharmacy distribution, urbanity and social deprivation in England. *BMJ Open*. 2014; 4:e005764. doi:10.1136/bmjopen-2014-005764.
2. Sukkar E. Infographic: community pharmacy in Great Britain 2016: a fragmented market. *The Pharmaceutical Journal*. 2016; 296(7889):282.

14. LIST OF SOURCE TABLES AND LISTINGS

090177e1918af5d7\Approved\Approved On: 24-Jul-2019 18:42 (GMT)

PFIZER CONFIDENTIAL

Table 1.1 Survey Administration Statistics

Parameter	Pharmacists n (%)
The number of paper invitations issued to pharmacists	4,000
The number of email reminder letters sent ^[1]	6,865
The number of waves paper or email reminder letters sent	1
The number of screened respondents (Response rate) ^[2]	387 (9.7)
The number of respondents eligible for participation (Eligibility rate) ^[3]	357 (92.2)
The number and percentages of eligible respondents who completed the survey; "Completers" (Completion rate) ^[4]	345 (96.6)

Source: Appendix B: Table 1.1

^[1] Total of one wave of reminder letters. If a single pharmacist is invited by a paper invitation and by email, the email invitation is counted as a reminder.

^[2] Response rate is calculated as the percentage of the invited pharmacists.

^[3] Eligibility rate is calculated as the percentage of the screened respondents. The screened respondents consists of all respondents who have accessed the survey using the unique code regardless of whether or not they answered any survey questions.

^[4] The completion rate is calculated as percentage of the eligible pharmacists.

Note: Paper and email invitations are not mutually exclusive.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 1.1b: Time to Complete Survey - Completed Surveys

Summary Statistic (minutes)	
N	345
Mean (SD)	19.6 (10.09)
Minimum	5
Median	16.6
Maximum	61
Category, n (%)	
0 to <5 Minutes	2 (0.6)
5 to <10 Minutes	46 (13.3)
10 to <15 Minutes	90 (26.1)
15 to <20 Minutes	79 (22.9)
20 to <25 Minutes	49 (14.2)
25 to <30 Minutes	27 (7.8)
30 Minutes or more	52 (15.1)

Source: Appendix B: Table 1.1b
SD = Standard Deviation

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 1.2 Survey Participant Eligibility Results - Screened Respondents

Question	Pharmacists (N=387) n (%)
Question 1: Do you agree to participate in this survey?	
Yes	366 (94.6)
No ^[1]	0
Discontinued ^[3]	21 (5.4)
Question 2: Are you a practising pharmacist in the UK?	
Yes	362 (93.5)
No ^[1]	4 (1.0)
Question not asked ^[2]	0
Discontinued ^[3]	21 (5.4)
Question 3: Have you received at least one patient face to face request for Viagra Connect in the past 6 months?	
Yes	360 (93.0)
No ^[1]	2 (0.5)
Question not asked ^[2]	4 (1.0)
Discontinued ^[3]	21 (5.4)
Question 4: Are you or any of your immediate family members currently employed by Pfizer, another pharmaceutical company, United BioSource Corporation (UBC) or contracted by regulatory bodies (eg, European Medicines Agency (EMA) or Medicines and Healthcare Products Regulatory Agency (MHRA))?	
Yes ^[1]	0
No	357 (92.2)
I do not know ^[1]	3 (0.8)
Question not asked ^[2]	6 (1.6)
Discontinued ^[3]	21 (5.4)
Question 5: Which best describe the type of pharmacy setting you primarily work in? Select one option.	
Face-to-face	349 (90.2)
Face-to-face & online	8 (2.1)
Online only ^[1]	0
Question not asked ^[2]	9 (2.3)

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 1.2 Survey Participant Eligibility Results - Screened Respondents

Question	Pharmacists (N=387) n (%)
<i>Discontinued</i> ^[3]	21 (5.4)

Source: Appendix B: Table 1.2

^[1] Ineligible to participate in the survey.

^[2] Question not asked due to previous question elimination.

^[3] Respondents who discontinued the survey before completing all eligibility questions without being identified as ineligible are counted as discontinued. Once a respondent is counted as discontinued, they will count as discontinued in all subsequent eligibility questions.

Note: The screened respondents consists of all respondents who have accessed the survey using the unique code regardless of whether or not they answered any survey questions. The number of screened respondents are used for the calculation of all percentages in this table.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 2 Description of Survey Participants - Completed Surveys

Question	Pharmacists (N=345) n (%)
Question 6: How many patients do you estimate have requested to purchase Viagra Connect from you in the past 6 months?	
1-2	23 (6.7)
3-5	65 (18.8)
6-10	82 (23.8)
11-20	73 (21.2)
21-30	44 (12.8)
More than 31	58 (16.8)
I don't know	0
Question 7: Of those patients who requested to purchase Viagra Connect from you, what percentage do you estimate were not suitable to be supplied the product?	
Up to than 10%	276 (80.0)
11-50%	37 (10.7)
51-90%	12 (3.5)
More than 90%	9 (2.6)
I don't know	11 (3.2)
Question 8: Which best describes the place of your pharmacy?	
Urban (city, large town or suburban area)	255 (73.9)
Rural (small town, village, countryside)	90 (26.1)
Question 9: What type of pharmacy setting do you primarily work in? Select one option.	
Large multiple pharmacy chain (more than 100 stores)	157 (45.5)
Small multiple pharmacy chain (6 to 99 stores)	61 (17.7)
Independent Pharmacy (1 to 5 stores)	127 (36.8)
Question 10: How long have you been dispensing medications as a pharmacist?	
Less than 2 years	24 (7.0)
2-5 years	39 (11.3)
6-10 years	64 (18.6)
11-20 years	99 (28.7)
Greater than 20 years	119 (34.5)

Table 2 Description of Survey Participants - Completed Surveys

Question	Pharmacists (N=345) n (%)
Question 11: Which best represents your age group:	
22-30 years	68 (19.7)
31-40 years	117 (33.9)
41-60 years	139 (40.3)
More than 61 years	21 (6.1)
Question 12: Which gender are you?	
Male	241 (69.9)
Female	102 (29.6)
Prefer not to answer	2 (0.6)

Source: Appendix B: Table 2

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 3 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect - Completed surveys

Question	Pharmacists (N=345) n (%) [95% CI] ^[1]
Question 13: Please answer True/False/Don't know for the following statements:	
Viagra Connect is only intended for use by men over 45 years of age who are experiencing Erectile Dysfunction (ED).	
True	18 (5.2)
False ^[2]	319 (92.5) [89.2 - 95.0]
Don't know	8 (2.3)
Viagra Connect must not be supplied to men who do not have Erectile Dysfunction (ED).	
True ^[2]	316 (91.6) [88.2 - 94.3]
False	25 (7.2)
Don't know	4 (1.2)
Men currently prescribed 50 mg sildenafil can be supplied Viagra Connect if a) they meet the criteria for pharmacy supply and b) they do not take more than 50 mg daily.	
True ^[2]	309 (89.6) [85.8 - 92.6]
False	28 (8.1)
Don't know	8 (2.3)
Men who are using a different dose of sildenafil or another Erectile Dysfunction (ED) treatment can also be supplied with Viagra Connect.	
True	63 (18.3)
False ^[2]	262 (75.9) [71.1 - 80.4]
Don't know	20 (5.8)
Question 14: The following patients should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.	
Those who have been advised by their doctor that they are not fit enough for physical or sexual activity.	
True ^[2]	341 (98.8) [97.1 - 99.7]
False	3 (0.9)
Don't know	1 (0.3)
B. Those who experience breathlessness or chest pain with light or moderate physical activity (eg walking briskly for 20 mins or climbing two flights of stairs).	
True ^[2]	340 (98.6) [96.7 - 99.5]

Table 3 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect - Completed surveys

Question	Pharmacists (N=345) n (%) [95% CI] ^[1]
False	4 (1.2)
Don't know	1 (0.3)
Those who have had a heart attack or stroke more than 6 months ago.	
True	194 (56.2)
False ^[2]	143 (41.4) [36.2 - 46.8]
Don't know	8 (2.3)
Question 15: A patient with which of the following cardiovascular conditions MAY be supplied with Viagra Connect? Complete Yes/No/Don't know.	
Low blood pressure	
Yes	53 (15.4)
No ^[2]	276 (80.0) [75.4 - 84.1]
Don't know	16 (4.6)
Uncontrolled hypertension	
Yes	7 (2.0)
No ^[2]	330 (95.7) [92.9 - 97.5]
Don't know	8 (2.3)
Controlled hypertension	
Yes ^[2]	296 (85.8) [81.7 - 89.3]
No	42 (12.2)
Don't know	7 (2.0)
Unstable angina	
Yes	4 (1.2)
No ^[2]	333 (96.5) [94.0 - 98.2]
Don't know	8 (2.3)
Arrhythmia	
Yes	38 (11.0)
No ^[2]	283 (82.0) [77.6 - 85.9]
Don't know	24 (7.0)

Table 3 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect - Completed surveys

Question	Pharmacists (N=345) n (%) [95% CI] ^[1]
Valvular heart disease	
Yes	27 (7.8)
No ^[2]	284 (82.3) [77.9 - 86.2]
Don't know	34 (9.9)
Cardiomyopathy	
Yes	17 (4.9)
No ^[2]	298 (86.4) [82.3 - 89.8]
Don't know	30 (8.7)
Left Ventricular outflow obstruction or aortic narrowing	
Yes	8 (2.3)
No ^[2]	292 (84.6) [80.4 - 88.3]
Don't know	45 (13.0)
Severe cardiac failure	
Yes	3 (0.9)
No ^[2]	338 (98.0) [95.9 - 99.2]
Don't know	4 (1.2)
Question 16: Look at the list of drugs below and select whether or not they can be used with Viagra Connect. Complete Yes/No/Don't know.	
Nitrates for chest pain	
Yes	10 (2.9)
No ^[2]	333 (96.5) [94.0 - 98.2]
Don't know	2 (0.6)
Riociguat for lung problems	
Yes	18 (5.2)
No ^[2]	248 (71.9) [66.8 - 76.6]
Don't know	79 (22.9)
Ritonavir for HIV infection	
Yes	26 (7.5)

Table 3 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect - Completed surveys

Question	Pharmacists (N=345) n (%) [95% CI] ^[1]
No ^[2]	290 (84.1) [79.8 - 87.8]
Don't know	29 (8.4)
Omeprazole or other proton pump inhibitors (PPIs)	
Yes ^[2]	321 (93.0) [89.8 - 95.5]
No	16 (4.6)
Don't know	8 (2.3)
CYP3A4 inhibitors (eg, saquinavir, cimetidine, itraconazole, ketoconazole, erythromycin or rifampicin, diltiazem)	
Yes	32 (9.3)
No ^[2]	289 (83.8) [79.4 - 87.5]
Don't know	24 (7.0)
Alpha blockers (eg, alfuzosin, doxazosin or tamsulosin)	
Yes	50 (14.5)
No ^[2]	290 (84.1) [79.8 - 87.8]
Don't know	5 (1.4)
Beta-blockers	
Yes ^[2]	264 (76.5) [71.7 - 80.9]
No	66 (19.1)
Don't know	15 (4.3)
Recreational drugs called “poppers” (eg, amyl nitrite)	
Yes	5 (1.4)
No ^[2]	329 (95.4) [92.6 - 97.3]
Don't know	11 (3.2)
Question 17: Patients with the following concomitant diseases should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.	
Hepatic disease	
True ^[2]	284 (82.3) [77.9 - 86.2]
False	36 (10.4)

Table 3 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect - Completed surveys

Question	Pharmacists (N=345) n (%) [95% CI] ^[1]
Don't know	25 (7.2)
Severe renal impairment	
True ^[2]	291 (84.3) [80.1 - 88.0]
False	36 (10.4)
Don't know	18 (5.2)
Osteoarthritis or other musculoskeletal disorders	
True	23 (6.7)
False ^[2]	310 (89.9) [86.2 - 92.8]
Don't know	12 (3.5)
Loss of vision due to optic nerve damage or inherited eye disease (such as retinitis pigmentosa)	
True ^[2]	296 (85.8) [81.7 - 89.3]
False	30 (8.7)
Don't know	19 (5.5)

Source: Appendix B: Table 3

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 3.1 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by participation in the Viagra Connect pharmacist training - Completed surveys

Question	Participation in the Viagra Connect Pharmacist Training		
	Yes (N=238) n (%) [95% CI] ^[1]	No (N=60) n (%) [95% CI] ^[1]	Don't recall (N=47) n (%) [95% CI] ^[1]
Question 13: Please answer True/False/Don't know for the following statements:			
Viagra Connect is only intended for use by men over 45 years of age who are experiencing Erectile Dysfunction (ED).			
True	8 (3.4)	6 (10.0)	4 (8.5)
False ^[2]	224 (94.1) [90.3-96.7]	53 (88.3) [77.4-95.2]	42 (89.4) [76.9-96.5]
Don't know	6 (2.5)	1 (1.7)	1 (2.1)
Viagra Connect must not be supplied to men who do not have Erectile Dysfunction (ED).			
True ^[2]	216 (90.8) [86.3-94.1]	53 (88.3) [77.4-95.2]	47 (100.0) [92.5-100.0]
False	19 (8.0)	6 (10.0)	0
Don't know	3 (1.3)	1 (1.7)	0
Men currently prescribed 50 mg sildenafil can be supplied Viagra Connect if a) they meet the criteria for pharmacy supply and b) they do not take more than 50 mg daily.			
True ^[2]	212 (89.1) [84.4-92.7]	54 (90.0) [79.5-96.2]	43 (91.5) [79.6-97.6]
False	21 (8.8)	5 (8.3)	2 (4.3)
Don't know	5 (2.1)	1 (1.7)	2 (4.3)
Men who are using a different dose of sildenafil or another Erectile Dysfunction (ED) treatment can also be supplied with Viagra Connect.			
True	47 (19.7)	9 (15.0)	7 (14.9)
False ^[2]	176 (73.9) [67.9-79.4]	50 (83.3) [71.5-91.7]	36 (76.6) [62.0-87.7]
Don't know	15 (6.3)	1 (1.7)	4 (8.5)
Question 14: The following patients should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.			
Those who have been advised by their doctor that they are not fit enough for physical or sexual activity.			
True ^[2]	236 (99.2) [97.0-99.9]	59 (98.3) [91.1-100.0]	46 (97.9) [88.7-99.9]

Table 3.1 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by participation in the Viagra Connect pharmacist training - Completed surveys

Question	Participation in the Viagra Connect Pharmacist Training		
	Yes (N=238) n (%) [95% CI] ^[1]	No (N=60) n (%) [95% CI] ^[1]	Don't recall (N=47) n (%) [95% CI] ^[1]
False	2 (0.8)	1 (1.7)	0
Don't know	0	0	1 (2.1)
B. Those who experience breathlessness or chest pain with light or moderate physical activity (eg walking briskly for 20 mins or climbing two flights of stairs).			
True ^[2]	233 (97.9) [95.2-99.3]	60 (100.0) [94.0-100.0]	47 (100.0) [92.5-100.0]
False	4 (1.7)	0	0
Don't know	1 (0.4)	0	0
Those who have had a heart attack or stroke more than 6 months ago.			
True	128 (53.8)	38 (63.3)	28 (59.6)
False ^[2]	104 (43.7) [37.3-50.3]	22 (36.7) [24.6-50.1]	17 (36.2) [22.7-51.5]
Don't know	6 (2.5)	0	2 (4.3)
Question 15: A patient with which of the following cardiovascular conditions MAY be supplied with Viagra Connect? Complete Yes/No/Don't know.			
Low blood pressure			
Yes	38 (16.0)	11 (18.3)	4 (8.5)
No ^[2]	190 (79.8) [74.2-84.7]	46 (76.7) [64.0-86.6]	40 (85.1) [71.7-93.8]
Don't know	10 (4.2)	3 (5.0)	3 (6.4)
Uncontrolled hypertension			
Yes	6 (2.5)	0	1 (2.1)
No ^[2]	225 (94.5) [90.8-97.1]	59 (98.3) [91.1-100.0]	46 (97.9) [88.7-99.9]
Don't know	7 (2.9)	1 (1.7)	0
Controlled hypertension			
Yes ^[2]	207 (87.0) [82.0-91.0]	52 (86.7) [75.4-94.1]	37 (78.7) [64.3-89.3]
No	26 (10.9)	8 (13.3)	8 (17.0)

Table 3.1 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by participation in the Viagra Connect pharmacist training - Completed surveys

Question	Participation in the Viagra Connect Pharmacist Training		
	Yes (N=238) n (%) [95% CI] ^[1]	No (N=60) n (%) [95% CI] ^[1]	Don't recall (N=47) n (%) [95% CI] ^[1]
Don't know	5 (2.1)	0	2 (4.3)
Unstable angina			
Yes	3 (1.3)	1 (1.7)	0
No ^[2]	230 (96.6) [93.5-98.5]	58 (96.7) [88.5-99.6]	45 (95.7) [85.5-99.5]
Don't know	5 (2.1)	1 (1.7)	2 (4.3)
Arrhythmia			
Yes	27 (11.3)	7 (11.7)	4 (8.5)
No ^[2]	193 (81.1) [75.5-85.9]	50 (83.3) [71.5-91.7]	40 (85.1) [71.7-93.8]
Don't know	18 (7.6)	3 (5.0)	3 (6.4)
Valvular heart disease			
Yes	19 (8.0)	5 (8.3)	3 (6.4)
No ^[2]	195 (81.9) [76.4-86.6]	51 (85.0) [73.4-92.9]	38 (80.9) [66.7-90.9]
Don't know	24 (10.1)	4 (6.7)	6 (12.8)
Cardiomyopathy			
Yes	15 (6.3)	1 (1.7)	1 (2.1)
No ^[2]	204 (85.7) [80.6-89.9]	54 (90.0) [79.5-96.2]	40 (85.1) [71.7-93.8]
Don't know	19 (8.0)	5 (8.3)	6 (12.8)
Left Ventricular outflow obstruction or aortic narrowing			
Yes	6 (2.5)	1 (1.7)	1 (2.1)
No ^[2]	200 (84.0) [78.7-88.4]	53 (88.3) [77.4-95.2]	39 (83.0) [69.2-92.4]
Don't know	32 (13.4)	6 (10.0)	7 (14.9)
Severe cardiac failure			
Yes	3 (1.3)	0	0

Table 3.1 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by participation in the Viagra Connect pharmacist training - Completed surveys

Question	Participation in the Viagra Connect Pharmacist Training		
	Yes (N=238) n (%) [95% CI] ^[1]	No (N=60) n (%) [95% CI] ^[1]	Don't recall (N=47) n (%) [95% CI] ^[1]
No ^[2]	231 (97.1) [94.0-98.8]	60 (100.0) [94.0-100.0]	47 (100.0) [92.5-100.0]
Don't know	4 (1.7)	0	0
Question 16: Look at the list of drugs below and select whether or not they can be used with Viagra Connect. Complete Yes/No/Don't know.			
Nitrates for chest pain			
Yes	6 (2.5)	1 (1.7)	3 (6.4)
No ^[2]	230 (96.6) [93.5-98.5]	59 (98.3) [91.1-100.0]	44 (93.6) [82.5-98.7]
Don't know	2 (0.8)	0	0
Riociguat for lung problems			
Yes	14 (5.9)	3 (5.0)	1 (2.1)
No ^[2]	170 (71.4) [65.2-77.1]	44 (73.3) [60.3-83.9]	34 (72.3) [57.4-84.4]
Don't know	54 (22.7)	13 (21.7)	12 (25.5)
Ritonavir for HIV infection			
Yes	18 (7.6)	5 (8.3)	3 (6.4)
No ^[2]	198 (83.2) [77.8-87.7]	53 (88.3) [77.4-95.2]	39 (83.0) [69.2-92.4]
Don't know	22 (9.2)	2 (3.3)	5 (10.6)
Omeprazole or other proton pump inhibitors (PPIs)			
Yes ^[2]	221 (92.9) [88.8-95.8]	56 (93.3) [83.8-98.2]	44 (93.6) [82.5-98.7]
No	13 (5.5)	3 (5.0)	0
Don't know	4 (1.7)	1 (1.7)	3 (6.4)
CYP3A4 inhibitors (eg, saquinavir, cimetidine, itraconazole, ketoconazole, erythromycin or rifampicin, diltiazem)			
Yes	20 (8.4)	5 (8.3)	7 (14.9)

Table 3.1 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by participation in the Viagra Connect pharmacist training - Completed surveys

Question	Participation in the Viagra Connect Pharmacist Training		
	Yes (N=238) n (%) [95% CI] ^[1]	No (N=60) n (%) [95% CI] ^[1]	Don't recall (N=47) n (%) [95% CI] ^[1]
No ^[2]	201 (84.5) [79.2-88.8]	52 (86.7) [75.4-94.1]	36 (76.6) [62.0-87.7]
Don't know	17 (7.1)	3 (5.0)	4 (8.5)
Alpha blockers (eg, alfuzosin, doxazosin or tamsulosin)			
Yes	33 (13.9)	13 (21.7)	4 (8.5)
No ^[2]	201 (84.5) [79.2-88.8]	47 (78.3) [65.8-87.9]	42 (89.4) [76.9-96.5]
Don't know	4 (1.7)	0	1 (2.1)
Beta-blockers			
Yes ^[2]	186 (78.2) [72.4-83.2]	43 (71.7) [58.6-82.5]	35 (74.5) [59.7-86.1]
No	41 (17.2)	16 (26.7)	9 (19.1)
Don't know	11 (4.6)	1 (1.7)	3 (6.4)
Recreational drugs called “poppers” (eg, amyl nitrite)			
Yes	3 (1.3)	2 (3.3)	0
No ^[2]	229 (96.2) [92.9-98.3]	57 (95.0) [86.1-99.0]	43 (91.5) [79.6-97.6]
Don't know	6 (2.5)	1 (1.7)	4 (8.5)
Question 17: Patients with the following concomitant diseases should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.			
Hepatic disease			
True ^[2]	194 (81.5) [76.0-86.2]	52 (86.7) [75.4-94.1]	38 (80.9) [66.7-90.9]
False	27 (11.3)	3 (5.0)	6 (12.8)
Don't know	17 (7.1)	5 (8.3)	3 (6.4)
Severe renal impairment			
True ^[2]	200 (84.0) [78.7-88.4]	50 (83.3) [71.5-91.7]	41 (87.2) [74.3-95.2]
False	24 (10.1)	8 (13.3)	4 (8.5)

Table 3.1 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by participation in the Viagra Connect pharmacist training - Completed surveys

Question	Participation in the Viagra Connect Pharmacist Training		
	Yes (N=238) n (%) [95% CI] ^[1]	No (N=60) n (%) [95% CI] ^[1]	Don't recall (N=47) n (%) [95% CI] ^[1]
Don't know	14 (5.9)	2 (3.3)	2 (4.3)
Osteoarthritis or other musculoskeletal disorders			
True	14 (5.9)	3 (5.0)	6 (12.8)
False ^[2]	216 (90.8) [86.3-94.1]	55 (91.7) [81.6-97.2]	39 (83.0) [69.2-92.4]
Don't know	8 (3.4)	2 (3.3)	2 (4.3)
Loss of vision due to optic nerve damage or inherited eye disease (such as retinitis pigmentosa)			
True ^[2]	212 (89.1) [84.4-92.7]	48 (80.0) [67.7-89.2]	36 (76.6) [62.0-87.7]
False	18 (7.6)	6 (10.0)	6 (12.8)
Don't know	8 (3.4)	6 (10.0)	5 (10.6)

Source: Appendix B: Table 3.1

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 3.2 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys

Question	Number of Patients Requested to Purchase Viagra Connect in the Last 6 months			
	1-10 (N=170) n (%) [95% CI] ^[1]	11-30 (N=117) n (%) [95% CI] ^[1]	More than 30 (N=58) n (%) [95% CI] ^[1]	I don't know (N=0) n (%) [95% CI] ^[1]
Question 13: Please answer True/False/Don't know for the following statements:				
Viagra Connect is only intended for use by men over 45 years of age who are experiencing Erectile Dysfunction (ED).				
True	7 (4.1)	8 (6.8)	3 (5.2)	0
False ^[2]	159 (93.5) [88.7-96.7]	106 (90.6) [83.8-95.2]	54 (93.1) [83.3-98.1]	0
Don't know	4 (2.4)	3 (2.6)	1 (1.7)	0
Viagra Connect must not be supplied to men who do not have Erectile Dysfunction (ED).				
True ^[2]	160 (94.1) [89.4-97.1]	105 (89.7) [82.8-94.6]	51 (87.9) [76.7-95.0]	0
False	8 (4.7)	11 (9.4)	6 (10.3)	0
Don't know	2 (1.2)	1 (0.9)	1 (1.7)	0
Men currently prescribed 50 mg sildenafil can be supplied Viagra Connect if a) they meet the criteria for pharmacy supply and b) they do not take more than 50 mg daily.				
True ^[2]	149 (87.6) [81.7-92.2]	108 (92.3) [85.9-96.4]	52 (89.7) [78.8-96.1]	0
False	16 (9.4)	6 (5.1)	6 (10.3)	0
Don't know	5 (2.9)	3 (2.6)	0	0
Men who are using a different dose of sildenafil or another Erectile Dysfunction (ED) treatment can also be supplied with Viagra Connect.				
True	21 (12.4)	28 (23.9)	14 (24.1)	0
False ^[2]	141 (82.9) [76.4-88.3]	79 (67.5) [58.2-75.9]	42 (72.4) [59.1-83.3]	0
Don't know	8 (4.7)	10 (8.5)	2 (3.4)	0
Question 14: The following patients should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.				
Those who have been advised by their doctor that they are not fit enough for physical or sexual activity.				

Table 3.2 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys

Question	Number of Patients Requested to Purchase Viagra Connect in the Last 6 months			
	1-10 (N=170) n (%) [95% CI] ^[1]	11-30 (N=117) n (%) [95% CI] ^[1]	More than 30 (N=58) n (%) [95% CI] ^[1]	I don't know (N=0) n (%) [95% CI] ^[1]
True ^[2]	166 (97.6) [94.1-99.4]	117 (100.0) [96.9-100.0]	58 (100.0) [93.8-100.0]	0
False	3 (1.8)	0	0	0
Don't know	1 (0.6)	0	0	0
B. Those who experience breathlessness or chest pain with light or moderate physical activity (eg walking briskly for 20 mins or climbing two flights of stairs).				
True ^[2]	167 (98.2) [94.9-99.6]	116 (99.1) [95.3-100.0]	57 (98.3) [90.8-100.0]	0
False	3 (1.8)	0	1 (1.7)	0
Don't know	0	1 (0.9)	0	0
Those who have had a heart attack or stroke more than 6 months ago.				
True	90 (52.9)	71 (60.7)	33 (56.9)	0
False ^[2]	73 (42.9) [35.4-50.7]	45 (38.5) [29.6-47.9]	25 (43.1) [30.2-56.8]	0
Don't know	7 (4.1)	1 (0.9)	0	0
Question 15: A patient with which of the following cardiovascular conditions MAY be supplied with Viagra Connect? Complete Yes/No/Don't know.				
Low blood pressure				
Yes	22 (12.9)	18 (15.4)	13 (22.4)	0
No ^[2]	136 (80.0) [73.2-85.7]	96 (82.1) [73.9-88.5]	44 (75.9) [62.8-86.1]	0
Don't know	12 (7.1)	3 (2.6)	1 (1.7)	0
Uncontrolled hypertension				
Yes	4 (2.4)	3 (2.6)	0	0
No ^[2]	162 (95.3) [90.9-97.9]	112 (95.7) [90.3-98.6]	56 (96.6) [88.1-99.6]	0
Don't know	4 (2.4)	2 (1.7)	2 (3.4)	0

Table 3.2 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys

Question	Number of Patients Requested to Purchase Viagra Connect in the Last 6 months			
	1-10 (N=170) n (%) [95% CI] ^[1]	11-30 (N=117) n (%) [95% CI] ^[1]	More than 30 (N=58) n (%) [95% CI] ^[1]	I don't know (N=0) n (%) [95% CI] ^[1]
Controlled hypertension				
Yes ^[2]	147 (86.5) [80.4-91.2]	101 (86.3) [78.7-92.0]	48 (82.8) [70.6-91.4]	0
No	21 (12.4)	13 (11.1)	8 (13.8)	0
Don't know	2 (1.2)	3 (2.6)	2 (3.4)	0
Unstable angina				
Yes	3 (1.8)	1 (0.9)	0	0
No ^[2]	165 (97.1) [93.3-99.0]	111 (94.9) [89.2-98.1]	57 (98.3) [90.8-100.0]	0
Don't know	2 (1.2)	5 (4.3)	1 (1.7)	0
Arrhythmia				
Yes	19 (11.2)	12 (10.3)	7 (12.1)	0
No ^[2]	139 (81.8) [75.1-87.3]	99 (84.6) [76.8-90.6]	45 (77.6) [64.7-87.5]	0
Don't know	12 (7.1)	6 (5.1)	6 (10.3)	0
Valvular heart disease				
Yes	13 (7.6)	9 (7.7)	5 (8.6)	0
No ^[2]	138 (81.2) [74.5-86.8]	95 (81.2) [72.9-87.8]	51 (87.9) [76.7-95.0]	0
Don't know	19 (11.2)	13 (11.1)	2 (3.4)	0
Cardiomyopathy				
Yes	7 (4.1)	8 (6.8)	2 (3.4)	0
No ^[2]	145 (85.3) [79.1-90.3]	103 (88.0) [80.7-93.3]	50 (86.2) [74.6-93.9]	0
Don't know	18 (10.6)	6 (5.1)	6 (10.3)	0
Left Ventricular outflow obstruction or aortic narrowing				

Table 3.2 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys

Question	Number of Patients Requested to Purchase Viagra Connect in the Last 6 months			
	1-10 (N=170) n (%) [95% CI] ^[1]	11-30 (N=117) n (%) [95% CI] ^[1]	More than 30 (N=58) n (%) [95% CI] ^[1]	I don't know (N=0) n (%) [95% CI] ^[1]
Yes	4 (2.4)	3 (2.6)	1 (1.7)	0
No ^[2]	141 (82.9) [76.4-88.3]	102 (87.2) [79.7-92.6]	49 (84.5) [72.6-92.7]	0
Don't know	25 (14.7)	12 (10.3)	8 (13.8)	0
Severe cardiac failure				
Yes	3 (1.8)	0	0	0
No ^[2]	165 (97.1) [93.3-99.0]	115 (98.3) [94.0-99.8]	58 (100.0) [93.8-100.0]	0
Don't know	2 (1.2)	2 (1.7)	0	0
Question 16: Look at the list of drugs below and select whether or not they can be used with Viagra Connect. Complete Yes/No/Don't know.				
Nitrates for chest pain				
Yes	3 (1.8)	3 (2.6)	4 (6.9)	0
No ^[2]	166 (97.6) [94.1-99.4]	113 (96.6) [91.5-99.1]	54 (93.1) [83.3-98.1]	0
Don't know	1 (0.6)	1 (0.9)	0	0
Riociguat for lung problems				
Yes	7 (4.1)	7 (6.0)	4 (6.9)	0
No ^[2]	131 (77.1) [70.0-83.1]	76 (65.0) [55.6-73.5]	41 (70.7) [57.3-81.9]	0
Don't know	32 (18.8)	34 (29.1)	13 (22.4)	0
Ritonavir for HIV infection				
Yes	10 (5.9)	13 (11.1)	3 (5.2)	0
No ^[2]	150 (88.2) [82.4-92.7]	90 (76.9) [68.2-84.2]	50 (86.2) [74.6-93.9]	0
Don't know	10 (5.9)	14 (12.0)	5 (8.6)	0

Table 3.2 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys

Question	Number of Patients Requested to Purchase Viagra Connect in the Last 6 months			
	1-10 (N=170) n (%) [95% CI] ^[1]	11-30 (N=117) n (%) [95% CI] ^[1]	More than 30 (N=58) n (%) [95% CI] ^[1]	I don't know (N=0) n (%) [95% CI] ^[1]
Omeprazole or other proton pump inhibitors (PPIs)				
Yes ^[2]	160 (94.1) [89.4-97.1]	109 (93.2) [87.0-97.0]	52 (89.7) [78.8-96.1]	0
No	6 (3.5)	7 (6.0)	3 (5.2)	0
Don't know	4 (2.4)	1 (0.9)	3 (5.2)	0
CYP3A4 inhibitors (eg, saquinavir, cimetidine, itraconazole, ketoconazole, erythromycin or rifampicin, diltiazem)				
Yes	12 (7.1)	15 (12.8)	5 (8.6)	0
No ^[2]	151 (88.8) [83.1-93.1]	87 (74.4) [65.5-82.0]	51 (87.9) [76.7-95.0]	0
Don't know	7 (4.1)	15 (12.8)	2 (3.4)	0
Alpha blockers (eg, alfuzosin, doxazosin or tamsulosin)				
Yes	23 (13.5)	17 (14.5)	10 (17.2)	0
No ^[2]	144 (84.7) [78.4-89.8]	99 (84.6) [76.8-90.6]	47 (81.0) [68.6-90.1]	0
Don't know	3 (1.8)	1 (0.9)	1 (1.7)	0
Beta-blockers				
Yes ^[2]	130 (76.5) [69.4-82.6]	91 (77.8) [69.2-84.9]	43 (74.1) [61.0-84.7]	0
No	33 (19.4)	23 (19.7)	10 (17.2)	0
Don't know	7 (4.1)	3 (2.6)	5 (8.6)	0
Recreational drugs called "poppers" (eg, amyl nitrite)				
Yes	3 (1.8)	1 (0.9)	1 (1.7)	0
No ^[2]	165 (97.1) [93.3-99.0]	109 (93.2) [87.0-97.0]	55 (94.8) [85.6-98.9]	0
Don't know	2 (1.2)	7 (6.0)	2 (3.4)	0

Table 3.2 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys

Question	Number of Patients Requested to Purchase Viagra Connect in the Last 6 months			
	1-10 (N=170) n (%) [95% CI] ^[1]	11-30 (N=117) n (%) [95% CI] ^[1]	More than 30 (N=58) n (%) [95% CI] ^[1]	I don't know (N=0) n (%) [95% CI] ^[1]
Question 17: Patients with the following concomitant diseases should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.				
Hepatic disease				
True ^[2]	135 (79.4) [72.5-85.2]	99 (84.6) [76.8-90.6]	50 (86.2) [74.6-93.9]	0
False	21 (12.4)	9 (7.7)	6 (10.3)	0
Don't know	14 (8.2)	9 (7.7)	2 (3.4)	0
Severe renal impairment				
True ^[2]	140 (82.4) [75.8-87.8]	99 (84.6) [76.8-90.6]	52 (89.7) [78.8-96.1]	0
False	19 (11.2)	14 (12.0)	3 (5.2)	0
Don't know	11 (6.5)	4 (3.4)	3 (5.2)	0
Osteoarthritis or other musculoskeletal disorders				
True	14 (8.2)	4 (3.4)	5 (8.6)	0
False ^[2]	150 (88.2) [82.4-92.7]	108 (92.3) [85.9-96.4]	52 (89.7) [78.8-96.1]	0
Don't know	6 (3.5)	5 (4.3)	1 (1.7)	0
Loss of vision due to optic nerve damage or inherited eye disease (such as retinitis pigmentosa)				
True ^[2]	145 (85.3) [79.1-90.3]	98 (83.8) [75.8-89.9]	53 (91.4) [81.0-97.1]	0
False	14 (8.2)	12 (10.3)	4 (6.9)	0
Don't know	11 (6.5)	7 (6.0)	1 (1.7)	0

Source: Appendix B: Table 3.2

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 3.3 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by place of pharmacy - Completed surveys

Question	Place of Pharmacy	
	Urban (N=255) n (%) [95% CI] ^[1]	Rural (N=90) n (%) [95% CI] ^[1]
Question 13: Please answer True/False/Don't know for the following statements:		
Viagra Connect is only intended for use by men over 45 years of age who are experiencing Erectile Dysfunction (ED).		
True	14 (5.5)	4 (4.4)
False ^[2]	234 (91.8) [87.7-94.8]	85 (94.4) [87.5-98.2]
Don't know	7 (2.7)	1 (1.1)
Viagra Connect must not be supplied to men who do not have Erectile Dysfunction (ED).		
True ^[2]	230 (90.2) [85.9-93.6]	86 (95.6) [89.0-98.8]
False	22 (8.6)	3 (3.3)
Don't know	3 (1.2)	1 (1.1)
Men currently prescribed 50 mg sildenafil can be supplied Viagra Connect if a) they meet the criteria for pharmacy supply and b) they do not take more than 50 mg daily.		
True ^[2]	231 (90.6) [86.3-93.9]	78 (86.7) [77.9-92.9]
False	19 (7.5)	9 (10.0)
Don't know	5 (2.0)	3 (3.3)
Men who are using a different dose of sildenafil or another Erectile Dysfunction (ED) treatment can also be supplied with Viagra Connect.		
True	50 (19.6)	13 (14.4)
False ^[2]	189 (74.1) [68.3-79.4]	73 (81.1) [71.5-88.6]
Don't know	16 (6.3)	4 (4.4)
Question 14: The following patients should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.		
Those who have been advised by their doctor that they are not fit enough for physical or sexual activity.		
True ^[2]	254 (99.6) [97.8-100.0]	87 (96.7) [90.6-99.3]

Table 3.3 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by place of pharmacy - Completed surveys

Question	Place of Pharmacy	
	Urban (N=255) n (%) [95% CI] ^[1]	Rural (N=90) n (%) [95% CI] ^[1]
False	0	3 (3.3)
Don't know	1 (0.4)	0
B. Those who experience breathlessness or chest pain with light or moderate physical activity (eg walking briskly for 20 mins or climbing two flights of stairs).		
True ^[2]	253 (99.2) [97.2-99.9]	87 (96.7) [90.6-99.3]
False	1 (0.4)	3 (3.3)
Don't know	1 (0.4)	0
Those who have had a heart attack or stroke more than 6 months ago.		
True	152 (59.6)	42 (46.7)
False ^[2]	97 (38.0) [32.1-44.3]	46 (51.1) [40.3-61.8]
Don't know	6 (2.4)	2 (2.2)
Question 15: A patient with which of the following cardiovascular conditions MAY be supplied with Viagra Connect? Complete Yes/No/Don't know.		
Low blood pressure		
Yes	39 (15.3)	14 (15.6)
No ^[2]	206 (80.8) [75.4-85.4]	70 (77.8) [67.8-85.9]
Don't know	10 (3.9)	6 (6.7)
Uncontrolled hypertension		
Yes	6 (2.4)	1 (1.1)
No ^[2]	244 (95.7) [92.4-97.8]	86 (95.6) [89.0-98.8]
Don't know	5 (2.0)	3 (3.3)
Controlled hypertension		
Yes ^[2]	217 (85.1) [80.1-89.2]	79 (87.8) [79.2-93.7]
No	33 (12.9)	9 (10.0)

Table 3.3 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by place of pharmacy - Completed surveys

Question	Place of Pharmacy	
	Urban (N=255) n (%) [95% CI] ^[1]	Rural (N=90) n (%) [95% CI] ^[1]
Don't know	5 (2.0)	2 (2.2)
Unstable angina		
Yes	3 (1.2)	1 (1.1)
No ^[2]	246 (96.5) [93.4-98.4]	87 (96.7) [90.6-99.3]
Don't know	6 (2.4)	2 (2.2)
Arrhythmia		
Yes	26 (10.2)	12 (13.3)
No ^[2]	213 (83.5) [78.4-87.9]	70 (77.8) [67.8-85.9]
Don't know	16 (6.3)	8 (8.9)
Valvular heart disease		
Yes	15 (5.9)	12 (13.3)
No ^[2]	215 (84.3) [79.3-88.6]	69 (76.7) [66.6-84.9]
Don't know	25 (9.8)	9 (10.0)
Cardiomyopathy		
Yes	12 (4.7)	5 (5.6)
No ^[2]	223 (87.5) [82.7-91.3]	75 (83.3) [74.0-90.4]
Don't know	20 (7.8)	10 (11.1)
Left Ventricular outflow obstruction or aortic narrowing		
Yes	7 (2.7)	1 (1.1)
No ^[2]	218 (85.5) [80.6-89.6]	74 (82.2) [72.7-89.5]
Don't know	30 (11.8)	15 (16.7)
Severe cardiac failure		
Yes	2 (0.8)	1 (1.1)

Table 3.3 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by place of pharmacy - Completed surveys

Question	Place of Pharmacy	
	Urban (N=255) n (%) [95% CI] ^[1]	Rural (N=90) n (%) [95% CI] ^[1]
No ^[2]	250 (98.0) [95.5-99.4]	88 (97.8) [92.2-99.7]
Don't know	3 (1.2)	1 (1.1)
Question 16: Look at the list of drugs below and select whether or not they can be used with Viagra Connect. Complete Yes/No/Don't know.		
Nitrates for chest pain		
Yes	9 (3.5)	1 (1.1)
No ^[2]	244 (95.7) [92.4-97.8]	89 (98.9) [94.0-100.0]
Don't know	2 (0.8)	0
Riociguat for lung problems		
Yes	12 (4.7)	6 (6.7)
No ^[2]	185 (72.5) [66.6-77.9]	63 (70.0) [59.4-79.2]
Don't know	58 (22.7)	21 (23.3)
Ritonavir for HIV infection		
Yes	19 (7.5)	7 (7.8)
No ^[2]	215 (84.3) [79.3-88.6]	75 (83.3) [74.0-90.4]
Don't know	21 (8.2)	8 (8.9)
Omeprazole or other proton pump inhibitors (PPIs)		
Yes ^[2]	236 (92.5) [88.6-95.5]	85 (94.4) [87.5-98.2]
No	12 (4.7)	4 (4.4)
Don't know	7 (2.7)	1 (1.1)
CYP3A4 inhibitors (eg, saquinavir, cimetidine, itraconazole, ketoconazole, erythromycin or rifampicin, diltiazem)		
Yes	25 (9.8)	7 (7.8)

Table 3.3 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by place of pharmacy - Completed surveys

Question	Place of Pharmacy	
	Urban (N=255) n (%) [95% CI] ^[1]	Rural (N=90) n (%) [95% CI] ^[1]
No ^[2]	211 (82.7) [77.5-87.2]	78 (86.7) [77.9-92.9]
Don't know	19 (7.5)	5 (5.6)
Alpha blockers (eg, alfuzosin, doxazosin or tamsulosin)		
Yes	35 (13.7)	15 (16.7)
No ^[2]	215 (84.3) [79.3-88.6]	75 (83.3) [74.0-90.4]
Don't know	5 (2.0)	0
Beta-blockers		
Yes ^[2]	194 (76.1) [70.4-81.2]	70 (77.8) [67.8-85.9]
No	50 (19.6)	16 (17.8)
Don't know	11 (4.3)	4 (4.4)
Recreational drugs called "poppers" (eg, amyl nitrite)		
Yes	2 (0.8)	3 (3.3)
No ^[2]	244 (95.7) [92.4-97.8]	85 (94.4) [87.5-98.2]
Don't know	9 (3.5)	2 (2.2)
Question 17: Patients with the following concomitant diseases should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.		
Hepatic disease		
True ^[2]	216 (84.7) [79.7-88.9]	68 (75.6) [65.4-84.0]
False	23 (9.0)	13 (14.4)
Don't know	16 (6.3)	9 (10.0)
Severe renal impairment		
True ^[2]	222 (87.1) [82.3-90.9]	69 (76.7) [66.6-84.9]
False	20 (7.8)	16 (17.8)

Table 3.3 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by place of pharmacy - Completed surveys

Question	Place of Pharmacy	
	Urban (N=255) n (%) [95% CI] ^[1]	Rural (N=90) n (%) [95% CI] ^[1]
Don't know	13 (5.1)	5 (5.6)
Osteoarthritis or other musculoskeletal disorders		
True	17 (6.7)	6 (6.7)
False ^[2]	227 (89.0) [84.5-92.6]	83 (92.2) [84.6-96.8]
Don't know	11 (4.3)	1 (1.1)
Loss of vision due to optic nerve damage or inherited eye disease (such as retinitis pigmentosa)		
True ^[2]	220 (86.3) [81.4-90.2]	76 (84.4) [75.3-91.2]
False	22 (8.6)	8 (8.9)
Don't know	13 (5.1)	6 (6.7)

Source: Appendix B: Table 3.3

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 3.4 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by type of pharmacy - Completed surveys

Question	Type of Pharmacy		
	Large Multiple Pharmacy Chain (more than 100 stores) (N=157) n (%) [95% CI] ^[1]	Small Multiple Pharmacy Chain (6 to 99 stores) (N=61) n (%) [95% CI] ^[1]	Independent Pharmacy (1 to 5 stores) (N=127) n (%) [95% CI] ^[1]
Question 13: Please answer True/False/Don't know for the following statements:			
Viagra Connect is only intended for use by men over 45 years of age who are experiencing Erectile Dysfunction (ED).			
True	4 (2.5)	4 (6.6)	10 (7.9)
False ^[2]	152 (96.8) [92.7-99.0]	56 (91.8) [81.9-97.3]	111 (87.4) [80.3-92.6]
Don't know	1 (0.6)	1 (1.6)	6 (4.7)
Viagra Connect must not be supplied to men who do not have Erectile Dysfunction (ED).			
True ^[2]	143 (91.1) [85.5-95.0]	60 (98.4) [91.2-100.0]	113 (89.0) [82.2-93.8]
False	13 (8.3)	1 (1.6)	11 (8.7)
Don't know	1 (0.6)	0	3 (2.4)
Men currently prescribed 50 mg sildenafil can be supplied Viagra Connect if a) they meet the criteria for pharmacy supply and b) they do not take more than 50 mg daily.			
True ^[2]	142 (90.4) [84.7-94.6]	55 (90.2) [79.8-96.3]	112 (88.2) [81.3-93.2]
False	11 (7.0)	5 (8.2)	12 (9.4)
Don't know	4 (2.5)	1 (1.6)	3 (2.4)
Men who are using a different dose of sildenafil or another Erectile Dysfunction (ED) treatment can also be supplied with Viagra Connect.			
True	30 (19.1)	8 (13.1)	25 (19.7)
False ^[2]	118 (75.2) [67.6-81.7]	50 (82.0) [70.0-90.6]	94 (74.0) [65.5-81.4]
Don't know	9 (5.7)	3 (4.9)	8 (6.3)
Question 14: The following patients should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.			
Those who have been advised by their doctor that they are not fit enough for physical or sexual activity.			

Table 3.4 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by type of pharmacy - Completed surveys

Question	Type of Pharmacy		
	Large Multiple Pharmacy Chain (more than 100 stores) (N=157) n (%) [95% CI] ^[1]	Small Multiple Pharmacy Chain (6 to 99 stores) (N=61) n (%) [95% CI] ^[1]	Independent Pharmacy (1 to 5 stores) (N=127) n (%) [95% CI] ^[1]
True ^[2]	155 (98.7) [95.5-99.8]	61 (100.0) [94.1-100.0]	125 (98.4) [94.4-99.8]
False	2 (1.3)	0	1 (0.8)
Don't know	0	0	1 (0.8)
B. Those who experience breathlessness or chest pain with light or moderate physical activity (eg walking briskly for 20 mins or climbing two flights of stairs).			
True ^[2]	156 (99.4) [96.5-100.0]	61 (100.0) [94.1-100.0]	123 (96.9) [92.1-99.1]
False	1 (0.6)	0	3 (2.4)
Don't know	0	0	1 (0.8)
Those who have had a heart attack or stroke more than 6 months ago.			
True	77 (49.0)	35 (57.4)	82 (64.6)
False ^[2]	77 (49.0) [41.0-57.1]	24 (39.3) [27.1-52.7]	42 (33.1) [25.0-42.0]
Don't know	3 (1.9)	2 (3.3)	3 (2.4)
Question 15: A patient with which of the following cardiovascular conditions MAY be supplied with Viagra Connect? Complete Yes/No/Don't know.			
Low blood pressure			
Yes	18 (11.5)	11 (18.0)	24 (18.9)
No ^[2]	131 (88.4) [76.7-88.9]	44 (72.1) [59.2-82.9]	101 (79.5) [71.5-86.2]
Don't know	8 (5.1)	6 (9.8)	2 (1.6)
Uncontrolled hypertension			
Yes	3 (1.9)	0	4 (3.1)
No ^[2]	153 (97.5) [93.6-99.3]	59 (96.7) [88.7-99.6]	118 (92.9) [87.0-96.7]
Don't know	1 (0.6)	2 (3.3)	5 (3.9)

Table 3.4 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by type of pharmacy - Completed surveys

Question	Type of Pharmacy		
	Large Multiple Pharmacy Chain (more than 100 stores) (N=157) n (%) [95% CI] ^[1]	Small Multiple Pharmacy Chain (6 to 99 stores) (N=61) n (%) [95% CI] ^[1]	Independent Pharmacy (1 to 5 stores) (N=127) n (%) [95% CI] ^[1]
Controlled hypertension			
Yes ^[2]	135 (86.0) [79.6-91.0]	55 (90.2) [79.8-96.3]	106 (83.5) [75.8-89.5]
No	16 (10.2)	5 (8.2)	21 (16.5)
Don't know	6 (3.8)	1 (1.6)	0
Unstable angina			
Yes	2 (1.3)	0	2 (1.6)
No ^[2]	151 (96.2) [91.9-98.6]	61 (100.0) [94.1-100.0]	121 (95.3) [90.0-98.2]
Don't know	4 (2.5)	0	4 (3.1)
Arrhythmia			
Yes	18 (11.5)	5 (8.2)	15 (11.8)
No ^[2]	125 (79.6) [72.5-85.6]	54 (88.5) [77.8-95.3]	104 (81.9) [74.1-88.2]
Don't know	14 (8.9)	2 (3.3)	8 (6.3)
Valvular heart disease			
Yes	14 (8.9)	2 (3.3)	11 (8.7)
No ^[2]	127 (80.9) [73.9-86.7]	54 (88.5) [77.8-95.3]	103 (81.1) [73.2-87.5]
Don't know	16 (10.2)	5 (8.2)	13 (10.2)
Cardiomyopathy			
Yes	8 (5.1)	1 (1.6)	8 (6.3)
No ^[2]	135 (86.0) [79.6-91.0]	57 (93.4) [84.1-98.2]	106 (83.5) [75.8-89.5]
Don't know	14 (8.9)	3 (4.9)	13 (10.2)
Left Ventricular outflow obstruction or aortic narrowing			

Table 3.4 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by type of pharmacy - Completed surveys

Question	Type of Pharmacy		
	Large Multiple Pharmacy Chain (more than 100 stores) (N=157) n (%) [95% CI] ^[1]	Small Multiple Pharmacy Chain (6 to 99 stores) (N=61) n (%) [95% CI] ^[1]	Independent Pharmacy (1 to 5 stores) (N=127) n (%) [95% CI] ^[1]
Yes	5 (3.2)	1 (1.6)	2 (1.6)
No ^[2]	133 (84.7) [78.1-90.0]	53 (86.9) [75.8-94.2]	106 (83.5) [75.8-89.5]
Don't know	19 (12.1)	7 (11.5)	19 (15.0)
Severe cardiac failure			
Yes	1 (0.6)	0	2 (1.6)
No ^[2]	153 (97.5) [93.6-99.3]	61 (100.0) [94.1-100.0]	124 (97.6) [93.3-99.5]
Don't know	3 (1.9)	0	1 (0.8)
Question 16: Look at the list of drugs below and select whether or not they can be used with Viagra Connect. Complete Yes/No/Don't know.			
Nitrates for chest pain			
Yes	4 (2.5)	2 (3.3)	4 (3.1)
No ^[2]	152 (96.8) [92.7-99.0]	59 (96.7) [88.7-99.6]	122 (96.1) [91.1-98.7]
Don't know	1 (0.6)	0	1 (0.8)
Riociguat for lung problems			
Yes	7 (4.5)	3 (4.9)	8 (6.3)
No ^[2]	120 (76.4) [69.0-82.8]	44 (72.1) [59.2-82.9]	84 (66.1) [57.2-74.3]
Don't know	30 (19.1)	14 (23.0)	35 (27.6)
Ritonavir for HIV infection			
Yes	10 (6.4)	2 (3.3)	14 (11.0)
No ^[2]	137 (87.3) [81.0-92.0]	53 (86.9) [75.8-94.2]	100 (78.7) [70.6-85.5]
Don't know	10 (6.4)	6 (9.8)	13 (10.2)

Table 3.4 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by type of pharmacy - Completed surveys

Question	Type of Pharmacy		
	Large Multiple Pharmacy Chain (more than 100 stores) (N=157) n (%) [95% CI] ^[1]	Small Multiple Pharmacy Chain (6 to 99 stores) (N=61) n (%) [95% CI] ^[1]	Independent Pharmacy (1 to 5 stores) (N=127) n (%) [95% CI] ^[1]
Omeprazole or other proton pump inhibitors (PPIs)			
Yes ^[2]	141 (89.8) [84.0-94.1]	61 (100.0) [94.1-100.0]	119 (93.7) [88.0-97.2]
No	11 (7.0)	0	5 (3.9)
Don't know	5 (3.2)	0	3 (2.4)
CYP3A4 inhibitors (eg, saquinavir, cimetidine, itraconazole, ketoconazole, erythromycin or rifampicin, diltiazem)			
Yes	12 (7.6)	5 (8.2)	15 (11.8)
No ^[2]	137 (87.3) [81.0-92.0]	49 (80.3) [68.2-89.4]	103 (81.1) [73.2-87.5]
Don't know	8 (5.1)	7 (11.5)	9 (7.1)
Alpha blockers (eg, alfuzosin, doxazosin or tamsulosin)			
Yes	20 (12.7)	11 (18.0)	19 (15.0)
No ^[2]	134 (85.4) [78.8-90.5]	49 (80.3) [68.2-89.4]	107 (84.3) [76.7-90.1]
Don't know	3 (1.9)	1 (1.6)	1 (0.8)
Beta-blockers			
Yes ^[2]	124 (79.0) [71.8-85.1]	54 (88.5) [77.8-95.3]	86 (67.7) [58.8-75.7]
No	27 (17.2)	5 (8.2)	34 (26.8)
Don't know	6 (3.8)	2 (3.3)	7 (5.5)
Recreational drugs called “poppers” (eg, amyl nitrite)			
Yes	1 (0.6)	1 (1.6)	3 (2.4)
No ^[2]	152 (96.8) [92.7-99.0]	58 (95.1) [86.3-99.0]	119 (93.7) [88.0-97.2]
Don't know	4 (2.5)	2 (3.3)	5 (3.9)

Table 3.4 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by type of pharmacy - Completed surveys

Question	Type of Pharmacy		
	Large Multiple Pharmacy Chain (more than 100 stores) (N=157) n (%) [95% CI] ^[1]	Small Multiple Pharmacy Chain (6 to 99 stores) (N=61) n (%) [95% CI] ^[1]	Independent Pharmacy (1 to 5 stores) (N=127) n (%) [95% CI] ^[1]
Question 17: Patients with the following concomitant diseases should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.			
Hepatic disease			
True ^[2]	130 (82.8) [76.0-88.4]	53 (86.9) [75.8-94.2]	101 (79.5) [71.5-86.2]
False	12 (7.6)	6 (9.8)	18 (14.2)
Don't know	15 (9.6)	2 (3.3)	8 (6.3)
Severe renal impairment			
True ^[2]	136 (86.6) [80.3-91.5]	50 (82.0) [70.0-90.6]	105 (82.7) [75.0-88.8]
False	12 (7.6)	8 (13.1)	16 (12.6)
Don't know	9 (5.7)	3 (4.9)	6 (4.7)
Osteoarthritis or other musculoskeletal disorders			
True	9 (5.7)	3 (4.9)	11 (8.7)
False ^[2]	143 (91.1) [85.5-95.0]	56 (91.8) [81.9-97.3]	111 (87.4) [80.3-92.6]
Don't know	5 (3.2)	2 (3.3)	5 (3.9)
Loss of vision due to optic nerve damage or inherited eye disease (such as retinitis pigmentosa)			
True ^[2]	135 (86.0) [79.6-91.0]	58 (95.1) [86.3-99.0]	103 (81.1) [73.2-87.5]
False	11 (7.0)	3 (4.9)	16 (12.6)
Don't know	11 (7.0)	0	8 (6.3)

Source: Appendix B: Table 3.4

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 3.5 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%) [95% CI] ^[1]	2-5 years (N=39) n (%) [95% CI] ^[1]	6-10 years (N=64) n (%) [95% CI] ^[1]	11-20 years (N=99) n (%) [95% CI] ^[1]	Greater than 20 years (N=119) n (%) [95% CI] ^[1]
Question 13: Please answer True/False/Don't know for the following statements:					
Viagra Connect is only intended for use by men over 45 years of age who are experiencing Erectile Dysfunction (ED).					
True	1 (4.2)	1 (2.6)	3 (4.7)	4 (4.0)	9 (7.6)
False ^[2]	23 (95.8) [78.9-99.9]	36 (92.3) [79.1-98.4]	60 (93.8) [84.8-98.3]	93 (93.9) [87.3-97.7]	107 (89.9) [83.0-94.7]
Don't know	0	2 (5.1)	1 (1.6)	2 (2.0)	3 (2.5)
Viagra Connect must not be supplied to men who do not have Erectile Dysfunction (ED).					
True ^[2]	23 (95.8) [78.9-99.9]	34 (87.2) [72.6-95.7]	59 (92.2) [82.7-97.4]	90 (90.9) [83.4-95.8]	110 (92.4) [86.1-96.5]
False	1 (4.2)	4 (10.3)	4 (6.3)	7 (7.1)	9 (7.6)
Don't know	0	1 (2.6)	1 (1.6)	2 (2.0)	0
Men currently prescribed 50 mg sildenafil can be supplied Viagra Connect if a) they meet the criteria for pharmacy supply and b) they do not take more than 50 mg daily.					
True ^[2]	23 (95.8) [78.9-99.9]	34 (87.2) [72.6-95.7]	55 (85.9) [75.0-93.4]	90 (90.9) [83.4-95.8]	107 (89.9) [83.0-94.7]
False	1 (4.2)	4 (10.3)	6 (9.4)	9 (9.1)	8 (6.7)
Don't know	0	1 (2.6)	3 (4.7)	0	4 (3.4)

Table 3.5 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%) [95% CI] ^[1]	2-5 years (N=39) n (%) [95% CI] ^[1]	6-10 years (N=64) n (%) [95% CI] ^[1]	11-20 years (N=99) n (%) [95% CI] ^[1]	Greater than 20 years (N=119) n (%) [95% CI] ^[1]
Men who are using a different dose of sildenafil or another Erectile Dysfunction (ED) treatment can also be supplied with Viagra Connect.					
True	2 (8.3)	4 (10.3)	11 (17.2)	22 (22.2)	24 (20.2)
False ^[2]	20 (83.3) [62.6-95.3]	33 (84.6) [69.5-94.1]	49 (76.6) [64.3-86.2]	70 (70.7) [60.7-79.4]	90 (75.6) [66.9-83.0]
Don't know	2 (8.3)	2 (5.1)	4 (6.3)	7 (7.1)	5 (4.2)
Question 14: The following patients should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.					
Those who have been advised by their doctor that they are not fit enough for physical or sexual activity.					
True ^[2]	24 (100.0) [85.8-100.0]	37 (94.9) [82.7-99.4]	64 (100.0) [94.4-100.0]	97 (98.0) [92.9-99.8]	119 (100.0) [96.9-100.0]
False	0	1 (2.6)	0	2 (2.0)	0
Don't know	0	1 (2.6)	0	0	0
B. Those who experience breathlessness or chest pain with light or moderate physical activity (eg walking briskly for 20 mins or climbing two flights of stairs).					
True ^[2]	24 (100.0) [85.8-100.0]	39 (100.0) [91.0-100.0]	63 (98.4) [91.6-100.0]	97 (98.0) [92.9-99.8]	117 (98.3) [94.1-99.8]
False	0	0	1 (1.6)	1 (1.0)	2 (1.7)

Table 3.5 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%) [95% CI] ^[1]	2-5 years (N=39) n (%) [95% CI] ^[1]	6-10 years (N=64) n (%) [95% CI] ^[1]	11-20 years (N=99) n (%) [95% CI] ^[1]	Greater than 20 years (N=119) n (%) [95% CI] ^[1]
Don't know	0	0	0	1 (1.0)	0
Those who have had a heart attack or stroke more than 6 months ago.					
True	17 (70.8)	23 (59.0)	32 (50.0)	54 (54.5)	68 (57.1)
False ^[2]	7 (29.2) [12.6-51.1]	14 (35.9) [21.2-52.8]	30 (46.9) [34.3-59.8]	43 (43.4) [33.5-53.8]	49 (41.2) [32.2-50.6]
Don't know	0	2 (5.1)	2 (3.1)	2 (2.0)	2 (1.7)
Question 15: A patient with which of the following cardiovascular conditions MAY be supplied with Viagra Connect? Complete Yes/No/Don't know.					
Low blood pressure					
Yes	2 (8.3)	4 (10.3)	9 (14.1)	14 (14.1)	24 (20.2)
No ^[2]	21 (87.5) [67.6-97.3]	33 (84.6) [69.5-94.1]	50 (78.1) [66.0-87.5]	81 (81.8) [72.8-88.9]	91 (76.5) [67.8-83.8]
Don't know	1 (4.2)	2 (5.1)	5 (7.8)	4 (4.0)	4 (3.4)
Uncontrolled hypertension					
Yes	0	0	2 (3.1)	3 (3.0)	2 (1.7)
No ^[2]	23 (95.8) [78.9-99.9]	39 (100.0) [91.0-100.0]	61 (95.3) [86.9-99.0]	91 (91.9) [84.7-96.4]	116 (97.5) [92.8-99.5]

Table 3.5 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%) [95% CI] ^[1]	2-5 years (N=39) n (%) [95% CI] ^[1]	6-10 years (N=64) n (%) [95% CI] ^[1]	11-20 years (N=99) n (%) [95% CI] ^[1]	Greater than 20 years (N=119) n (%) [95% CI] ^[1]
Don't know	1 (4.2)	0	1 (1.6)	5 (5.1)	1 (0.8)
Controlled hypertension					
Yes ^[2]	21 (87.5) [67.6-97.3]	31 (79.5) [63.5-90.7]	54 (84.4) [73.1-92.2]	87 (87.9) [79.8-93.6]	103 (86.6) [79.1-92.1]
No	3 (12.5)	7 (17.9)	9 (14.1)	10 (10.1)	13 (10.9)
Don't know	0	1 (2.6)	1 (1.6)	2 (2.0)	3 (2.5)
Unstable angina					
Yes	0	0	2 (3.1)	2 (2.0)	0
No ^[2]	23 (95.8) [78.9-99.9]	38 (97.4) [86.5-99.9]	61 (95.3) [86.9-99.0]	94 (94.9) [88.6-98.3]	117 (98.3) [94.1-99.8]
Don't know	1 (4.2)	1 (2.6)	1 (1.6)	3 (3.0)	2 (1.7)
Arrhythmia					
Yes	2 (8.3)	1 (2.6)	6 (9.4)	14 (14.1)	15 (12.6)
No ^[2]	20 (83.3) [62.6-95.3]	35 (89.7) [75.8-97.1]	55 (85.9) [75.0-93.4]	74 (74.7) [65.0-82.9]	99 (83.2) [75.2-89.4]
Don't know	2 (8.3)	3 (7.7)	3 (4.7)	11 (11.1)	5 (4.2)
Valvular heart disease					

Table 3.5 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%) [95% CI] ^[1]	2-5 years (N=39) n (%) [95% CI] ^[1]	6-10 years (N=64) n (%) [95% CI] ^[1]	11-20 years (N=99) n (%) [95% CI] ^[1]	Greater than 20 years (N=119) n (%) [95% CI] ^[1]
Yes	2 (8.3)	1 (2.6)	4 (6.3)	9 (9.1)	11 (9.2)
No ^[2]	19 (79.2) [57.8-92.9]	30 (76.9) [60.7-88.9]	56 (87.5) [76.8-94.4]	83 (83.8) [75.1-90.5]	96 (80.7) [72.4-87.3]
Don't know	3 (12.5)	8 (20.5)	4 (6.3)	7 (7.1)	12 (10.1)
Cardiomyopathy					
Yes	0	1 (2.6)	4 (6.3)	7 (7.1)	5 (4.2)
No ^[2]	22 (91.7) [73.0-99.0]	32 (82.1) [66.5-92.5]	54 (84.4) [73.1-92.2]	83 (83.8) [75.1-90.5]	107 (89.9) [83.0-94.7]
Don't know	2 (8.3)	6 (15.4)	6 (9.4)	9 (9.1)	7 (5.9)
Left Ventricular outflow obstruction or aortic narrowing					
Yes	0	1 (2.6)	2 (3.1)	3 (3.0)	2 (1.7)
No ^[2]	21 (87.5) [67.6-97.3]	30 (76.9) [60.7-88.9]	54 (84.4) [73.1-92.2]	83 (83.8) [75.1-90.5]	104 (87.4) [80.1-92.8]
Don't know	3 (12.5)	8 (20.5)	8 (12.5)	13 (13.1)	13 (10.9)
Severe cardiac failure					
Yes	0	1 (2.6)	2 (3.1)	0	0

Table 3.5 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%) [95% CI] ^[1]	2-5 years (N=39) n (%) [95% CI] ^[1]	6-10 years (N=64) n (%) [95% CI] ^[1]	11-20 years (N=99) n (%) [95% CI] ^[1]	Greater than 20 years (N=119) n (%) [95% CI] ^[1]
No ^[2]	24 (100.0) [85.8-100.0]	37 (94.9) [82.7-99.4]	61 (95.3) [86.9-99.0]	97 (98.0) [92.9-99.8]	119 (100.0) [96.9-100.0]
Don't know	0	1 (2.6)	1 (1.6)	2 (2.0)	0
Question 16: Look at the list of drugs below and select whether or not they can be used with Viagra Connect. Complete Yes/No/Don't know.					
Nitrates for chest pain					
Yes	0	0	3 (4.7)	3 (3.0)	4 (3.4)
No ^[2]	24 (100.0) [85.8-100.0]	39 (100.0) [91.0-100.0]	60 (93.8) [84.8-98.3]	96 (97.0) [91.4-99.4]	114 (95.8) [90.5-98.6]
Don't know	0	0	1 (1.6)	0	1 (0.8)
Riociguat for lung problems					
Yes	1 (4.2)	2 (5.1)	3 (4.7)	9 (9.1)	3 (2.5)
No ^[2]	19 (79.2) [57.8-92.9]	25 (64.1) [47.2-78.8]	54 (84.4) [73.1-92.2]	66 (66.7) [56.5-75.8]	84 (70.6) [61.5-78.6]
Don't know	4 (16.7)	12 (30.8)	7 (10.9)	24 (24.2)	32 (26.9)
Ritonavir for HIV infection					
Yes	0	4 (10.3)	5 (7.8)	6 (6.1)	11 (9.2)

Table 3.5 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%) [95% CI] ^[1]	2-5 years (N=39) n (%) [95% CI] ^[1]	6-10 years (N=64) n (%) [95% CI] ^[1]	11-20 years (N=99) n (%) [95% CI] ^[1]	Greater than 20 years (N=119) n (%) [95% CI] ^[1]
No ^[2]	23 (95.8) [78.9-99.9]	34 (87.2) [72.6-95.7]	57 (89.1) [78.8-95.5]	79 (79.8) [70.5-87.2]	97 (81.5) [73.4-88.0]
Don't know	1 (4.2)	1 (2.6)	2 (3.1)	14 (14.1)	11 (9.2)
Omeprazole or other proton pump inhibitors (PPIs)					
Yes ^[2]	20 (83.3) [62.6-95.3]	36 (92.3) [79.1-98.4]	60 (93.8) [84.8-98.3]	96 (97.0) [91.4-99.4]	109 (91.6) [85.1-95.9]
No	1 (4.2)	2 (5.1)	3 (4.7)	2 (2.0)	8 (6.7)
Don't know	3 (12.5)	1 (2.6)	1 (1.6)	1 (1.0)	2 (1.7)
CYP3A4 inhibitors (eg, saquinavir, cimetidine, itraconazole, ketoconazole, erythromycin or rifampicin, diltiazem)					
Yes	4 (16.7)	4 (10.3)	4 (6.3)	10 (10.1)	10 (8.4)
No ^[2]	18 (75.0) [53.3-90.2]	31 (79.5) [63.5-90.7]	56 (87.5) [76.8-94.4]	82 (82.8) [73.9-89.7]	102 (85.7) [78.1-91.5]
Don't know	2 (8.3)	4 (10.3)	4 (6.3)	7 (7.1)	7 (5.9)
Alpha blockers (eg, alfuzosin, doxazosin or tamsulosin)					
Yes	5 (20.8)	4 (10.3)	11 (17.2)	12 (12.1)	18 (15.1)
No ^[2]	19 (79.2) [57.8-92.9]	35 (89.7) [75.8-97.1]	52 (81.3) [69.5-89.9]	85 (85.9) [77.4-92.0]	99 (83.2) [75.2-89.4]

Table 3.5 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%) [95% CI] ^[1]	2-5 years (N=39) n (%) [95% CI] ^[1]	6-10 years (N=64) n (%) [95% CI] ^[1]	11-20 years (N=99) n (%) [95% CI] ^[1]	Greater than 20 years (N=119) n (%) [95% CI] ^[1]
Don't know	0	0	1 (1.6)	2 (2.0)	2 (1.7)
Beta-blockers					
Yes ^[2]	20 (83.3) [62.6-95.3]	30 (76.9) [60.7-88.9]	51 (79.7) [67.8-88.7]	76 (76.8) [67.2-84.7]	87 (73.1) [64.2-80.8]
No	3 (12.5)	8 (20.5)	7 (10.9)	20 (20.2)	28 (23.5)
Don't know	1 (4.2)	1 (2.6)	6 (9.4)	3 (3.0)	4 (3.4)
Recreational drugs called “poppers” (eg, amyl nitrite)					
Yes	0	0	1 (1.6)	2 (2.0)	2 (1.7)
No ^[2]	23 (95.8) [78.9-99.9]	38 (97.4) [86.5-99.9]	61 (95.3) [86.9-99.0]	94 (94.9) [88.6-98.3]	113 (95.0) [89.3-98.1]
Don't know	1 (4.2)	1 (2.6)	2 (3.1)	3 (3.0)	4 (3.4)
Question 17: Patients with the following concomitant diseases should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.					
Hepatic disease					
True ^[2]	17 (70.8) [48.9-87.4]	30 (76.9) [60.7-88.9]	59 (92.2) [82.7-97.4]	80 (80.8) [71.7-88.0]	98 (82.4) [74.3-88.7]
False	2 (8.3)	6 (15.4)	4 (6.3)	12 (12.1)	12 (10.1)

Table 3.5 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%) [95% CI] ^[1]	2-5 years (N=39) n (%) [95% CI] ^[1]	6-10 years (N=64) n (%) [95% CI] ^[1]	11-20 years (N=99) n (%) [95% CI] ^[1]	Greater than 20 years (N=119) n (%) [95% CI] ^[1]
Don't know	5 (20.8)	3 (7.7)	1 (1.6)	7 (7.1)	9 (7.6)
Severe renal impairment					
True ^[2]	18 (75.0) [53.3-90.2]	35 (89.7) [75.8-97.1]	56 (87.5) [76.8-94.4]	81 (81.8) [72.8-88.9]	101 (84.9) [77.2-90.8]
False	3 (12.5)	3 (7.7)	7 (10.9)	13 (13.1)	10 (8.4)
Don't know	3 (12.5)	1 (2.6)	1 (1.6)	5 (5.1)	8 (6.7)
Osteoarthritis or other musculoskeletal disorders					
True	1 (4.2)	3 (7.7)	5 (7.8)	6 (6.1)	8 (6.7)
False ^[2]	21 (87.5) [67.6-97.3]	36 (92.3) [79.1-98.4]	56 (87.5) [76.8-94.4]	92 (92.9) [86.0-97.1]	105 (88.2) [81.0-93.4]
Don't know	2 (8.3)	0	3 (4.7)	1 (1.0)	6 (5.0)
Loss of vision due to optic nerve damage or inherited eye disease (such as retinitis pigmentosa)					
True ^[2]	20 (83.3) [62.6-95.3]	33 (84.6) [69.5-94.1]	58 (90.6) [80.7-96.5]	85 (85.9) [77.4-92.0]	100 (84.0) [76.2-90.1]
False	2 (8.3)	3 (7.7)	4 (6.3)	9 (9.1)	12 (10.1)

Table 3.5 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%) [95% CI] ^[1]	2-5 years (N=39) n (%) [95% CI] ^[1]	6-10 years (N=64) n (%) [95% CI] ^[1]	11-20 years (N=99) n (%) [95% CI] ^[1]	Greater than 20 years (N=119) n (%) [95% CI] ^[1]
Don't know	2 (8.3)	3 (7.7)	2 (3.1)	5 (5.1)	7 (5.9)

Source: Appendix B: Table 3.5

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 3.6 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by age group - Completed surveys

Question	Age Group			
	22-30 years (N=68) n (%) [95% CI] ^[1]	31-40 years (N=117) n (%) [95% CI] ^[1]	41-60 years (N=139) n (%) [95% CI] ^[1]	Greater than 61 years (N=21) n (%) [95% CI] ^[1]
Question 13: Please answer True/False/Don't know for the following statements:				
Viagra Connect is only intended for use by men over 45 years of age who are experiencing Erectile Dysfunction (ED).				
True	2 (2.9)	5 (4.3)	11 (7.9)	0
False ^[2]	63 (92.6) [83.7-97.6]	111 (94.9) [89.2-98.1]	124 (89.2) [82.8-93.8]	21 (100.0) [83.9-100.0]
Don't know	3 (4.4)	1 (0.9)	4 (2.9)	0
Viagra Connect must not be supplied to men who do not have Erectile Dysfunction (ED).				
True ^[2]	63 (92.6) [83.7-97.6]	108 (92.3) [85.9-96.4]	129 (92.8) [87.2-96.5]	16 (76.2) [52.8-91.8]
False	5 (7.4)	6 (5.1)	9 (6.5)	5 (23.8)
Don't know	0	3 (2.6)	1 (0.7)	0
Men currently prescribed 50 mg sildenafil can be supplied Viagra Connect if a) they meet the criteria for pharmacy supply and b) they do not take more than 50 mg daily.				
True ^[2]	63 (92.6) [83.7-97.6]	105 (89.7) [82.8-94.6]	123 (88.5) [82.0-93.3]	18 (85.7) [63.7-97.0]
False	4 (5.9)	9 (7.7)	13 (9.4)	2 (9.5)
Don't know	1 (1.5)	3 (2.6)	3 (2.2)	1 (4.8)
Men who are using a different dose of sildenafil or another Erectile Dysfunction (ED) treatment can also be supplied with Viagra Connect.				
True	4 (5.9)	24 (20.5)	29 (20.9)	6 (28.6)
False ^[2]	58 (85.3) [74.6-92.7]	85 (72.6) [63.6-80.5]	105 (75.5) [67.5-82.4]	14 (66.7) [43.0-85.4]
Don't know	6 (8.8)	8 (6.8)	5 (3.6)	1 (4.8)
Question 14: The following patients should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.				
Those who have been advised by their doctor that they are not fit enough for physical or sexual activity.				

Table 3.6 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by age group - Completed surveys

Question	Age Group			
	22-30 years (N=68) n (%) [95% CI] ^[1]	31-40 years (N=117) n (%) [95% CI] ^[1]	41-60 years (N=139) n (%) [95% CI] ^[1]	Greater than 61 years (N=21) n (%) [95% CI] ^[1]
True ^[2]	67 (98.5) [92.1-100.0]	114 (97.4) [92.7-99.5]	139 (100.0) [97.4-100.0]	21 (100.0) [83.9-100.0]
False	1 (1.5)	2 (1.7)	0	0
Don't know	0	1 (0.9)	0	0
B. Those who experience breathlessness or chest pain with light or moderate physical activity (eg walking briskly for 20 mins or climbing two flights of stairs).				
True ^[2]	68 (100.0) [94.7-100.0]	115 (98.3) [94.0-99.8]	136 (97.8) [93.8-99.6]	21 (100.0) [83.9-100.0]
False	0	2 (1.7)	2 (1.4)	0
Don't know	0	0	1 (0.7)	0
Those who have had a heart attack or stroke more than 6 months ago.				
True	37 (54.4)	61 (52.1)	82 (59.0)	14 (66.7)
False ^[2]	29 (42.6) [30.7-55.2]	52 (44.4) [35.3-53.9]	55 (39.6) [31.4-48.2]	7 (33.3) [14.6-57.0]
Don't know	2 (2.9)	4 (3.4)	2 (1.4)	0
Question 15: A patient with which of the following cardiovascular conditions MAY be supplied with Viagra Connect? Complete Yes/No/Don't know.				
Low blood pressure				
Yes	5 (7.4)	17 (14.5)	24 (17.3)	7 (33.3)
No ^[2]	57 (83.8) [72.9-91.6]	95 (81.2) [72.9-87.8]	111 (79.9) [72.2-86.2]	13 (61.9) [38.4-81.9]
Don't know	6 (8.8)	5 (4.3)	4 (2.9)	1 (4.8)
Uncontrolled hypertension				
Yes	0	3 (2.6)	3 (2.2)	1 (4.8)
No ^[2]	67 (98.5) [92.1-100.0]	110 (94.0) [88.1-97.6]	133 (95.7) [90.8-98.4]	20 (95.2) [76.2-99.9]
Don't know	1 (1.5)	4 (3.4)	3 (2.2)	0

Table 3.6 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by age group - Completed surveys

Question	Age Group			
	22-30 years (N=68) n (%) [95% CI] ^[1]	31-40 years (N=117) n (%) [95% CI] ^[1]	41-60 years (N=139) n (%) [95% CI] ^[1]	Greater than 61 years (N=21) n (%) [95% CI] ^[1]
Controlled hypertension				
Yes ^[2]	60 (88.2) [78.1-94.8]	99 (84.6) [76.8-90.6]	122 (87.8) [81.1-92.7]	15 (71.4) [47.8-88.7]
No	8 (11.8)	15 (12.8)	14 (10.1)	5 (23.8)
Don't know	0	3 (2.6)	3 (2.2)	1 (4.8)
Unstable angina				
Yes	0	3 (2.6)	1 (0.7)	0
No ^[2]	65 (95.6) [87.6-99.1]	113 (96.6) [91.5-99.1]	134 (96.4) [91.8-98.8]	21 (100.0) [83.9-100.0]
Don't know	3 (4.4)	1 (0.9)	4 (2.9)	0
Arrhythmia				
Yes	4 (5.9)	11 (9.4)	22 (15.8)	1 (4.8)
No ^[2]	59 (86.8) [76.4-93.8]	95 (81.2) [72.9-87.8]	109 (78.4) [70.6-84.9]	20 (95.2) [76.2-99.9]
Don't know	5 (7.4)	11 (9.4)	8 (5.8)	0
Valvular heart disease				
Yes	4 (5.9)	8 (6.8)	14 (10.1)	1 (4.8)
No ^[2]	52 (76.5) [64.6-85.9]	101 (86.3) [78.7-92.0]	114 (82.0) [74.6-88.0]	17 (81.0) [58.1-94.6]
Don't know	12 (17.6)	8 (6.8)	11 (7.9)	3 (14.3)
Cardiomyopathy				
Yes	2 (2.9)	6 (5.1)	8 (5.8)	1 (4.8)
No ^[2]	58 (85.3) [74.6-92.7]	99 (84.6) [76.8-90.6]	123 (88.5) [82.0-93.3]	18 (85.7) [63.7-97.0]
Don't know	8 (11.8)	12 (10.3)	8 (5.8)	2 (9.5)
Left Ventricular outflow obstruction or aortic narrowing				
Yes	1 (1.5)	3 (2.6)	4 (2.9)	0

Table 3.6 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by age group - Completed surveys

Question	Age Group			
	22-30 years (N=68) n (%) [95% CI] ^[1]	31-40 years (N=117) n (%) [95% CI] ^[1]	41-60 years (N=139) n (%) [95% CI] ^[1]	Greater than 61 years (N=21) n (%) [95% CI] ^[1]
No ^[2]	56 (82.4) [71.2-90.5]	98 (83.8) [75.8-89.9]	120 (86.3) [79.5-91.6]	18 (85.7) [63.7-97.0]
Don't know	11 (16.2)	16 (13.7)	15 (10.8)	3 (14.3)
Severe cardiac failure				
Yes	1 (1.5)	2 (1.7)	0	0
No ^[2]	65 (95.6) [87.6-99.1]	114 (97.4) [92.7-99.5]	138 (99.3) [96.1-100.0]	21 (100.0) [83.9-100.0]
Don't know	2 (2.9)	1 (0.9)	1 (0.7)	0
Question 16: Look at the list of drugs below and select whether or not they can be used with Viagra Connect. Complete Yes/No/Don't know.				
Nitrates for chest pain				
Yes	1 (1.5)	4 (3.4)	4 (2.9)	1 (4.8)
No ^[2]	66 (97.1) [89.8-99.6]	113 (96.6) [91.5-99.1]	134 (96.4) [91.8-98.8]	20 (95.2) [76.2-99.9]
Don't know	1 (1.5)	0	1 (0.7)	0
Riociguat for lung problems				
Yes	3 (4.4)	9 (7.7)	5 (3.6)	1 (4.8)
No ^[2]	50 (73.5) [61.4-83.5]	86 (73.5) [64.5-81.2]	97 (69.8) [61.4-77.3]	15 (71.4) [47.8-88.7]
Don't know	15 (22.1)	22 (18.8)	37 (26.6)	5 (23.8)
Ritonavir for HIV infection				
Yes	4 (5.9)	9 (7.7)	12 (8.6)	1 (4.8)
No ^[2]	61 (89.7) [79.9-95.8]	98 (83.8) [75.8-89.9]	114 (82.0) [74.6-88.0]	17 (81.0) [58.1-94.6]
Don't know	3 (4.4)	10 (8.5)	13 (9.4)	3 (14.3)
Omeprazole or other proton pump inhibitors (PPIs)				

Table 3.6 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by age group - Completed surveys

Question	Age Group			
	22-30 years (N=68) n (%) [95% CI] ^[1]	31-40 years (N=117) n (%) [95% CI] ^[1]	41-60 years (N=139) n (%) [95% CI] ^[1]	Greater than 61 years (N=21) n (%) [95% CI] ^[1]
Yes ^[2]	62 (91.2) [81.8-96.7]	111 (94.9) [89.2-98.1]	130 (93.5) [88.1-97.0]	18 (85.7) [63.7-97.0]
No	2 (2.9)	5 (4.3)	8 (5.8)	1 (4.8)
Don't know	4 (5.9)	1 (0.9)	1 (0.7)	2 (9.5)
CYP3A4 inhibitors (eg, saquinavir, cimetidine, itraconazole, ketoconazole, erythromycin or rifampicin, diltiazem)				
Yes	9 (13.2)	11 (9.4)	10 (7.2)	2 (9.5)
No ^[2]	52 (76.5) [64.6-85.9]	99 (84.6) [76.8-90.6]	122 (87.8) [81.1-92.7]	16 (76.2) [52.8-91.8]
Don't know	7 (10.3)	7 (6.0)	7 (5.0)	3 (14.3)
Alpha blockers (eg, alfuzosin, doxazosin or tamsulosin)				
Yes	10 (14.7)	18 (15.4)	19 (13.7)	3 (14.3)
No ^[2]	57 (83.8) [72.9-91.6]	97 (82.9) [74.8-89.2]	119 (85.6) [78.7-91.0]	17 (81.0) [58.1-94.6]
Don't know	1 (1.5)	2 (1.7)	1 (0.7)	1 (4.8)
Beta-blockers				
Yes ^[2]	55 (80.9) [69.5-89.4]	91 (77.8) [69.2-84.9]	108 (77.7) [69.9-84.3]	10 (47.6) [25.7-70.2]
No	11 (16.2)	19 (16.2)	27 (19.4)	9 (42.9)
Don't know	2 (2.9)	7 (6.0)	4 (2.9)	2 (9.5)
Recreational drugs called “poppers” (eg, amyl nitrite)				
Yes	0	2 (1.7)	3 (2.2)	0
No ^[2]	65 (95.6) [87.6-99.1]	112 (95.7) [90.3-98.6]	132 (95.0) [89.9-98.0]	20 (95.2) [76.2-99.9]
Don't know	3 (4.4)	3 (2.6)	4 (2.9)	1 (4.8)
Question 17: Patients with the following concomitant diseases should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.				

Table 3.6 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by age group - Completed surveys

Question	Age Group			
	22-30 years (N=68) n (%) [95% CI] ^[1]	31-40 years (N=117) n (%) [95% CI] ^[1]	41-60 years (N=139) n (%) [95% CI] ^[1]	Greater than 61 years (N=21) n (%) [95% CI] ^[1]
Hepatic disease				
True ^[2]	52 (76.5) [64.6-85.9]	101 (86.3) [78.7-92.0]	115 (82.7) [75.4-88.6]	16 (76.2) [52.8-91.8]
False	9 (13.2)	9 (7.7)	16 (11.5)	2 (9.5)
Don't know	7 (10.3)	7 (6.0)	8 (5.8)	3 (14.3)
Severe renal impairment				
True ^[2]	58 (85.3) [74.6-92.7]	98 (83.8) [75.8-89.9]	116 (83.5) [76.2-89.2]	19 (90.5) [69.6-98.8]
False	6 (8.8)	14 (12.0)	15 (10.8)	1 (4.8)
Don't know	4 (5.9)	5 (4.3)	8 (5.8)	1 (4.8)
Osteoarthritis or other musculoskeletal disorders				
True	4 (5.9)	5 (4.3)	14 (10.1)	0
False ^[2]	62 (91.2) [81.8-96.7]	108 (92.3) [85.9-96.4]	124 (89.2) [82.8-93.8]	16 (76.2) [52.8-91.8]
Don't know	2 (2.9)	4 (3.4)	1 (0.7)	5 (23.8)
Loss of vision due to optic nerve damage or inherited eye disease (such as retinitis pigmentosa)				
True ^[2]	59 (86.8) [76.4-93.8]	103 (88.0) [80.7-93.3]	118 (84.9) [77.8-90.4]	16 (76.2) [52.8-91.8]
False	5 (7.4)	9 (7.7)	12 (8.6)	4 (19.0)
Don't know	4 (5.9)	5 (4.3)	9 (6.5)	1 (4.8)

Source: Appendix B: Table 3.6

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 3.7 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by gender - Completed surveys

Question	Gender		
	Male (N=241) n (%) [95% CI] ^[1]	Female (N=102) n (%) [95% CI] ^[1]	Prefer not to answer (N=2) n (%) [95% CI] ^[1]
Question 13: Please answer True/False/Don't know for the following statements:			
Viagra Connect is only intended for use by men over 45 years of age who are experiencing Erectile Dysfunction (ED).			
True	11 (4.6)	7 (6.9)	0
False ^[2]	224 (92.9) [88.9-95.8]	93 (91.2) [83.9-95.9]	2 (100.0) [15.8-100.0]
Don't know	6 (2.5)	2 (2.0)	0
Viagra Connect must not be supplied to men who do not have Erectile Dysfunction (ED).			
True ^[2]	220 (91.3) [87.0-94.5]	94 (92.2) [85.1-96.6]	2 (100.0) [15.8-100.0]
False	18 (7.5)	7 (6.9)	0
Don't know	3 (1.2)	1 (1.0)	0
Men currently prescribed 50 mg sildenafil can be supplied Viagra Connect if a) they meet the criteria for pharmacy supply and b) they do not take more than 50 mg daily.			
True ^[2]	216 (89.6) [85.1-93.2]	91 (89.2) [81.5-94.5]	2 (100.0) [15.8-100.0]
False	20 (8.3)	8 (7.8)	0
Don't know	5 (2.1)	3 (2.9)	0
Men who are using a different dose of sildenafil or another Erectile Dysfunction (ED) treatment can also be supplied with Viagra Connect.			
True	49 (20.3)	13 (12.7)	1 (50.0)
False ^[2]	178 (73.9) [67.8-79.3]	83 (81.4) [72.4-88.4]	1 (50.0) [1.3-98.7]
Don't know	14 (5.8)	6 (5.9)	0
Question 14: The following patients should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.			
Those who have been advised by their doctor that they are not fit enough for physical or sexual activity.			
True ^[2]	237 (98.3) [95.8-99.5]	102 (100.0) [96.4-100.0]	2 (100.0) [15.8-100.0]

Table 3.7 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by gender - Completed surveys

Question	Gender		
	Male (N=241) n (%) [95% CI] ^[1]	Female (N=102) n (%) [95% CI] ^[1]	Prefer not to answer (N=2) n (%) [95% CI] ^[1]
False	3 (1.2)	0	0
Don't know	1 (0.4)	0	0
B. Those who experience breathlessness or chest pain with light or moderate physical activity (eg walking briskly for 20 mins or climbing two flights of stairs).			
True ^[2]	236 (97.9) [95.2-99.3]	102 (100.0) [96.4-100.0]	2 (100.0) [15.8-100.0]
False	4 (1.7)	0	0
Don't know	1 (0.4)	0	0
Those who have had a heart attack or stroke more than 6 months ago.			
True	138 (57.3)	54 (52.9)	2 (100.0)
False ^[2]	99 (41.1) [34.8-47.6]	44 (43.1) [33.4-53.3]	0 [0.0-84.2]
Don't know	4 (1.7)	4 (3.9)	0
Question 15: A patient with which of the following cardiovascular conditions MAY be supplied with Viagra Connect? Complete Yes/No/Don't know.			
Low blood pressure			
Yes	34 (14.1)	19 (18.6)	0
No ^[2]	195 (80.9) [75.4-85.7]	79 (77.5) [68.1-85.1]	2 (100.0) [15.8-100.0]
Don't know	12 (5.0)	4 (3.9)	0
Uncontrolled hypertension			
Yes	6 (2.5)	1 (1.0)	0
No ^[2]	230 (95.4) [92.0-97.7]	98 (96.1) [90.3-98.9]	2 (100.0) [15.8-100.0]
Don't know	5 (2.1)	3 (2.9)	0
Controlled hypertension			
Yes ^[2]	204 (84.6) [79.5-89.0]	90 (88.2) [80.4-93.8]	2 (100.0) [15.8-100.0]
No	33 (13.7)	9 (8.8)	0

Table 3.7 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by gender - Completed surveys

Question	Gender		
	Male (N=241) n (%) [95% CI] ^[1]	Female (N=102) n (%) [95% CI] ^[1]	Prefer not to answer (N=2) n (%) [95% CI] ^[1]
Don't know	4 (1.7)	3 (2.9)	0
Unstable angina			
Yes	3 (1.2)	1 (1.0)	0
No ^[2]	232 (96.3) [93.0-98.3]	99 (97.1) [91.6-99.4]	2 (100.0) [15.8-100.0]
Don't know	6 (2.5)	2 (2.0)	0
Arrhythmia			
Yes	31 (12.9)	7 (6.9)	0
No ^[2]	194 (80.5) [74.9-85.3]	87 (85.3) [76.9-91.5]	2 (100.0) [15.8-100.0]
Don't know	16 (6.6)	8 (7.8)	0
Valvular heart disease			
Yes	20 (8.3)	7 (6.9)	0
No ^[2]	197 (81.7) [76.3-86.4]	85 (83.3) [74.7-90.0]	2 (100.0) [15.8-100.0]
Don't know	24 (10.0)	10 (9.8)	0
Cardiomyopathy			
Yes	13 (5.4)	4 (3.9)	0
No ^[2]	206 (85.5) [80.4-89.7]	90 (88.2) [80.4-93.8]	2 (100.0) [15.8-100.0]
Don't know	22 (9.1)	8 (7.8)	0
Left Ventricular outflow obstruction or aortic narrowing			
Yes	7 (2.9)	1 (1.0)	0
No ^[2]	201 (83.4) [78.1-87.9]	89 (87.3) [79.2-93.0]	2 (100.0) [15.8-100.0]
Don't know	33 (13.7)	12 (11.8)	0
Severe cardiac failure			
Yes	2 (0.8)	1 (1.0)	0

Table 3.7 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by gender - Completed surveys

Question	Gender		
	Male (N=241) n (%) [95% CI] ^[1]	Female (N=102) n (%) [95% CI] ^[1]	Prefer not to answer (N=2) n (%) [95% CI] ^[1]
No ^[2]	235 (97.5) [94.7-99.1]	101 (99.0) [94.7-100.0]	2 (100.0) [15.8-100.0]
Don't know	4 (1.7)	0	0
Question 16: Look at the list of drugs below and select whether or not they can be used with Viagra Connect. Complete Yes/No/Don't know.			
Nitrates for chest pain			
Yes	8 (3.3)	2 (2.0)	0
No ^[2]	231 (95.9) [92.5-98.0]	100 (98.0) [93.1-99.8]	2 (100.0) [15.8-100.0]
Don't know	2 (0.8)	0	0
Riociguat for lung problems			
Yes	13 (5.4)	4 (3.9)	1 (50.0)
No ^[2]	169 (70.1) [63.9-75.8]	78 (76.5) [67.0-84.3]	1 (50.0) [1.3-98.7]
Don't know	59 (24.5)	20 (19.6)	0
Ritonavir for HIV infection			
Yes	21 (8.7)	5 (4.9)	0
No ^[2]	197 (81.7) [76.3-86.4]	91 (89.2) [81.5-94.5]	2 (100.0) [15.8-100.0]
Don't know	23 (9.5)	6 (5.9)	0
Omeprazole or other proton pump inhibitors (PPIs)			
Yes ^[2]	226 (93.8) [89.9-96.5]	93 (91.2) [83.9-95.9]	2 (100.0) [15.8-100.0]
No	10 (4.1)	6 (5.9)	0
Don't know	5 (2.1)	3 (2.9)	0
CYP3A4 inhibitors (eg, saquinavir, cimetidine, itraconazole, ketoconazole, erythromycin or rifampicin, diltiazem)			
Yes	25 (10.4)	7 (6.9)	0

Table 3.7 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by gender - Completed surveys

Question	Gender		
	Male (N=241) n (%) [95% CI] ^[1]	Female (N=102) n (%) [95% CI] ^[1]	Prefer not to answer (N=2) n (%) [95% CI] ^[1]
No ^[2]	200 (83.0) [77.6-87.5]	87 (85.3) [76.9-91.5]	2 (100.0) [15.8-100.0]
Don't know	16 (6.6)	8 (7.8)	0
Alpha blockers (eg, alfuzosin, doxazosin or tamsulosin)			
Yes	41 (17.0)	9 (8.8)	0
No ^[2]	196 (81.3) [75.8-86.0]	92 (90.2) [82.7-95.2]	2 (100.0) [15.8-100.0]
Don't know	4 (1.7)	1 (1.0)	0
Beta-blockers			
Yes ^[2]	182 (75.5) [69.6-80.8]	80 (78.4) [69.2-86.0]	2 (100.0) [15.8-100.0]
No	47 (19.5)	19 (18.6)	0
Don't know	12 (5.0)	3 (2.9)	0
Recreational drugs called "poppers" (eg, amyl nitrite)			
Yes	5 (2.1)	0	0
No ^[2]	228 (94.6) [91.0-97.1]	99 (97.1) [91.6-99.4]	2 (100.0) [15.8-100.0]
Don't know	8 (3.3)	3 (2.9)	0
Question 17: Patients with the following concomitant diseases should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.			
Hepatic disease			
True ^[2]	194 (80.5) [74.9-85.3]	89 (87.3) [79.2-93.0]	1 (50.0) [1.3-98.7]
False	27 (11.2)	8 (7.8)	1 (50.0)
Don't know	20 (8.3)	5 (4.9)	0
Severe renal impairment			
True ^[2]	196 (81.3) [75.8-86.0]	93 (91.2) [83.9-95.9]	2 (100.0) [15.8-100.0]
False	29 (12.0)	7 (6.9)	0

Table 3.7 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by gender - Completed surveys

Question	Gender		
	Male (N=241) n (%) [95% CI] ^[1]	Female (N=102) n (%) [95% CI] ^[1]	Prefer not to answer (N=2) n (%) [95% CI] ^[1]
Don't know	16 (6.6)	2 (2.0)	0
Osteoarthritis or other musculoskeletal disorders			
True	14 (5.8)	9 (8.8)	0
False ^[2]	218 (90.5) [86.0-93.9]	90 (88.2) [80.4-93.8]	2 (100.0) [15.8-100.0]
Don't know	9 (3.7)	3 (2.9)	0
Loss of vision due to optic nerve damage or inherited eye disease (such as retinitis pigmentosa)			
True ^[2]	206 (85.5) [80.4-89.7]	88 (86.3) [78.0-92.3]	2 (100.0) [15.8-100.0]
False	21 (8.7)	9 (8.8)	0
Don't know	14 (5.8)	5 (4.9)	0

Source: Appendix B: Table 3.7

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 3.8 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists" - Completed surveys

Question	Reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists"	
	Yes (N=334) n (%) [95% CI] ^[1]	No (N=11) n (%) [95% CI] ^[1]
Question 13: Please answer True/False/Don't know for the following statements:		
Viagra Connect is only intended for use by men over 45 years of age who are experiencing Erectile Dysfunction (ED).		
True	16 (4.8)	2 (18.2)
False ^[2]	310 (92.8) [89.5-95.3]	9 (81.8) [48.2-97.7]
Don't know	8 (2.4)	0
Viagra Connect must not be supplied to men who do not have Erectile Dysfunction (ED).		
True ^[2]	307 (91.9) [88.5-94.6]	9 (81.8) [48.2-97.7]
False	24 (7.2)	1 (9.1)
Don't know	3 (0.9)	1 (9.1)
Men currently prescribed 50 mg sildenafil can be supplied Viagra Connect if a) they meet the criteria for pharmacy supply and b) they do not take more than 50 mg daily.		
True ^[2]	299 (89.5) [85.7-92.6]	10 (90.9) [58.7-99.8]
False	27 (8.1)	1 (9.1)
Don't know	8 (2.4)	0
Men who are using a different dose of sildenafil or another Erectile Dysfunction (ED) treatment can also be supplied with Viagra Connect.		
True	61 (18.3)	2 (18.2)
False ^[2]	253 (75.7) [70.8-80.2]	9 (81.8) [48.2-97.7]
Don't know	20 (6.0)	0
Question 14: The following patients should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.		
Those who have been advised by their doctor that they are not fit enough for physical or sexual activity.		

Table 3.8 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists" - Completed surveys

Question	Reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists"	
	Yes (N=334) n (%) [95% CI] ^[1]	No (N=11) n (%) [95% CI] ^[1]
True ^[2]	330 (98.8) [97.0-99.7]	11 (100.0) [71.5-100.0]
False	3 (0.9)	0
Don't know	1 (0.3)	0
B. Those who experience breathlessness or chest pain with light or moderate physical activity (eg walking briskly for 20 mins or climbing two flights of stairs).		
True ^[2]	330 (98.8) [97.0-99.7]	10 (90.9) [58.7-99.8]
False	4 (1.2)	0
Don't know	0	1 (9.1)
Those who have had a heart attack or stroke more than 6 months ago.		
True	188 (56.3)	6 (54.5)
False ^[2]	138 (41.3) [36.0-46.8]	5 (45.5) [16.7-76.6]
Don't know	8 (2.4)	0
Question 15: A patient with which of the following cardiovascular conditions MAY be supplied with Viagra Connect? Complete Yes/No/Don't know.		
Low blood pressure		
Yes	51 (15.3)	2 (18.2)
No ^[2]	269 (80.5) [75.9-84.6]	7 (63.6) [30.8-89.1]
Don't know	14 (4.2)	2 (18.2)
Uncontrolled hypertension		
Yes	6 (1.8)	1 (9.1)
No ^[2]	320 (95.8) [93.1-97.7]	10 (90.9) [58.7-99.8]
Don't know	8 (2.4)	0

Table 3.8 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists" - Completed surveys

Question	Reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists"	
	Yes (N=334) n (%) [95% CI] ^[1]	No (N=11) n (%) [95% CI] ^[1]
Controlled hypertension		
Yes ^[2]	288 (86.2) [82.1-89.7]	8 (72.7) [39.0-94.0]
No	40 (12.0)	2 (18.2)
Don't know	6 (1.8)	1 (9.1)
Unstable angina		
Yes	3 (0.9)	1 (9.1)
No ^[2]	324 (97.0) [94.6-98.6]	9 (81.8) [48.2-97.7]
Don't know	7 (2.1)	1 (9.1)
Arrhythmia		
Yes	35 (10.5)	3 (27.3)
No ^[2]	276 (82.6) [78.1-86.5]	7 (63.6) [30.8-89.1]
Don't know	23 (6.9)	1 (9.1)
Valvular heart disease		
Yes	26 (7.8)	1 (9.1)
No ^[2]	275 (82.3) [77.8-86.3]	9 (81.8) [48.2-97.7]
Don't know	33 (9.9)	1 (9.1)
Cardiomyopathy		
Yes	15 (4.5)	2 (18.2)
No ^[2]	290 (86.8) [82.7-90.3]	8 (72.7) [39.0-94.0]
Don't know	29 (8.7)	1 (9.1)
Left Ventricular outflow obstruction or aortic narrowing		

Table 3.8 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists" - Completed surveys

Question	Reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists"	
	Yes (N=334) n (%) [95% CI] ^[1]	No (N=11) n (%) [95% CI] ^[1]
Yes	7 (2.1)	1 (9.1)
No ^[2]	283 (84.7) [80.4-88.4]	9 (81.8) [48.2-97.7]
Don't know	44 (13.2)	1 (9.1)
Severe cardiac failure		
Yes	3 (0.9)	0
No ^[2]	327 (97.9) [95.7-99.2]	11 (100.0) [71.5-100.0]
Don't know	4 (1.2)	0
Question 16: Look at the list of drugs below and select whether or not they can be used with Viagra Connect. Complete Yes/No/Don't know.		
Nitrates for chest pain		
Yes	9 (2.7)	1 (9.1)
No ^[2]	323 (96.7) [94.2-98.3]	10 (90.9) [58.7-99.8]
Don't know	2 (0.6)	0
Riociguat for lung problems		
Yes	16 (4.8)	2 (18.2)
No ^[2]	242 (72.5) [67.3-77.2]	6 (54.5) [23.4-83.3]
Don't know	76 (22.8)	3 (27.3)
Ritonavir for HIV infection		
Yes	24 (7.2)	2 (18.2)
No ^[2]	281 (84.1) [79.8-87.9]	9 (81.8) [48.2-97.7]
Don't know	29 (8.7)	0

Table 3.8 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists" - Completed surveys

Question	Reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists"	
	Yes (N=334) n (%) [95% CI] ^[1]	No (N=11) n (%) [95% CI] ^[1]
Omeprazole or other proton pump inhibitors (PPIs)		
Yes ^[2]	314 (94.0) [90.9-96.3]	7 (63.6) [30.8-89.1]
No	14 (4.2)	2 (18.2)
Don't know	6 (1.8)	2 (18.2)
CYP3A4 inhibitors (eg, saquinavir, cimetidine, itraconazole, ketoconazole, erythromycin or rifampicin, diltiazem)		
Yes	31 (9.3)	1 (9.1)
No ^[2]	280 (83.8) [79.4-87.6]	9 (81.8) [48.2-97.7]
Don't know	23 (6.9)	1 (9.1)
Alpha blockers (eg, alfuzosin, doxazosin or tamsulosin)		
Yes	47 (14.1)	3 (27.3)
No ^[2]	282 (84.4) [80.1-88.1]	8 (72.7) [39.0-94.0]
Don't know	5 (1.5)	0
Beta-blockers		
Yes ^[2]	258 (77.2) [72.4-81.6]	6 (54.5) [23.4-83.3]
No	62 (18.6)	4 (36.4)
Don't know	14 (4.2)	1 (9.1)
Recreational drugs called "poppers" (eg, amyl nitrite)		
Yes	5 (1.5)	0
No ^[2]	319 (95.5) [92.7-97.5]	10 (90.9) [58.7-99.8]
Don't know	10 (3.0)	1 (9.1)

Table 3.8 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists" - Completed surveys

Question	Reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists"	
	Yes (N=334) n (%) [95% CI] ^[1]	No (N=11) n (%) [95% CI] ^[1]
Question 17: Patients with the following concomitant diseases should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.		
Hepatic disease		
True ^[2]	275 (82.3) [77.8-86.3]	9 (81.8) [48.2-97.7]
False	35 (10.5)	1 (9.1)
Don't know	24 (7.2)	1 (9.1)
Severe renal impairment		
True ^[2]	280 (83.8) [79.4-87.6]	11 (100.0) [71.5-100.0]
False	36 (10.8)	0
Don't know	18 (5.4)	0
Osteoarthritis or other musculoskeletal disorders		
True	21 (6.3)	2 (18.2)
False ^[2]	301 (90.1) [86.4-93.1]	9 (81.8) [48.2-97.7]
Don't know	12 (3.6)	0
Loss of vision due to optic nerve damage or inherited eye disease (such as retinitis pigmentosa)		
True ^[2]	288 (86.2) [82.1-89.7]	8 (72.7) [39.0-94.0]
False	29 (8.7)	1 (9.1)
Don't know	17 (5.1)	2 (18.2)

Source: Appendix B: Table 3.8

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e1918187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 3.9 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by using the optional Viagra Connect Pharmacy Checklist at the point of supply - Completed surveys

Question	Using the Optional Viagra Connect Pharmacy Checklist at the Point of Supply		
	Yes (N=317) n (%) [95% CI] ^[1]	No (N=18) n (%) [95% CI] ^[1]	I do not recall (N=10) n (%) [95% CI] ^[1]
Question 13: Please answer True/False/Don't know for the following statements:			
Viagra Connect is only intended for use by men over 45 years of age who are experiencing Erectile Dysfunction (ED).			
True	13 (4.1)	3 (16.7)	2 (20.0)
False ^[2]	297 (93.7) [90.4-96.1]	14 (77.8) [52.4-93.6]	8 (80.0) [44.4-97.5]
Don't know	7 (2.2)	1 (5.6)	0
Viagra Connect must not be supplied to men who do not have Erectile Dysfunction (ED).			
True ^[2]	294 (92.7) [89.3-95.3]	14 (77.8) [52.4-93.6]	8 (80.0) [44.4-97.5]
False	20 (6.3)	4 (22.2)	1 (10.0)
Don't know	3 (0.9)	0	1 (10.0)
Men currently prescribed 50 mg sildenafil can be supplied Viagra Connect if a) they meet the criteria for pharmacy supply and b) they do not take more than 50 mg daily.			
True ^[2]	284 (89.6) [85.7-92.7]	16 (88.9) [65.3-98.6]	9 (90.0) [55.5-99.7]
False	27 (8.5)	1 (5.6)	0
Don't know	6 (1.9)	1 (5.6)	1 (10.0)
Men who are using a different dose of sildenafil or another Erectile Dysfunction (ED) treatment can also be supplied with Viagra Connect.			
True	55 (17.4)	6 (33.3)	2 (20.0)
False ^[2]	245 (77.3) [72.3-81.8]	11 (61.1) [35.7-82.7]	6 (60.0) [26.2-87.8]
Don't know	17 (5.4)	1 (5.6)	2 (20.0)
Question 14: The following patients should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.			
Those who have been advised by their doctor that they are not fit enough for physical or sexual activity.			

Table 3.9 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by using the optional Viagra Connect Pharmacy Checklist at the point of supply - Completed surveys

Question	Using the Optional Viagra Connect Pharmacy Checklist at the Point of Supply		
	Yes (N=317) n (%) [95% CI] ^[1]	No (N=18) n (%) [95% CI] ^[1]	I do not recall (N=10) n (%) [95% CI] ^[1]
True ^[2]	313 (98.7) [96.8-99.7]	18 (100.0) [81.5-100.0]	10 (100.0) [69.2-100.0]
False	3 (0.9)	0	0
Don't know	1 (0.3)	0	0
B. Those who experience breathlessness or chest pain with light or moderate physical activity (eg walking briskly for 20 mins or climbing two flights of stairs).			
True ^[2]	314 (99.1) [97.3-99.8]	18 (100.0) [81.5-100.0]	8 (80.0) [44.4-97.5]
False	3 (0.9)	0	1 (10.0)
Don't know	0	0	1 (10.0)
Those who have had a heart attack or stroke more than 6 months ago.			
True	179 (56.5)	12 (66.7)	3 (30.0)
False ^[2]	131 (41.3) [35.9-47.0]	6 (33.3) [13.3-59.0]	6 (60.0) [26.2-87.8]
Don't know	7 (2.2)	0	1 (10.0)
Question 15: A patient with which of the following cardiovascular conditions MAY be supplied with Viagra Connect? Complete Yes/No/Don't know.			
Low blood pressure			
Yes	46 (14.5)	3 (16.7)	4 (40.0)
No ^[2]	256 (80.8) [76.0-84.9]	15 (83.3) [58.6-96.4]	5 (50.0) [18.7-81.3]
Don't know	15 (4.7)	0	1 (10.0)
Uncontrolled hypertension			
Yes	5 (1.6)	1 (5.6)	1 (10.0)
No ^[2]	305 (96.2) [93.5-98.0]	17 (94.4) [72.7-99.9]	8 (80.0) [44.4-97.5]
Don't know	7 (2.2)	0	1 (10.0)

Table 3.9 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by using the optional Viagra Connect Pharmacy Checklist at the point of supply - Completed surveys

Question	Using the Optional Viagra Connect Pharmacy Checklist at the Point of Supply		
	Yes (N=317) n (%) [95% CI] ^[1]	No (N=18) n (%) [95% CI] ^[1]	I do not recall (N=10) n (%) [95% CI] ^[1]
Controlled hypertension			
Yes ^[2]	274 (86.4) [82.2-90.0]	14 (77.8) [52.4-93.6]	8 (80.0) [44.4-97.5]
No	38 (12.0)	4 (22.2)	0
Don't know	5 (1.6)	0	2 (20.0)
Unstable angina			
Yes	3 (0.9)	0	1 (10.0)
No ^[2]	308 (97.2) [94.7-98.7]	18 (100.0) [81.5-100.0]	7 (70.0) [34.8-93.3]
Don't know	6 (1.9)	0	2 (20.0)
Arrhythmia			
Yes	33 (10.4)	2 (11.1)	3 (30.0)
No ^[2]	263 (83.0) [78.4-86.9]	16 (88.9) [65.3-98.6]	4 (40.0) [12.2-73.8]
Don't know	21 (6.6)	0	3 (30.0)
Valvular heart disease			
Yes	25 (7.9)	0	2 (20.0)
No ^[2]	265 (83.6) [79.1-87.5]	15 (83.3) [58.6-96.4]	4 (40.0) [12.2-73.8]
Don't know	27 (8.5)	3 (16.7)	4 (40.0)
Cardiomyopathy			
Yes	13 (4.1)	1 (5.6)	3 (30.0)
No ^[2]	276 (87.1) [82.9-90.6]	17 (94.4) [72.7-99.9]	5 (50.0) [18.7-81.3]
Don't know	28 (8.8)	0	2 (20.0)
Left Ventricular outflow obstruction or aortic narrowing			
Yes	6 (1.9)	1 (5.6)	1 (10.0)

Table 3.9 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by using the optional Viagra Connect Pharmacy Checklist at the point of supply - Completed surveys

Question	Using the Optional Viagra Connect Pharmacy Checklist at the Point of Supply		
	Yes (N=317) n (%) [95% CI] ^[1]	No (N=18) n (%) [95% CI] ^[1]	I do not recall (N=10) n (%) [95% CI] ^[1]
No ^[2]	272 (85.8) [81.5-89.5]	15 (83.3) [58.6-96.4]	5 (50.0) [18.7-81.3]
Don't know	39 (12.3)	2 (11.1)	4 (40.0)
Severe cardiac failure			
Yes	2 (0.6)	1 (5.6)	0
No ^[2]	312 (98.4) [96.4-99.5]	17 (94.4) [72.7-99.9]	9 (90.0) [55.5-99.7]
Don't know	3 (0.9)	0	1 (10.0)
Question 16: Look at the list of drugs below and select whether or not they can be used with Viagra Connect. Complete Yes/No/Don't know.			
Nitrates for chest pain			
Yes	9 (2.8)	0	1 (10.0)
No ^[2]	306 (96.5) [93.9-98.3]	18 (100.0) [81.5-100.0]	9 (90.0) [55.5-99.7]
Don't know	2 (0.6)	0	0
Riociguat for lung problems			
Yes	15 (4.7)	1 (5.6)	2 (20.0)
No ^[2]	233 (73.5) [68.3-78.3]	12 (66.7) [41.0-86.7]	3 (30.0) [6.7-65.2]
Don't know	69 (21.8)	5 (27.8)	5 (50.0)
Ritonavir for HIV infection			
Yes	21 (6.6)	3 (16.7)	2 (20.0)
No ^[2]	270 (85.2) [80.8-88.9]	14 (77.8) [52.4-93.6]	6 (60.0) [26.2-87.8]
Don't know	26 (8.2)	1 (5.6)	2 (20.0)
Omeprazole or other proton pump inhibitors (PPIs)			

Table 3.9 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by using the optional Viagra Connect Pharmacy Checklist at the point of supply - Completed surveys

Question	Using the Optional Viagra Connect Pharmacy Checklist at the Point of Supply		
	Yes (N=317) n (%) [95% CI] ^[1]	No (N=18) n (%) [95% CI] ^[1]	I do not recall (N=10) n (%) [95% CI] ^[1]
Yes ^[2]	296 (93.4) [90.1-95.9]	17 (94.4) [72.7-99.9]	8 (80.0) [44.4-97.5]
No	14 (4.4)	1 (5.6)	1 (10.0)
Don't know	7 (2.2)	0	1 (10.0)
CYP3A4 inhibitors (eg, saquinavir, cimetidine, itraconazole, ketoconazole, erythromycin or rifampicin, diltiazem)			
Yes	23 (7.3)	7 (38.9)	2 (20.0)
No ^[2]	272 (85.8) [81.5-89.5]	11 (61.1) [35.7-82.7]	6 (60.0) [26.2-87.8]
Don't know	22 (6.9)	0	2 (20.0)
Alpha blockers (eg, alfuzosin, doxazosin or tamsulosin)			
Yes	40 (12.6)	6 (33.3)	4 (40.0)
No ^[2]	272 (85.8) [81.5-89.5]	12 (66.7) [41.0-86.7]	6 (60.0) [26.2-87.8]
Don't know	5 (1.6)	0	0
Beta-blockers			
Yes ^[2]	241 (76.0) [70.9-80.6]	14 (77.8) [52.4-93.6]	9 (90.0) [55.5-99.7]
No	61 (19.2)	4 (22.2)	1 (10.0)
Don't know	15 (4.7)	0	0
Recreational drugs called "poppers" (eg, amyl nitrite)			
Yes	5 (1.6)	0	0
No ^[2]	302 (95.3) [92.3-97.3]	18 (100.0) [81.5-100.0]	9 (90.0) [55.5-99.7]
Don't know	10 (3.2)	0	1 (10.0)
Question 17: Patients with the following concomitant diseases should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.			

Table 3.9 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by using the optional Viagra Connect Pharmacy Checklist at the point of supply - Completed surveys

Question	Using the Optional Viagra Connect Pharmacy Checklist at the Point of Supply		
	Yes (N=317) n (%) [95% CI] ^[1]	No (N=18) n (%) [95% CI] ^[1]	I do not recall (N=10) n (%) [95% CI] ^[1]
Hepatic disease			
True ^[2]	266 (83.9) [79.4-87.8]	12 (66.7) [41.0-86.7]	6 (60.0) [26.2-87.8]
False	31 (9.8)	3 (16.7)	2 (20.0)
Don't know	20 (6.3)	3 (16.7)	2 (20.0)
Severe renal impairment			
True ^[2]	273 (86.1) [81.8-89.7]	12 (66.7) [41.0-86.7]	6 (60.0) [26.2-87.8]
False	29 (9.1)	3 (16.7)	4 (40.0)
Don't know	15 (4.7)	3 (16.7)	0
Osteoarthritis or other musculoskeletal disorders			
True	22 (6.9)	1 (5.6)	0
False ^[2]	284 (89.6) [85.7-92.7]	16 (88.9) [65.3-98.6]	10 (100.0) [69.2-100.0]
Don't know	11 (3.5)	1 (5.6)	0
Loss of vision due to optic nerve damage or inherited eye disease (such as retinitis pigmentosa)			
True ^[2]	275 (86.8) [82.5-90.3]	14 (77.8) [52.4-93.6]	7 (70.0) [34.8-93.3]
False	26 (8.2)	3 (16.7)	1 (10.0)
Don't know	16 (5.0)	1 (5.6)	2 (20.0)

Source: Appendix B: Table 3.9

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 3.10 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
Question 13: Please answer True/False/Don't know for the following statements:					
Viagra Connect is only intended for use by men over 45 years of age who are experiencing Erectile Dysfunction (ED).					
True	3 (5.6)	15 (5.3)	0	0	0
False ^[2]	50 (92.6) [82.1-97.9]	260 (92.2) [88.4-95.0]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
Don't know	1 (1.9)	7 (2.5)	0	0	0
Viagra Connect must not be supplied to men who do not have Erectile Dysfunction (ED).					
True ^[2]	47 (87.0) [75.1-94.6]	261 (92.6) [88.8-95.3]	7 (87.5) [47.3-99.7]	1 (100.0) [2.5-100.0]	0
False	6 (11.1)	18 (6.4)	1 (12.5)	0	0
Don't know	1 (1.9)	3 (1.1)	0	0	0
Men currently prescribed 50 mg sildenafil can be supplied Viagra Connect if a) they meet the criteria for pharmacy supply and b) they do not take more than 50 mg daily.					
True ^[2]	48 (88.9) [77.4-95.8]	254 (90.1) [86.0-93.3]	6 (75.0) [34.9-96.8]	1 (100.0) [2.5-100.0]	0
False	5 (9.3)	21 (7.4)	2 (25.0)	0	0

Table 3.10 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
Don't know	1 (1.9)	7 (2.5)	0	0	0
Men who are using a different dose of sildenafil or another Erectile Dysfunction (ED) treatment can also be supplied with Viagra Connect.					
True	6 (11.1)	57 (20.2)	0	0	0
False ^[2]	43 (79.6) [66.5-89.4]	210 (74.5) [69.0-79.5]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
Don't know	5 (9.3)	15 (5.3)	0	0	0
Question 14: The following patients should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.					
Those who have been advised by their doctor that they are not fit enough for physical or sexual activity.					
True ^[2]	53 (98.1) [90.1-100.0]	279 (98.9) [96.9-99.8]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
False	0	3 (1.1)	0	0	0
Don't know	1 (1.9)	0	0	0	0
B. Those who experience breathlessness or chest pain with light or moderate physical activity (eg walking briskly for 20 mins or climbing two flights of stairs).					

Table 3.10 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
True ^[2]	52 (96.3) [87.3-99.5]	279 (98.9) [96.9-99.8]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
False	1 (1.9)	3 (1.1)	0	0	0
Don't know	1 (1.9)	0	0	0	0
Those who have had a heart attack or stroke more than 6 months ago.					
True	34 (63.0)	155 (55.0)	5 (62.5)	0	0
False ^[2]	19 (35.2) [22.7-49.4]	120 (42.6) [36.7-48.6]	3 (37.5) [8.5-75.5]	1 (100.0) [2.5-100.0]	0
Don't know	1 (1.9)	7 (2.5)	0	0	0
Question 15: A patient with which of the following cardiovascular conditions MAY be supplied with Viagra Connect? Complete Yes/No/Don't know.					
Low blood pressure					
Yes	8 (14.8)	45 (16.0)	0	0	0
No ^[2]	44 (81.5) [68.6-90.7]	224 (79.4) [74.2-84.0]	7 (87.5) [47.3-99.7]	1 (100.0) [2.5-100.0]	0
Don't know	2 (3.7)	13 (4.6)	1 (12.5)	0	0

Table 3.10 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
Uncontrolled hypertension					
Yes	3 (5.6)	4 (1.4)	0	0	0
No ^[2]	49 (90.7) [79.7-96.9]	272 (96.5) [93.6-98.3]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
Don't know	2 (3.7)	6 (2.1)	0	0	0
Controlled hypertension					
Yes ^[2]	46 (85.2) [72.9-93.4]	244 (86.5) [82.0-90.3]	5 (62.5) [24.5-91.5]	1 (100.0) [2.5-100.0]	0
No	8 (14.8)	31 (11.0)	3 (37.5)	0	0
Don't know	0	7 (2.5)	0	0	0
Unstable angina					
Yes	2 (3.7)	2 (0.7)	0	0	0
No ^[2]	49 (90.7) [79.7-96.9]	275 (97.5) [95.0-99.0]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
Don't know	3 (5.6)	5 (1.8)	0	0	0

Table 3.10 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
Arrhythmia					
Yes	8 (14.8)	29 (10.3)	1 (12.5)	0	0
No ^[2]	42 (77.8) [64.4-88.0]	233 (82.6) [77.7-86.9]	7 (87.5) [47.3-99.7]	1 (100.0) [2.5-100.0]	0
Don't know	4 (7.4)	20 (7.1)	0	0	0
Valvular heart disease					
Yes	6 (11.1)	21 (7.4)	0	0	0
No ^[2]	44 (81.5) [68.6-90.7]	231 (81.9) [76.9-86.2]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
Don't know	4 (7.4)	30 (10.6)	0	0	0
Cardiomyopathy					
Yes	5 (9.3)	12 (4.3)	0	0	0
No ^[2]	45 (83.3) [70.7-92.1]	244 (86.5) [82.0-90.3]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
Don't know	4 (7.4)	26 (9.2)	0	0	0

Table 3.10 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
Left Ventricular outflow obstruction or aortic narrowing					
Yes	4 (7.4)	4 (1.4)	0	0	0
No ^[2]	42 (77.8) [64.4-88.0]	241 (85.5) [80.8-89.4]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
Don't know	8 (14.8)	37 (13.1)	0	0	0
Severe cardiac failure					
Yes	1 (1.9)	2 (0.7)	0	0	0
No ^[2]	52 (96.3) [87.3-99.5]	277 (98.2) [95.9-99.4]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
Don't know	1 (1.9)	3 (1.1)	0	0	0
Question 16: Look at the list of drugs below and select whether or not they can be used with Viagra Connect. Complete Yes/No/Don't know.					
Nitrates for chest pain					
Yes	2 (3.7)	8 (2.8)	0	0	0
No ^[2]	52 (96.3) [87.3-99.5]	272 (96.5) [93.6-98.3]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0

Table 3.10 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
Don't know	0	2 (0.7)	0	0	0
Riociguat for lung problems					
Yes	3 (5.6)	14 (5.0)	1 (12.5)	0	0
No ^[2]	36 (66.7) [52.5-78.9]	204 (72.3) [66.7-77.5]	7 (87.5) [47.3-99.7]	1 (100.0) [2.5-100.0]	0
Don't know	15 (27.8)	64 (22.7)	0	0	0
Ritonavir for HIV infection					
Yes	4 (7.4)	21 (7.4)	1 (12.5)	0	0
No ^[2]	47 (87.0) [75.1-94.6]	235 (83.3) [78.5-87.5]	7 (87.5) [47.3-99.7]	1 (100.0) [2.5-100.0]	0
Don't know	3 (5.6)	26 (9.2)	0	0	0
Omeprazole or other proton pump inhibitors (PPIs)					
Yes ^[2]	51 (94.4) [84.6-98.8]	263 (93.3) [89.7-95.9]	6 (75.0) [34.9-96.8]	1 (100.0) [2.5-100.0]	0
No	2 (3.7)	12 (4.3)	2 (25.0)	0	0

Table 3.10 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
Don't know	1 (1.9)	7 (2.5)	0	0	0
CYP3A4 inhibitors (eg, saquinavir, cimetidine, itraconazole, ketoconazole, erythromycin or rifampicin, diltiazem)					
Yes	7 (13.0)	24 (8.5)	1 (12.5)	0	0
No ^[2]	42 (77.8) [64.4-88.0]	239 (84.8) [80.0-88.7]	7 (87.5) [47.3-99.7]	1 (100.0) [2.5-100.0]	0
Don't know	5 (9.3)	19 (6.7)	0	0	0
Alpha blockers (eg, alfuzosin, doxazosin or tamsulosin)					
Yes	10 (18.5)	39 (13.8)	1 (12.5)	0	0
No ^[2]	43 (79.6) [66.5-89.4]	239 (84.8) [80.0-88.7]	7 (87.5) [47.3-99.7]	1 (100.0) [2.5-100.0]	0
Don't know	1 (1.9)	4 (1.4)	0	0	0
Beta-blockers					
Yes ^[2]	33 (61.1) [46.9-74.1]	224 (79.4) [74.2-84.0]	6 (75.0) [34.9-96.8]	1 (100.0) [2.5-100.0]	0
No	18 (33.3)	46 (16.3)	2 (25.0)	0	0

Table 3.10 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
Don't know	3 (5.6)	12 (4.3)	0	0	0
Recreational drugs called “poppers” (eg, amyl nitrite)					
Yes	0	5 (1.8)	0	0	0
No ^[2]	52 (96.3) [87.3-99.5]	268 (95.0) [91.8-97.3]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
Don't know	2 (3.7)	9 (3.2)	0	0	0
Question 17: Patients with the following concomitant diseases should NOT be supplied with Viagra Connect but should be referred to their doctor. Complete True/False/Don't know.					
Hepatic disease					
True ^[2]	45 (83.3) [70.7-92.1]	232 (82.3) [77.3-86.5]	6 (75.0) [34.9-96.8]	1 (100.0) [2.5-100.0]	0
False	4 (7.4)	30 (10.6)	2 (25.0)	0	0
Don't know	5 (9.3)	20 (7.1)	0	0	0
Severe renal impairment					
True ^[2]	45 (83.3) [70.7-92.1]	238 (84.4) [79.6-88.4]	7 (87.5) [47.3-99.7]	1 (100.0) [2.5-100.0]	0

Table 3.10 Responses to all Questions about pharmacist knowledge of part I key risk messages for pharmacists to consider when determining the suitability of patient for Viagra Connect by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
False	6 (11.1)	29 (10.3)	1 (12.5)	0	0
Don't know	3 (5.6)	15 (5.3)	0	0	0
Osteoarthritis or other musculoskeletal disorders					
True	4 (7.4)	17 (6.0)	2 (25.0)	0	0
False ^[2]	49 (90.7) [79.7-96.9]	254 (90.1) [86.0-93.3]	6 (75.0) [34.9-96.8]	1 (100.0) [2.5-100.0]	0
Don't know	1 (1.9)	11 (3.9)	0	0	0
Loss of vision due to optic nerve damage or inherited eye disease (such as retinitis pigmentosa)					
True ^[2]	45 (83.3) [70.7-92.1]	243 (86.2) [81.6-90.0]	7 (87.5) [47.3-99.7]	1 (100.0) [2.5-100.0]	0
False	5 (9.3)	24 (8.5)	1 (12.5)	0	0
Don't know	4 (7.4)	15 (5.3)	0	0	0

Source: Appendix B: Table 3.10

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 4 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation - Completed surveys

Question	Pharmacists (N=345) n (%) [95% CI] ^[1]
Question 18: Which of the following MAY be a cause of Erectile Dysfunction (ED) and should be considered when assessing a patient for suitability for Viagra Connect. Please select True/False/Don't Know.	
Undiagnosed depression	
True ^[2]	308 (89.3) [85.5 - 92.3]
False	27 (7.8)
Don't know	10 (2.9)
Anxiety	
True ^[2]	324 (93.9) [90.8 - 96.2]
False	13 (3.8)
Don't know	8 (2.3)
Excessive alcohol use	
True ^[2]	335 (97.1) [94.7 - 98.6]
False	8 (2.3)
Don't know	2 (0.6)
Hypertension	
True ^[2]	242 (70.1) [65.0 - 74.9]
False	83 (24.1)
Don't know	20 (5.8)
Diabetes mellitus	
True ^[2]	322 (93.3) [90.2 - 95.7]
False	15 (4.3)
Don't know	8 (2.3)
Hypercholesterolemia	
True ^[2]	196 (56.8) [51.4 - 62.1]
False	109 (31.6)
Don't know	40 (11.6)
Cardiovascular disease	
True ^[2]	311 (90.1) [86.5 - 93.1]

Table 4 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation - Completed surveys

Question	Pharmacists (N=345) n (%) [95% CI] ^[1]
False	28 (8.1)
Don't know	6 (1.7)
Osteoarthritis	
True	20 (5.8)
False ^[2]	290 (84.1) [79.8 - 87.8]
Don't know	35 (10.1)
Question 19: If a patient requests Viagra Connect but shows evidence of undiagnosed depression, anxiety or excessive alcohol use, which action should you take? Please select True/False/Don't Know.	
Provide lifestyle advice	
True ^[2]	336 (97.4) [95.1 - 98.8]
False	9 (2.6)
Don't know	0
Recommend follow up with his doctor	
True ^[2]	340 (98.6) [96.7 - 99.5]
False	4 (1.2)
Don't know	1 (0.3)
Question 20: Please select True/False/Don't Know for the following statements.	
Pharmacists should provide lifestyle advice to all men with Erectile Dysfunction (ED) who request Viagra Connect.	
True ^[2]	299 (86.7) [82.6 - 90.1]
False	36 (10.4)
Don't know	10 (2.9)
Lifestyle advice includes losing weight, stopping smoking, cutting back on alcohol and recreational drugs, exercising regularly and reducing stress.	
True ^[2]	344 (99.7) [98.4 - 100.0]
False	1 (0.3)
Don't know	0
All patients supplied with Viagra Connect should be advised to consult their doctor within 6 months from the first supply.	

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 4 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation - Completed surveys

Question	Pharmacists (N=345) n (%) [95% CI] ^[1]
True ^[2]	301 (87.2) [83.3 - 90.6]
False	32 (9.3)
Don't know	12 (3.5)
All patients who are refused Viagra Connect should be advised to contact their doctor.	
True ^[2]	312 (90.4) [86.8 - 93.3]
False	30 (8.7)
Don't know	3 (0.9)
Question 21: Complete True/False/Don't know for the following statement: Patients should be advised to STOP TAKING Viagra Connect and seek medical attention immediately if they experience the following symptoms.	
Chest pains	
True ^[2]	344 (99.7) [98.4 - 100.0]
False	0
Don't know	1 (0.3)
Persistent and sometimes painful erection lasting longer than 4 hours	
True ^[2]	340 (98.6) [96.7 - 99.5]
False	1 (0.3)
Don't know	4 (1.2)
Dyspepsia	
True	43 (12.5)
False ^[2]	291 (84.3) [80.1 - 88.0]
Don't know	11 (3.2)
Sudden decrease or loss of vision	
True ^[2]	344 (99.7) [98.4 - 100.0]
False	0
Don't know	1 (0.3)
Headache	
True	72 (20.9)
False ^[2]	263 (76.2) [71.4 - 80.6]

Table 4 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation - Completed surveys

Question	Pharmacists (N=345) n (%) [95% CI] ^[1]
Don't know	10 (2.9)
Allergic reaction (with symptoms of wheeziness, difficulty breathing or dizziness)	
True ^[2]	345 (100.0) [98.9 - 100.0]
False	0
Don't know	0
Nausea	
True	53 (15.4)
False ^[2]	274 (79.4) [74.8 - 83.6]
Don't know	18 (5.2)
Serious skin reactions (eg, Stevens-Johnson Syndrome (SJS))	
True ^[2]	340 (98.6) [96.7 - 99.5]
False	2 (0.6)
Don't know	3 (0.9)
Seizures or fits	
True ^[2]	339 (98.3) [96.3 - 99.4]
False	1 (0.3)
Don't know	5 (1.4)

Source: Appendix B: Table 4

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 4.1 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by participation in the Viagra Connect pharmacist training - Completed surveys

Question	Participation in the Viagra Connect Pharmacist Training		
	Yes (N=238) n (%) [95% CI] ^[1]	No (N=60) n (%) [95% CI] ^[1]	Don't recall (N=47) n (%) [95% CI] ^[1]
Question 18: Which of the following MAY be a cause of Erectile Dysfunction (ED) and should be considered when assessing a patient for suitability for Viagra Connect. Please select True/False/Don't Know.			
Undiagnosed depression			
True ^[2]	211 (88.7) [83.9-92.4]	56 (93.3) [83.8-98.2]	41 (87.2) [74.3-95.2]
False	21 (8.8)	1 (1.7)	5 (10.6)
Don't know	6 (2.5)	3 (5.0)	1 (2.1)
Anxiety			
True ^[2]	223 (93.7) [89.8-96.4]	59 (98.3) [91.1-100.0]	42 (89.4) [76.9-96.5]
False	9 (3.8)	0	4 (8.5)
Don't know	6 (2.5)	1 (1.7)	1 (2.1)
Excessive alcohol use			
True ^[2]	231 (97.1) [94.0-98.8]	59 (98.3) [91.1-100.0]	45 (95.7) [85.5-99.5]
False	5 (2.1)	1 (1.7)	2 (4.3)
Don't know	2 (0.8)	0	0
Hypertension			
True ^[2]	166 (69.7) [63.5-75.5]	41 (68.3) [55.0-79.7]	35 (74.5) [59.7-86.1]
False	58 (24.4)	17 (28.3)	8 (17.0)
Don't know	14 (5.9)	2 (3.3)	4 (8.5)
Diabetes mellitus			
True ^[2]	225 (94.5) [90.8-97.1]	55 (91.7) [81.6-97.2]	42 (89.4) [76.9-96.5]
False	9 (3.8)	4 (6.7)	2 (4.3)
Don't know	4 (1.7)	1 (1.7)	3 (6.4)
Hypercholesterolemia			

Table 4.1 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by participation in the Viagra Connect pharmacist training - Completed surveys

Question	Participation in the Viagra Connect Pharmacist Training		
	Yes (N=238) n (%) [95% CI] ^[1]	No (N=60) n (%) [95% CI] ^[1]	Don't recall (N=47) n (%) [95% CI] ^[1]
True ^[2]	143 (60.1) [53.6-66.4]	29 (48.3) [35.2-61.6]	24 (51.1) [36.1-65.9]
False	70 (29.4)	27 (45.0)	12 (25.5)
Don't know	25 (10.5)	4 (6.7)	11 (23.4)
Cardiovascular disease			
True ^[2]	219 (92.0) [87.8-95.1]	48 (80.0) [67.7-89.2]	44 (93.6) [82.5-98.7]
False	15 (6.3)	10 (16.7)	3 (6.4)
Don't know	4 (1.7)	2 (3.3)	0
Osteoarthritis			
True	11 (4.6)	5 (8.3)	4 (8.5)
False ^[2]	203 (85.3) [80.1-89.5]	50 (83.3) [71.5-91.7]	37 (78.7) [64.3-89.3]
Don't know	24 (10.1)	5 (8.3)	6 (12.8)
Question 19: If a patient requests Viagra Connect but shows evidence of undiagnosed depression, anxiety or excessive alcohol use, which action should you take? Please select True/False/Don't Know.			
Provide lifestyle advice			
True ^[2]	234 (98.3) [95.8-99.5]	57 (95.0) [86.1-99.0]	45 (95.7) [85.5-99.5]
False	4 (1.7)	3 (5.0)	2 (4.3)
Don't know	0	0	0
Recommend follow up with his doctor			
True ^[2]	234 (98.3) [95.8-99.5]	60 (100.0) [94.0-100.0]	46 (97.9) [88.7-99.9]
False	3 (1.3)	0	1 (2.1)
Don't know	1 (0.4)	0	0
Question 20: Please select True/False/Don't Know for the following statements.			
Pharmacists should provide lifestyle advice to all men with Erectile Dysfunction (ED) who request Viagra Connect.			

Table 4.1 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by participation in the Viagra Connect pharmacist training - Completed surveys

Question	Participation in the Viagra Connect Pharmacist Training		
	Yes (N=238) n (%) [95% CI] ^[1]	No (N=60) n (%) [95% CI] ^[1]	Don't recall (N=47) n (%) [95% CI] ^[1]
True ^[2]	206 (86.6) [81.6-90.6]	52 (86.7) [75.4-94.1]	41 (87.2) [74.3-95.2]
False	23 (9.7)	8 (13.3)	5 (10.6)
Don't know	9 (3.8)	0	1 (2.1)
Lifestyle advice includes losing weight, stopping smoking, cutting back on alcohol and recreational drugs, exercising regularly and reducing stress.			
True ^[2]	237 (99.6) [97.7-100.0]	60 (100.0) [94.0-100.0]	47 (100.0) [92.5-100.0]
False	1 (0.4)	0	0
Don't know	0	0	0
All patients supplied with Viagra Connect should be advised to consult their doctor within 6 months from the first supply.			
True ^[2]	215 (90.3) [85.9-93.8]	48 (80.0) [67.7-89.2]	38 (80.9) [66.7-90.9]
False	17 (7.1)	9 (15.0)	6 (12.8)
Don't know	6 (2.5)	3 (5.0)	3 (6.4)
All patients who are refused Viagra Connect should be advised to contact their doctor.			
True ^[2]	212 (89.1) [84.4-92.7]	55 (91.7) [81.6-97.2]	45 (95.7) [85.5-99.5]
False	23 (9.7)	5 (8.3)	2 (4.3)
Don't know	3 (1.3)	0	0
Question 21: Complete True/False/Don't know for the following statement: Patients should be advised to STOP TAKING Viagra Connect and seek medical attention immediately if they experience the following symptoms.			
Chest pains			
True ^[2]	237 (99.6) [97.7-100.0]	60 (100.0) [94.0-100.0]	47 (100.0) [92.5-100.0]
False	0	0	0
Don't know	1 (0.4)	0	0

Table 4.1 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by participation in the Viagra Connect pharmacist training - Completed surveys

Question	Participation in the Viagra Connect Pharmacist Training		
	Yes (N=238) n (%) [95% CI] ^[1]	No (N=60) n (%) [95% CI] ^[1]	Don't recall (N=47) n (%) [95% CI] ^[1]
Persistent and sometimes painful erection lasting longer than 4 hours			
True ^[2]	234 (98.3) [95.8-99.5]	60 (100.0) [94.0-100.0]	46 (97.9) [88.7-99.9]
False	1 (0.4)	0	0
Don't know	3 (1.3)	0	1 (2.1)
Dyspepsia			
True	32 (13.4)	6 (10.0)	5 (10.6)
False ^[2]	199 (83.6) [78.3-88.1]	52 (86.7) [75.4-94.1]	40 (85.1) [71.7-93.8]
Don't know	7 (2.9)	2 (3.3)	2 (4.3)
Sudden decrease or loss of vision			
True ^[2]	238 (100.0) [98.5-100.0]	60 (100.0) [94.0-100.0]	46 (97.9) [88.7-99.9]
False	0	0	0
Don't know	0	0	1 (2.1)
Headache			
True	50 (21.0)	16 (26.7)	6 (12.8)
False ^[2]	183 (76.9) [71.0-82.1]	41 (68.3) [55.0-79.7]	39 (83.0) [69.2-92.4]
Don't know	5 (2.1)	3 (5.0)	2 (4.3)
Allergic reaction (with symptoms of wheeziness, difficulty breathing or dizziness)			
True ^[2]	238 (100.0) [98.5-100.0]	60 (100.0) [94.0-100.0]	47 (100.0) [92.5-100.0]
False	0	0	0
Don't know	0	0	0
Nausea			
True	32 (13.4)	13 (21.7)	8 (17.0)

Table 4.1 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by participation in the Viagra Connect pharmacist training - Completed surveys

Question	Participation in the Viagra Connect Pharmacist Training		
	Yes (N=238) n (%) [95% CI] ^[1]	No (N=60) n (%) [95% CI] ^[1]	Don't recall (N=47) n (%) [95% CI] ^[1]
False ^[2]	194 (81.5) [76.0-86.2]	44 (73.3) [60.3-83.9]	36 (76.6) [62.0-87.7]
Don't know	12 (5.0)	3 (5.0)	3 (6.4)
Serious skin reactions (eg, Stevens-Johnson Syndrome (SJS))			
True ^[2]	233 (97.9) [95.2-99.3]	60 (100.0) [94.0-100.0]	47 (100.0) [92.5-100.0]
False	2 (0.8)	0	0
Don't know	3 (1.3)	0	0
Seizures or fits			
True ^[2]	233 (97.9) [95.2-99.3]	59 (98.3) [91.1-100.0]	47 (100.0) [92.5-100.0]
False	1 (0.4)	0	0
Don't know	4 (1.7)	1 (1.7)	0

Source: Appendix B: Table 4.1

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 4.2 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys

Question	Number of Patients Requested to Purchase Viagra Connect in the Last 6 months			
	1-10 (N=170) n (%) [95% CI] ^[1]	11-30 (N=117) n (%) [95% CI] ^[1]	More than 30 (N=58) n (%) [95% CI] ^[1]	I don't know (N=0) n (%) [95% CI] ^[1]
Question 18: Which of the following MAY be a cause of Erectile Dysfunction (ED) and should be considered when assessing a patient for suitability for Viagra Connect. Please select True/False/Don't Know.				
Undiagnosed depression				
True ^[2]	153 (90.0) [84.5-94.1]	101 (86.3) [78.7-92.0]	54 (93.1) [83.3-98.1]	0
False	13 (7.6)	12 (10.3)	2 (3.4)	0
Don't know	4 (2.4)	4 (3.4)	2 (3.4)	0
Anxiety				
True ^[2]	161 (94.7) [90.2-97.6]	108 (92.3) [85.9-96.4]	55 (94.8) [85.6-98.9]	0
False	5 (2.9)	6 (5.1)	2 (3.4)	0
Don't know	4 (2.4)	3 (2.6)	1 (1.7)	0
Excessive alcohol use				
True ^[2]	165 (97.1) [93.3-99.0]	115 (98.3) [94.0-99.8]	55 (94.8) [85.6-98.9]	0
False	3 (1.8)	2 (1.7)	3 (5.2)	0
Don't know	2 (1.2)	0	0	0
Hypertension				
True ^[2]	124 (72.9) [65.6-79.5]	76 (65.0) [55.6-73.5]	42 (72.4) [59.1-83.3]	0
False	39 (22.9)	32 (27.4)	12 (20.7)	0
Don't know	7 (4.1)	9 (7.7)	4 (6.9)	0
Diabetes mellitus				
True ^[2]	159 (93.5) [88.7-96.7]	108 (92.3) [85.9-96.4]	55 (94.8) [85.6-98.9]	0
False	7 (4.1)	6 (5.1)	2 (3.4)	0

Table 4.2 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys

Question	Number of Patients Requested to Purchase Viagra Connect in the Last 6 months			
	1-10 (N=170) n (%) [95% CI] ^[1]	11-30 (N=117) n (%) [95% CI] ^[1]	More than 30 (N=58) n (%) [95% CI] ^[1]	I don't know (N=0) n (%) [95% CI] ^[1]
Don't know	4 (2.4)	3 (2.6)	1 (1.7)	0
Hypercholesterolemia				
True ^[2]	102 (60.0) [52.2-67.4]	63 (53.8) [44.4-63.1]	31 (53.4) [39.9-66.7]	0
False	52 (30.6)	39 (33.3)	18 (31.0)	0
Don't know	16 (9.4)	15 (12.8)	9 (15.5)	0
Cardiovascular disease				
True ^[2]	156 (91.8) [86.6-95.4]	99 (84.6) [76.8-90.6]	56 (96.6) [88.1-99.6]	0
False	12 (7.1)	14 (12.0)	2 (3.4)	0
Don't know	2 (1.2)	4 (3.4)	0	0
Osteoarthritis				
True	9 (5.3)	7 (6.0)	4 (6.9)	0
False ^[2]	144 (84.7) [78.4-89.8]	100 (85.5) [77.8-91.3]	46 (79.3) [66.6-88.8]	0
Don't know	17 (10.0)	10 (8.5)	8 (13.8)	0
Question 19: If a patient requests Viagra Connect but shows evidence of undiagnosed depression, anxiety or excessive alcohol use, which action should you take? Please select True/False/Don't Know.				
Provide lifestyle advice				
True ^[2]	164 (96.5) [92.5-98.7]	115 (98.3) [94.0-99.8]	57 (98.3) [90.8-100.0]	0
False	6 (3.5)	2 (1.7)	1 (1.7)	0
Don't know	0	0	0	0
Recommend follow up with his doctor				
True ^[2]	168 (98.8) [95.8-99.9]	115 (98.3) [94.0-99.8]	57 (98.3) [90.8-100.0]	0
False	2 (1.2)	2 (1.7)	0	0

Table 4.2 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys

Question	Number of Patients Requested to Purchase Viagra Connect in the Last 6 months			
	1-10 (N=170) n (%) [95% CI] ^[1]	11-30 (N=117) n (%) [95% CI] ^[1]	More than 30 (N=58) n (%) [95% CI] ^[1]	I don't know (N=0) n (%) [95% CI] ^[1]
Don't know	0	0	1 (1.7)	0
Question 20: Please select True/False/Don't Know for the following statements.				
Pharmacists should provide lifestyle advice to all men with Erectile Dysfunction (ED) who request Viagra Connect.				
True ^[2]	152 (89.4) [83.8-93.6]	99 (84.6) [76.8-90.6]	48 (82.8) [70.6-91.4]	0
False	12 (7.1)	15 (12.8)	9 (15.5)	0
Don't know	6 (3.5)	3 (2.6)	1 (1.7)	0
Lifestyle advice includes losing weight, stopping smoking, cutting back on alcohol and recreational drugs, exercising regularly and reducing stress.				
True ^[2]	170 (100.0) [97.9-100.0]	116 (99.1) [95.3-100.0]	58 (100.0) [93.8-100.0]	0
False	0	1 (0.9)	0	0
Don't know	0	0	0	0
All patients supplied with Viagra Connect should be advised to consult their doctor within 6 months from the first supply.				
True ^[2]	153 (90.0) [84.5-94.1]	96 (82.1) [73.9-88.5]	52 (89.7) [78.8-96.1]	0
False	11 (6.5)	17 (14.5)	4 (6.9)	0
Don't know	6 (3.5)	4 (3.4)	2 (3.4)	0
All patients who are refused Viagra Connect should be advised to contact their doctor.				
True ^[2]	154 (90.6) [85.2-94.5]	107 (91.5) [84.8-95.8]	51 (87.9) [76.7-95.0]	0
False	14 (8.2)	9 (7.7)	7 (12.1)	0
Don't know	2 (1.2)	1 (0.9)	0	0
Question 21: Complete True/False/Don't know for the following statement: Patients should be advised to STOP TAKING Viagra Connect and seek medical attention immediately if they experience the following symptoms.				

Table 4.2 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys

Question	Number of Patients Requested to Purchase Viagra Connect in the Last 6 months			
	1-10 (N=170) n (%) [95% CI] ^[1]	11-30 (N=117) n (%) [95% CI] ^[1]	More than 30 (N=58) n (%) [95% CI] ^[1]	I don't know (N=0) n (%) [95% CI] ^[1]
Chest pains				
True ^[2]	170 (100.0) [97.9-100.0]	117 (100.0) [96.9-100.0]	57 (98.3) [90.8-100.0]	0
False	0	0	0	0
Don't know	0	0	1 (1.7)	0
Persistent and sometimes painful erection lasting longer than 4 hours				
True ^[2]	170 (100.0) [97.9-100.0]	116 (99.1) [95.3-100.0]	54 (93.1) [83.3-98.1]	0
False	0	0	1 (1.7)	0
Don't know	0	1 (0.9)	3 (5.2)	0
Dyspepsia				
True	16 (9.4)	18 (15.4)	9 (15.5)	0
False ^[2]	148 (87.1) [81.1-91.7]	98 (83.8) [75.8-89.9]	45 (77.6) [64.7-87.5]	0
Don't know	6 (3.5)	1 (0.9)	4 (6.9)	0
Sudden decrease or loss of vision				
True ^[2]	170 (100.0) [97.9-100.0]	117 (100.0) [96.9-100.0]	57 (98.3) [90.8-100.0]	0
False	0	0	0	0
Don't know	0	0	1 (1.7)	0
Headache				
True	32 (18.8)	31 (26.5)	9 (15.5)	0
False ^[2]	132 (77.6) [70.6-83.7]	83 (70.9) [61.8-79.0]	48 (82.8) [70.6-91.4]	0
Don't know	6 (3.5)	3 (2.6)	1 (1.7)	0
Allergic reaction (with symptoms of wheeziness, difficulty breathing or dizziness)				

Table 4.2 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys

Question	Number of Patients Requested to Purchase Viagra Connect in the Last 6 months			
	1-10 (N=170) n (%) [95% CI] ^[1]	11-30 (N=117) n (%) [95% CI] ^[1]	More than 30 (N=58) n (%) [95% CI] ^[1]	I don't know (N=0) n (%) [95% CI] ^[1]
True ^[2]	170 (100.0) [97.9-100.0]	117 (100.0) [96.9-100.0]	58 (100.0) [93.8-100.0]	0
False	0	0	0	0
Don't know	0	0	0	0
Nausea				
True	23 (13.5)	21 (17.9)	9 (15.5)	0
False ^[2]	135 (79.4) [72.5-85.2]	92 (78.6) [70.1-85.7]	47 (81.0) [68.6-90.1]	0
Don't know	12 (7.1)	4 (3.4)	2 (3.4)	0
Serious skin reactions (eg, Stevens-Johnson Syndrome (SJS))				
True ^[2]	168 (98.8) [95.8-99.9]	114 (97.4) [92.7-99.5]	58 (100.0) [93.8-100.0]	0
False	1 (0.6)	1 (0.9)	0	0
Don't know	1 (0.6)	2 (1.7)	0	0
Seizures or fits				
True ^[2]	170 (100.0) [97.9-100.0]	114 (97.4) [92.7-99.5]	55 (94.8) [85.6-98.9]	0
False	0	1 (0.9)	0	0
Don't know	0	2 (1.7)	3 (5.2)	0

Source: Appendix B: Table 4.2

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 4.3 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by place of pharmacy - Completed surveys

Question	Place of Pharmacy	
	Urban (N=255) n (%) [95% CI] ^[1]	Rural (N=90) n (%) [95% CI] ^[1]
Question 18: Which of the following MAY be a cause of Erectile Dysfunction (ED) and should be considered when assessing a patient for suitability for Viagra Connect. Please select True/False/Don't Know.		
Undiagnosed depression		
True ^[2]	230 (90.2) [85.9-93.6]	78 (86.7) [77.9-92.9]
False	17 (6.7)	10 (11.1)
Don't know	8 (3.1)	2 (2.2)
Anxiety		
True ^[2]	240 (94.1) [90.5-96.7]	84 (93.3) [86.1-97.5]
False	9 (3.5)	4 (4.4)
Don't know	6 (2.4)	2 (2.2)
Excessive alcohol use		
True ^[2]	248 (97.3) [94.4-98.9]	87 (96.7) [90.6-99.3]
False	6 (2.4)	2 (2.2)
Don't know	1 (0.4)	1 (1.1)
Hypertension		
True ^[2]	181 (71.0) [65.0-76.5]	61 (67.8) [57.1-77.2]
False	58 (22.7)	25 (27.8)
Don't know	16 (6.3)	4 (4.4)
Diabetes mellitus		
True ^[2]	240 (94.1) [90.5-96.7]	82 (91.1) [83.2-96.1]
False	9 (3.5)	6 (6.7)
Don't know	6 (2.4)	2 (2.2)
Hypercholesterolemia		

Table 4.3 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by place of pharmacy - Completed surveys

Question	Place of Pharmacy	
	Urban (N=255) n (%) [95% CI] ^[1]	Rural (N=90) n (%) [95% CI] ^[1]
True ^[2]	140 (54.9) [48.6-61.1]	56 (62.2) [51.4-72.2]
False	81 (31.8)	28 (31.1)
Don't know	34 (13.3)	6 (6.7)
Cardiovascular disease		
True ^[2]	227 (89.0) [84.5-92.6]	84 (93.3) [86.1-97.5]
False	23 (9.0)	5 (5.6)
Don't know	5 (2.0)	1 (1.1)
Osteoarthritis		
True	11 (4.3)	9 (10.0)
False ^[2]	214 (83.9) [78.8-88.2]	76 (84.4) [75.3-91.2]
Don't know	30 (11.8)	5 (5.6)
Question 19: If a patient requests Viagra Connect but shows evidence of undiagnosed depression, anxiety or excessive alcohol use, which action should you take? Please select True/False/Don't Know.		
Provide lifestyle advice		
True ^[2]	246 (96.5) [93.4-98.4]	90 (100.0) [96.0-100.0]
False	9 (3.5)	0
Don't know	0	0
Recommend follow up with his doctor		
True ^[2]	250 (98.0) [95.5-99.4]	90 (100.0) [96.0-100.0]
False	4 (1.6)	0
Don't know	1 (0.4)	0
Question 20: Please select True/False/Don't Know for the following statements.		
Pharmacists should provide lifestyle advice to all men with Erectile Dysfunction (ED) who request Viagra Connect.		

Table 4.3 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by place of pharmacy - Completed surveys

Question	Place of Pharmacy	
	Urban (N=255) n (%) [95% CI] ^[1]	Rural (N=90) n (%) [95% CI] ^[1]
True ^[2]	216 (84.7) [79.7-88.9]	83 (92.2) [84.6-96.8]
False	31 (12.2)	5 (5.6)
Don't know	8 (3.1)	2 (2.2)
Lifestyle advice includes losing weight, stopping smoking, cutting back on alcohol and recreational drugs, exercising regularly and reducing stress.		
True ^[2]	254 (99.6) [97.8-100.0]	90 (100.0) [96.0-100.0]
False	1 (0.4)	0
Don't know	0	0
All patients supplied with Viagra Connect should be advised to consult their doctor within 6 months from the first supply.		
True ^[2]	220 (86.3) [81.4-90.2]	81 (90.0) [81.9-95.3]
False	26 (10.2)	6 (6.7)
Don't know	9 (3.5)	3 (3.3)
All patients who are refused Viagra Connect should be advised to contact their doctor.		
True ^[2]	231 (90.6) [86.3-93.9]	81 (90.0) [81.9-95.3]
False	22 (8.6)	8 (8.9)
Don't know	2 (0.8)	1 (1.1)
Question 21: Complete True/False/Don't know for the following statement: Patients should be advised to STOP TAKING Viagra Connect and seek medical attention immediately if they experience the following symptoms.		
Chest pains		
True ^[2]	254 (99.6) [97.8-100.0]	90 (100.0) [96.0-100.0]
False	0	0
Don't know	1 (0.4)	0

Table 4.3 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by place of pharmacy - Completed surveys

Question	Place of Pharmacy	
	Urban (N=255) n (%) [95% CI] ^[1]	Rural (N=90) n (%) [95% CI] ^[1]
Persistent and sometimes painful erection lasting longer than 4 hours		
True ^[2]	250 (98.0) [95.5-99.4]	90 (100.0) [96.0-100.0]
False	1 (0.4)	0
Don't know	4 (1.6)	0
Dyspepsia		
True	35 (13.7)	8 (8.9)
False ^[2]	211 (82.7) [77.5-87.2]	80 (88.9) [80.5-94.5]
Don't know	9 (3.5)	2 (2.2)
Sudden decrease or loss of vision		
True ^[2]	254 (99.6) [97.8-100.0]	90 (100.0) [96.0-100.0]
False	0	0
Don't know	1 (0.4)	0
Headache		
True	51 (20.0)	21 (23.3)
False ^[2]	195 (76.5) [70.8-81.5]	68 (75.6) [65.4-84.0]
Don't know	9 (3.5)	1 (1.1)
Allergic reaction (with symptoms of wheeziness, difficulty breathing or dizziness)		
True ^[2]	255 (100.0) [98.6-100.0]	90 (100.0) [96.0-100.0]
False	0	0
Don't know	0	0
Nausea		
True	40 (15.7)	13 (14.4)

Table 4.3 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by place of pharmacy - Completed surveys

Question	Place of Pharmacy	
	Urban (N=255) n (%) [95% CI] ^[1]	Rural (N=90) n (%) [95% CI] ^[1]
False ^[2]	200 (78.4) [72.9-83.3]	74 (82.2) [72.7-89.5]
Don't know	15 (5.9)	3 (3.3)
Serious skin reactions (eg, Stevens-Johnson Syndrome (SJS))		
True ^[2]	251 (98.4) [96.0-99.6]	89 (98.9) [94.0-100.0]
False	1 (0.4)	1 (1.1)
Don't know	3 (1.2)	0
Seizures or fits		
True ^[2]	250 (98.0) [95.5-99.4]	89 (98.9) [94.0-100.0]
False	1 (0.4)	0
Don't know	4 (1.6)	1 (1.1)

Source: Appendix B: Table 4.3

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 4.4 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by type of pharmacy - Completed surveys

Question	Type of Pharmacy		
	Large Multiple Pharmacy Chain (more than 100 stores) (N=157) n (%) [95% CI] ^[1]	Small Multiple Pharmacy Chain (6 to 99 stores) (N=61) n (%) [95% CI] ^[1]	Independent Pharmacy (1 to 5 stores) (N=127) n (%) [95% CI] ^[1]
Question 18: Which of the following MAY be a cause of Erectile Dysfunction (ED) and should be considered when assessing a patient for suitability for Viagra Connect. Please select True/False/Don't Know.			
Undiagnosed depression			
True ^[2]	139 (88.5) [82.5-93.1]	56 (91.8) [81.9-97.3]	113 (89.0) [82.2-93.8]
False	14 (8.9)	3 (4.9)	10 (7.9)
Don't know	4 (2.5)	2 (3.3)	4 (3.1)
Anxiety			
True ^[2]	145 (92.4) [87.0-96.0]	59 (96.7) [88.7-99.6]	120 (94.5) [89.0-97.8]
False	8 (5.1)	2 (3.3)	3 (2.4)
Don't know	4 (2.5)	0	4 (3.1)
Excessive alcohol use			
True ^[2]	152 (96.8) [92.7-99.0]	59 (96.7) [88.7-99.6]	124 (97.6) [93.3-99.5]
False	4 (2.5)	2 (3.3)	2 (1.6)
Don't know	1 (0.6)	0	1 (0.8)
Hypertension			
True ^[2]	109 (69.4) [61.6-76.5]	40 (65.6) [52.3-77.3]	93 (73.2) [64.6-80.7]
False	37 (23.6)	17 (27.9)	29 (22.8)
Don't know	11 (7.0)	4 (6.6)	5 (3.9)
Diabetes mellitus			
True ^[2]	147 (93.6) [88.6-96.9]	57 (93.4) [84.1-98.2]	118 (92.9) [87.0-96.7]
False	5 (3.2)	4 (6.6)	6 (4.7)

Table 4.4 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by type of pharmacy - Completed surveys

Question	Type of Pharmacy		
	Large Multiple Pharmacy Chain (more than 100 stores) (N=157) n (%) [95% CI] ^[1]	Small Multiple Pharmacy Chain (6 to 99 stores) (N=61) n (%) [95% CI] ^[1]	Independent Pharmacy (1 to 5 stores) (N=127) n (%) [95% CI] ^[1]
Don't know	5 (3.2)	0	3 (2.4)
Hypercholesterolemia			
True ^[2]	93 (59.2) [51.1-67.0]	36 (59.0) [45.7-71.4]	67 (52.8) [43.7-61.7]
False	43 (27.4)	24 (39.3)	42 (33.1)
Don't know	21 (13.4)	1 (1.6)	18 (14.2)
Cardiovascular disease			
True ^[2]	144 (91.7) [86.3-95.5]	54 (88.5) [77.8-95.3]	113 (89.0) [82.2-93.8]
False	8 (5.1)	7 (11.5)	13 (10.2)
Don't know	5 (3.2)	0	1 (0.8)
Osteoarthritis			
True	8 (5.1)	6 (9.8)	6 (4.7)
False ^[2]	132 (84.1) [77.4-89.4]	50 (82.0) [70.0-90.6]	108 (85.0) [77.6-90.7]
Don't know	17 (10.8)	5 (8.2)	13 (10.2)
Question 19: If a patient requests Viagra Connect but shows evidence of undiagnosed depression, anxiety or excessive alcohol use, which action should you take? Please select True/False/Don't Know.			
Provide lifestyle advice			
True ^[2]	154 (98.1) [94.5-99.6]	59 (96.7) [88.7-99.6]	123 (96.9) [92.1-99.1]
False	3 (1.9)	2 (3.3)	4 (3.1)
Don't know	0	0	0
Recommend follow up with his doctor			
True ^[2]	155 (98.7) [95.5-99.8]	60 (98.4) [91.2-100.0]	125 (98.4) [94.4-99.8]

Table 4.4 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by type of pharmacy - Completed surveys

Question	Type of Pharmacy		
	Large Multiple Pharmacy Chain (more than 100 stores) (N=157) n (%) [95% CI] ^[1]	Small Multiple Pharmacy Chain (6 to 99 stores) (N=61) n (%) [95% CI] ^[1]	Independent Pharmacy (1 to 5 stores) (N=127) n (%) [95% CI] ^[1]
False	2 (1.3)	0	2 (1.6)
Don't know	0	1 (1.6)	0
Question 20: Please select True/False/Don't Know for the following statements.			
Pharmacists should provide lifestyle advice to all men with Erectile Dysfunction (ED) who request Viagra Connect.			
True ^[2]	133 (84.7) [78.1-90.0]	56 (91.8) [81.9-97.3]	110 (86.6) [79.4-92.0]
False	16 (10.2)	4 (6.6)	16 (12.6)
Don't know	8 (5.1)	1 (1.6)	1 (0.8)
Lifestyle advice includes losing weight, stopping smoking, cutting back on alcohol and recreational drugs, exercising regularly and reducing stress.			
True ^[2]	157 (100.0) [97.7-100.0]	61 (100.0) [94.1-100.0]	126 (99.2) [95.7-100.0]
False	0	0	1 (0.8)
Don't know	0	0	0
All patients supplied with Viagra Connect should be advised to consult their doctor within 6 months from the first supply.			
True ^[2]	149 (94.9) [90.2-97.8]	54 (88.5) [77.8-95.3]	98 (77.2) [68.9-84.1]
False	4 (2.5)	4 (6.6)	24 (18.9)
Don't know	4 (2.5)	3 (4.9)	5 (3.9)
All patients who are refused Viagra Connect should be advised to contact their doctor.			
True ^[2]	140 (89.2) [83.2-93.6]	56 (91.8) [81.9-97.3]	116 (91.3) [85.0-95.6]
False	15 (9.6)	5 (8.2)	10 (7.9)
Don't know	2 (1.3)	0	1 (0.8)

Table 4.4 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by type of pharmacy - Completed surveys

Question	Type of Pharmacy		
	Large Multiple Pharmacy Chain (more than 100 stores) (N=157) n (%) [95% CI] ^[1]	Small Multiple Pharmacy Chain (6 to 99 stores) (N=61) n (%) [95% CI] ^[1]	Independent Pharmacy (1 to 5 stores) (N=127) n (%) [95% CI] ^[1]
Question 21: Complete True/False/Don't know for the following statement: Patients should be advised to STOP TAKING Viagra Connect and seek medical attention immediately if they experience the following symptoms.			
Chest pains			
True ^[2]	157 (100.0) [97.7-100.0]	60 (98.4) [91.2-100.0]	127 (100.0) [97.1-100.0]
False	0	0	0
Don't know	0	1 (1.6)	0
Persistent and sometimes painful erection lasting longer than 4 hours			
True ^[2]	156 (99.4) [96.5-100.0]	60 (98.4) [91.2-100.0]	124 (97.6) [93.3-99.5]
False	0	0	1 (0.8)
Don't know	1 (0.6)	1 (1.6)	2 (1.6)
Dyspepsia			
True	19 (12.1)	5 (8.2)	19 (15.0)
False ^[2]	133 (84.7) [78.1-90.0]	54 (88.5) [77.8-95.3]	104 (81.9) [74.1-88.2]
Don't know	5 (3.2)	2 (3.3)	4 (3.1)
Sudden decrease or loss of vision			
True ^[2]	157 (100.0) [97.7-100.0]	61 (100.0) [94.1-100.0]	126 (99.2) [95.7-100.0]
False	0	0	0
Don't know	0	0	1 (0.8)
Headache			
True	32 (20.4)	9 (14.8)	31 (24.4)
False ^[2]	122 (77.7) [70.4-84.0]	51 (83.6) [71.9-91.8]	90 (70.9) [62.1-78.6]

Table 4.4 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by type of pharmacy - Completed surveys

Question	Type of Pharmacy		
	Large Multiple Pharmacy Chain (more than 100 stores) (N=157) n (%) [95% CI] ^[1]	Small Multiple Pharmacy Chain (6 to 99 stores) (N=61) n (%) [95% CI] ^[1]	Independent Pharmacy (1 to 5 stores) (N=127) n (%) [95% CI] ^[1]
Don't know	3 (1.9)	1 (1.6)	6 (4.7)
Allergic reaction (with symptoms of wheeziness, difficulty breathing or dizziness)			
True ^[2]	157 (100.0) [97.7-100.0]	61 (100.0) [94.1-100.0]	127 (100.0) [97.1-100.0]
False	0	0	0
Don't know	0	0	0
Nausea			
True	19 (12.1)	8 (13.1)	26 (20.5)
False ^[2]	129 (82.2) [75.3-87.8]	51 (83.6) [71.9-91.8]	94 (74.0) [65.5-81.4]
Don't know	9 (5.7)	2 (3.3)	7 (5.5)
Serious skin reactions (eg, Stevens-Johnson Syndrome (SJS))			
True ^[2]	157 (100.0) [97.7-100.0]	61 (100.0) [94.1-100.0]	122 (96.1) [91.1-98.7]
False	0	0	2 (1.6)
Don't know	0	0	3 (2.4)
Seizures or fits			
True ^[2]	155 (98.7) [95.5-99.8]	60 (98.4) [91.2-100.0]	124 (97.6) [93.3-99.5]
False	0	0	1 (0.8)
Don't know	2 (1.3)	1 (1.6)	2 (1.6)

Source: Appendix B: Table 4.4

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 4.5 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%) [95% CI] ^[1]	2-5 years (N=39) n (%) [95% CI] ^[1]	6-10 years (N=64) n (%) [95% CI] ^[1]	11-20 years (N=99) n (%) [95% CI] ^[1]	Greater than 20 years (N=119) n (%) [95% CI] ^[1]
Question 18: Which of the following MAY be a cause of Erectile Dysfunction (ED) and should be considered when assessing a patient for suitability for Viagra Connect. Please select True/False/Don't Know.					
Undiagnosed depression					
True ^[2]	23 (95.8) [78.9-99.9]	36 (92.3) [79.1-98.4]	59 (92.2) [82.7-97.4]	84 (84.8) [76.2-91.3]	106 (89.1) [82.0-94.1]
False	1 (4.2)	2 (5.1)	3 (4.7)	11 (11.1)	10 (8.4)
Don't know	0	1 (2.6)	2 (3.1)	4 (4.0)	3 (2.5)
Anxiety					
True ^[2]	24 (100.0) [85.8-100.0]	38 (97.4) [86.5-99.9]	60 (93.8) [84.8-98.3]	90 (90.9) [83.4-95.8]	112 (94.1) [88.3-97.6]
False	0	1 (2.6)	2 (3.1)	3 (3.0)	7 (5.9)
Don't know	0	0	2 (3.1)	6 (6.1)	0
Excessive alcohol use					
True ^[2]	24 (100.0) [85.8-100.0]	38 (97.4) [86.5-99.9]	62 (96.9) [89.2-99.6]	94 (94.9) [88.6-98.3]	117 (98.3) [94.1-99.8]
False	0	1 (2.6)	1 (1.6)	4 (4.0)	2 (1.7)
Don't know	0	0	1 (1.6)	1 (1.0)	0
Hypertension					

Table 4.5 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%) [95% CI] ^[1]	2-5 years (N=39) n (%) [95% CI] ^[1]	6-10 years (N=64) n (%) [95% CI] ^[1]	11-20 years (N=99) n (%) [95% CI] ^[1]	Greater than 20 years (N=119) n (%) [95% CI] ^[1]
True ^[2]	18 (75.0) [53.3-90.2]	27 (69.2) [52.4-83.0]	46 (71.9) [59.2-82.4]	65 (65.7) [55.4-74.9]	86 (72.3) [63.3-80.1]
False	3 (12.5)	9 (23.1)	15 (23.4)	28 (28.3)	28 (23.5)
Don't know	3 (12.5)	3 (7.7)	3 (4.7)	6 (6.1)	5 (4.2)
Diabetes mellitus					
True ^[2]	22 (91.7) [73.0-99.0]	34 (87.2) [72.6-95.7]	61 (95.3) [86.9-99.0]	91 (91.9) [84.7-96.4]	114 (95.8) [90.5-98.6]
False	0	3 (7.7)	2 (3.1)	5 (5.1)	5 (4.2)
Don't know	2 (8.3)	2 (5.1)	1 (1.6)	3 (3.0)	0
Hypercholesterolemia					
True ^[2]	14 (58.3) [36.6-77.9]	15 (38.5) [23.4-55.4]	36 (56.3) [43.3-68.6]	62 (62.6) [52.3-72.1]	69 (58.0) [48.6-67.0]
False	7 (29.2)	20 (51.3)	20 (31.3)	24 (24.2)	38 (31.9)
Don't know	3 (12.5)	4 (10.3)	8 (12.5)	13 (13.1)	12 (10.1)
Cardiovascular disease					
True ^[2]	23 (95.8) [78.9-99.9]	34 (87.2) [72.6-95.7]	55 (85.9) [75.0-93.4]	89 (89.9) [82.2-95.0]	110 (92.4) [86.1-96.5]
False	1 (4.2)	4 (10.3)	7 (10.9)	7 (7.1)	9 (7.6)

Table 4.5 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%) [95% CI] ^[1]	2-5 years (N=39) n (%) [95% CI] ^[1]	6-10 years (N=64) n (%) [95% CI] ^[1]	11-20 years (N=99) n (%) [95% CI] ^[1]	Greater than 20 years (N=119) n (%) [95% CI] ^[1]
Don't know	0	1 (2.6)	2 (3.1)	3 (3.0)	0
Osteoarthritis					
True	0	3 (7.7)	6 (9.4)	6 (6.1)	5 (4.2)
False ^[2]	20 (83.3) [62.6-95.3]	33 (84.6) [69.5-94.1]	46 (71.9) [59.2-82.4]	84 (84.8) [76.2-91.3]	107 (89.9) [83.0-94.7]
Don't know	4 (16.7)	3 (7.7)	12 (18.8)	9 (9.1)	7 (5.9)
Question 19: If a patient requests Viagra Connect but shows evidence of undiagnosed depression, anxiety or excessive alcohol use, which action should you take? Please select True/False/Don't Know.					
Provide lifestyle advice					
True ^[2]	23 (95.8) [78.9-99.9]	39 (100.0) [91.0-100.0]	62 (96.9) [89.2-99.6]	98 (99.0) [94.5-100.0]	114 (95.8) [90.5-98.6]
False	1 (4.2)	0	2 (3.1)	1 (1.0)	5 (4.2)
Don't know	0	0	0	0	0
Recommend follow up with his doctor					
True ^[2]	23 (95.8) [78.9-99.9]	39 (100.0) [91.0-100.0]	64 (100.0) [94.4-100.0]	97 (98.0) [92.9-99.8]	117 (98.3) [94.1-99.8]
False	1 (4.2)	0	0	1 (1.0)	2 (1.7)
Don't know	0	0	0	1 (1.0)	0

Table 4.5 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%) [95% CI] ^[1]	2-5 years (N=39) n (%) [95% CI] ^[1]	6-10 years (N=64) n (%) [95% CI] ^[1]	11-20 years (N=99) n (%) [95% CI] ^[1]	Greater than 20 years (N=119) n (%) [95% CI] ^[1]
Question 20: Please select True/False/Don't Know for the following statements.					
Pharmacists should provide lifestyle advice to all men with Erectile Dysfunction (ED) who request Viagra Connect.					
True ^[2]	20 (83.3) [62.6-95.3]	37 (94.9) [82.7-99.4]	54 (84.4) [73.1-92.2]	83 (83.8) [75.1-90.5]	105 (88.2) [81.0-93.4]
False	4 (16.7)	1 (2.6)	6 (9.4)	12 (12.1)	13 (10.9)
Don't know	0	1 (2.6)	4 (6.3)	4 (4.0)	1 (0.8)
Lifestyle advice includes losing weight, stopping smoking, cutting back on alcohol and recreational drugs, exercising regularly and reducing stress.					
True ^[2]	24 (100.0) [85.8-100.0]	39 (100.0) [91.0-100.0]	64 (100.0) [94.4-100.0]	99 (100.0) [96.3-100.0]	118 (99.2) [95.4-100.0]
False	0	0	0	0	1 (0.8)
Don't know	0	0	0	0	0
All patients supplied with Viagra Connect should be advised to consult their doctor within 6 months from the first supply.					
True ^[2]	22 (91.7) [73.0-99.0]	36 (92.3) [79.1-98.4]	60 (93.8) [84.8-98.3]	83 (83.8) [75.1-90.5]	100 (84.0) [76.2-90.1]
False	0	3 (7.7)	3 (4.7)	11 (11.1)	15 (12.6)
Don't know	2 (8.3)	0	1 (1.6)	5 (5.1)	4 (3.4)
All patients who are refused Viagra Connect should be advised to contact their doctor.					

Table 4.5 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%) [95% CI] ^[1]	2-5 years (N=39) n (%) [95% CI] ^[1]	6-10 years (N=64) n (%) [95% CI] ^[1]	11-20 years (N=99) n (%) [95% CI] ^[1]	Greater than 20 years (N=119) n (%) [95% CI] ^[1]
True ^[2]	23 (95.8) [78.9-99.9]	33 (84.6) [69.5-94.1]	59 (92.2) [82.7-97.4]	88 (88.9) [81.0-94.3]	109 (91.6) [85.1-95.9]
False	1 (4.2)	5 (12.8)	5 (7.8)	9 (9.1)	10 (8.4)
Don't know	0	1 (2.6)	0	2 (2.0)	0
Question 21: Complete True/False/Don't know for the following statement: Patients should be advised to STOP TAKING Viagra Connect and seek medical attention immediately if they experience the following symptoms.					
Chest pains					
True ^[2]	24 (100.0) [85.8-100.0]	39 (100.0) [91.0-100.0]	64 (100.0) [94.4-100.0]	98 (99.0) [94.5-100.0]	119 (100.0) [96.9-100.0]
False	0	0	0	0	0
Don't know	0	0	0	1 (1.0)	0
Persistent and sometimes painful erection lasting longer than 4 hours					
True ^[2]	24 (100.0) [85.8-100.0]	39 (100.0) [91.0-100.0]	63 (98.4) [91.6-100.0]	97 (98.0) [92.9-99.8]	117 (98.3) [94.1-99.8]
False	0	0	0	1 (1.0)	0
Don't know	0	0	1 (1.6)	1 (1.0)	2 (1.7)
Dyspepsia					
True	2 (8.3)	5 (12.8)	9 (14.1)	12 (12.1)	15 (12.6)

Table 4.5 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%) [95% CI] ^[1]	2-5 years (N=39) n (%) [95% CI] ^[1]	6-10 years (N=64) n (%) [95% CI] ^[1]	11-20 years (N=99) n (%) [95% CI] ^[1]	Greater than 20 years (N=119) n (%) [95% CI] ^[1]
False ^[2]	21 (87.5) [67.6-97.3]	34 (87.2) [72.6-95.7]	52 (81.3) [69.5-89.9]	84 (84.8) [76.2-91.3]	100 (84.0) [76.2-90.1]
Don't know	1 (4.2)	0	3 (4.7)	3 (3.0)	4 (3.4)
Sudden decrease or loss of vision					
True ^[2]	24 (100.0) [85.8-100.0]	39 (100.0) [91.0-100.0]	64 (100.0) [94.4-100.0]	99 (100.0) [96.3-100.0]	118 (99.2) [95.4-100.0]
False	0	0	0	0	0
Don't know	0	0	0	0	1 (0.8)
Headache					
True	6 (25.0)	9 (23.1)	11 (17.2)	19 (19.2)	27 (22.7)
False ^[2]	17 (70.8) [48.9-87.4]	29 (74.4) [57.9-87.0]	51 (79.7) [67.8-88.7]	77 (77.8) [68.3-85.5]	89 (74.8) [66.0-82.3]
Don't know	1 (4.2)	1 (2.6)	2 (3.1)	3 (3.0)	3 (2.5)
Allergic reaction (with symptoms of wheeziness, difficulty breathing or dizziness)					
True ^[2]	24 (100.0) [85.8-100.0]	39 (100.0) [91.0-100.0]	64 (100.0) [94.4-100.0]	99 (100.0) [96.3-100.0]	119 (100.0) [96.9-100.0]
False	0	0	0	0	0
Don't know	0	0	0	0	0

Table 4.5 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%) [95% CI] ^[1]	2-5 years (N=39) n (%) [95% CI] ^[1]	6-10 years (N=64) n (%) [95% CI] ^[1]	11-20 years (N=99) n (%) [95% CI] ^[1]	Greater than 20 years (N=119) n (%) [95% CI] ^[1]
Nausea					
True	2 (8.3)	6 (15.4)	11 (17.2)	14 (14.1)	20 (16.8)
False ^[2]	18 (75.0) [53.3-90.2]	32 (82.1) [66.5-92.5]	50 (78.1) [66.0-87.5]	82 (82.8) [73.9-89.7]	92 (77.3) [68.7-84.5]
Don't know	4 (16.7)	1 (2.6)	3 (4.7)	3 (3.0)	7 (5.9)
Serious skin reactions (eg, Stevens-Johnson Syndrome (SJS))					
True ^[2]	24 (100.0) [85.8-100.0]	39 (100.0) [91.0-100.0]	64 (100.0) [94.4-100.0]	95 (96.0) [90.0-98.9]	118 (99.2) [95.4-100.0]
False	0	0	0	2 (2.0)	0
Don't know	0	0	0	2 (2.0)	1 (0.8)
Seizures or fits					
True ^[2]	22 (91.7) [73.0-99.0]	39 (100.0) [91.0-100.0]	62 (96.9) [89.2-99.6]	97 (98.0) [92.9-99.8]	119 (100.0) [96.9-100.0]
False	0	0	0	1 (1.0)	0

Table 4.5 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%) [95% CI] ^[1]	2-5 years (N=39) n (%) [95% CI] ^[1]	6-10 years (N=64) n (%) [95% CI] ^[1]	11-20 years (N=99) n (%) [95% CI] ^[1]	Greater than 20 years (N=119) n (%) [95% CI] ^[1]
Don't know	2 (8.3)	0	2 (3.1)	1 (1.0)	0

Source: Appendix B: Table 4.5

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 4.6 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by age group - Completed surveys

Question	Age Group			
	22-30 years (N=68) n (%) [95% CI] ^[1]	31-40 years (N=117) n (%) [95% CI] ^[1]	41-60 years (N=139) n (%) [95% CI] ^[1]	Greater than 61 years (N=21) n (%) [95% CI] ^[1]
Question 18: Which of the following MAY be a cause of Erectile Dysfunction (ED) and should be considered when assessing a patient for suitability for Viagra Connect. Please select True/False/Don't Know.				
Undiagnosed depression				
True ^[2]	64 (94.1) [85.6-98.4]	105 (89.7) [82.8-94.6]	120 (86.3) [79.5-91.6]	19 (90.5) [69.6-98.8]
False	3 (4.4)	8 (6.8)	15 (10.8)	1 (4.8)
Don't know	1 (1.5)	4 (3.4)	4 (2.9)	1 (4.8)
Anxiety				
True ^[2]	66 (97.1) [89.8-99.6]	108 (92.3) [85.9-96.4]	129 (92.8) [87.2-96.5]	21 (100.0) [83.9-100.0]
False	2 (2.9)	2 (1.7)	9 (6.5)	0
Don't know	0	7 (6.0)	1 (0.7)	0
Excessive alcohol use				
True ^[2]	66 (97.1) [89.8-99.6]	112 (95.7) [90.3-98.6]	136 (97.8) [93.8-99.6]	21 (100.0) [83.9-100.0]
False	1 (1.5)	4 (3.4)	3 (2.2)	0
Don't know	1 (1.5)	1 (0.9)	0	0
Hypertension				
True ^[2]	46 (67.6) [55.2-78.5]	78 (66.7) [57.4-75.1]	102 (73.4) [65.2-80.5]	16 (76.2) [52.8-91.8]
False	16 (23.5)	32 (27.4)	31 (22.3)	4 (19.0)
Don't know	6 (8.8)	7 (6.0)	6 (4.3)	1 (4.8)
Diabetes mellitus				
True ^[2]	61 (89.7) [79.9-95.8]	106 (90.6) [83.8-95.2]	134 (96.4) [91.8-98.8]	21 (100.0) [83.9-100.0]
False	3 (4.4)	7 (6.0)	5 (3.6)	0

Table 4.6 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by age group - Completed surveys

Question	Age Group			
	22-30 years (N=68) n (%) [95% CI] ^[1]	31-40 years (N=117) n (%) [95% CI] ^[1]	41-60 years (N=139) n (%) [95% CI] ^[1]	Greater than 61 years (N=21) n (%) [95% CI] ^[1]
Don't know	4 (5.9)	4 (3.4)	0	0
Hypercholesterolemia				
True ^[2]	32 (47.1) [34.8-59.6]	68 (58.1) [48.6-67.2]	89 (64.0) [55.5-72.0]	7 (33.3) [14.6-57.0]
False	30 (44.1)	32 (27.4)	39 (28.1)	8 (38.1)
Don't know	6 (8.8)	17 (14.5)	11 (7.9)	6 (28.6)
Cardiovascular disease				
True ^[2]	59 (86.8) [76.4-93.8]	103 (88.0) [80.7-93.3]	131 (94.2) [89.0-97.5]	18 (85.7) [63.7-97.0]
False	7 (10.3)	10 (8.5)	8 (5.8)	3 (14.3)
Don't know	2 (2.9)	4 (3.4)	0	0
Osteoarthritis				
True	3 (4.4)	7 (6.0)	8 (5.8)	2 (9.5)
False ^[2]	58 (85.3) [74.6-92.7]	93 (79.5) [71.0-86.4]	123 (88.5) [82.0-93.3]	16 (76.2) [52.8-91.8]
Don't know	7 (10.3)	17 (14.5)	8 (5.8)	3 (14.3)
Question 19: If a patient requests Viagra Connect but shows evidence of undiagnosed depression, anxiety or excessive alcohol use, which action should you take? Please select True/False/Don't Know.				
Provide lifestyle advice				
True ^[2]	67 (98.5) [92.1-100.0]	114 (97.4) [92.7-99.5]	135 (97.1) [92.8-99.2]	20 (95.2) [76.2-99.9]
False	1 (1.5)	3 (2.6)	4 (2.9)	1 (4.8)
Don't know	0	0	0	0
Recommend follow up with his doctor				
True ^[2]	67 (98.5) [92.1-100.0]	116 (99.1) [95.3-100.0]	137 (98.6) [94.9-99.8]	20 (95.2) [76.2-99.9]
False	1 (1.5)	0	2 (1.4)	1 (4.8)

Table 4.6 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by age group - Completed surveys

Question	Age Group			
	22-30 years (N=68) n (%) [95% CI] ^[1]	31-40 years (N=117) n (%) [95% CI] ^[1]	41-60 years (N=139) n (%) [95% CI] ^[1]	Greater than 61 years (N=21) n (%) [95% CI] ^[1]
Don't know	0	1 (0.9)	0	0
Question 20: Please select True/False/Don't Know for the following statements.				
Pharmacists should provide lifestyle advice to all men with Erectile Dysfunction (ED) who request Viagra Connect.				
True ^[2]	60 (88.2) [78.1-94.8]	101 (86.3) [78.7-92.0]	119 (85.6) [78.7-91.0]	19 (90.5) [69.6-98.8]
False	5 (7.4)	13 (11.1)	16 (11.5)	2 (9.5)
Don't know	3 (4.4)	3 (2.6)	4 (2.9)	0
Lifestyle advice includes losing weight, stopping smoking, cutting back on alcohol and recreational drugs, exercising regularly and reducing stress.				
True ^[2]	68 (100.0) [94.7-100.0]	117 (100.0) [96.9-100.0]	139 (100.0) [97.4-100.0]	20 (95.2) [76.2-99.9]
False	0	0	0	1 (4.8)
Don't know	0	0	0	0
All patients supplied with Viagra Connect should be advised to consult their doctor within 6 months from the first supply.				
True ^[2]	62 (91.2) [81.8-96.7]	106 (90.6) [83.8-95.2]	116 (83.5) [76.2-89.2]	17 (81.0) [58.1-94.6]
False	4 (5.9)	6 (5.1)	18 (12.9)	4 (19.0)
Don't know	2 (2.9)	5 (4.3)	5 (3.6)	0
All patients who are refused Viagra Connect should be advised to contact their doctor.				
True ^[2]	61 (89.7) [79.9-95.8]	104 (88.9) [81.7-93.9]	128 (92.1) [86.3-96.0]	19 (90.5) [69.6-98.8]
False	6 (8.8)	12 (10.3)	10 (7.2)	2 (9.5)
Don't know	1 (1.5)	1 (0.9)	1 (0.7)	0
Question 21: Complete True/False/Don't know for the following statement: Patients should be advised to STOP TAKING Viagra Connect and seek medical attention immediately if they experience the following symptoms.				

Table 4.6 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by age group - Completed surveys

Question	Age Group			
	22-30 years (N=68) n (%) [95% CI] ^[1]	31-40 years (N=117) n (%) [95% CI] ^[1]	41-60 years (N=139) n (%) [95% CI] ^[1]	Greater than 61 years (N=21) n (%) [95% CI] ^[1]
Chest pains				
True ^[2]	68 (100.0) [94.7-100.0]	116 (99.1) [95.3-100.0]	139 (100.0) [97.4-100.0]	21 (100.0) [83.9-100.0]
False	0	0	0	0
Don't know	0	1 (0.9)	0	0
Persistent and sometimes painful erection lasting longer than 4 hours				
True ^[2]	68 (100.0) [94.7-100.0]	116 (99.1) [95.3-100.0]	136 (97.8) [93.8-99.6]	20 (95.2) [76.2-99.9]
False	0	0	1 (0.7)	0
Don't know	0	1 (0.9)	2 (1.4)	1 (4.8)
Dyspepsia				
True	5 (7.4)	14 (12.0)	21 (15.1)	3 (14.3)
False ^[2]	61 (89.7) [79.9-95.8]	100 (85.5) [77.8-91.3]	114 (82.0) [74.6-88.0]	16 (76.2) [52.8-91.8]
Don't know	2 (2.9)	3 (2.6)	4 (2.9)	2 (9.5)
Sudden decrease or loss of vision				
True ^[2]	68 (100.0) [94.7-100.0]	117 (100.0) [96.9-100.0]	138 (99.3) [96.1-100.0]	21 (100.0) [83.9-100.0]
False	0	0	0	0
Don't know	0	0	1 (0.7)	0
Headache				
True	14 (20.6)	19 (16.2)	28 (20.1)	11 (52.4)
False ^[2]	52 (76.5) [64.6-85.9]	96 (82.1) [73.9-88.5]	105 (75.5) [67.5-82.4]	10 (47.6) [25.7-70.2]
Don't know	2 (2.9)	2 (1.7)	6 (4.3)	0
Allergic reaction (with symptoms of wheeziness, difficulty breathing or dizziness)				

Table 4.6 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by age group - Completed surveys

Question	Age Group			
	22-30 years (N=68) n (%) [95% CI] ^[1]	31-40 years (N=117) n (%) [95% CI] ^[1]	41-60 years (N=139) n (%) [95% CI] ^[1]	Greater than 61 years (N=21) n (%) [95% CI] ^[1]
True ^[2]	68 (100.0) [94.7-100.0]	117 (100.0) [96.9-100.0]	139 (100.0) [97.4-100.0]	21 (100.0) [83.9-100.0]
False	0	0	0	0
Don't know	0	0	0	0
Nausea				
True	7 (10.3)	17 (14.5)	24 (17.3)	5 (23.8)
False ^[2]	56 (82.4) [71.2-90.5]	96 (82.1) [73.9-88.5]	108 (77.7) [69.9-84.3]	14 (66.7) [43.0-85.4]
Don't know	5 (7.4)	4 (3.4)	7 (5.0)	2 (9.5)
Serious skin reactions (eg, Stevens-Johnson Syndrome (SJS))				
True ^[2]	68 (100.0) [94.7-100.0]	116 (99.1) [95.3-100.0]	135 (97.1) [92.8-99.2]	21 (100.0) [83.9-100.0]
False	0	1 (0.9)	1 (0.7)	0
Don't know	0	0	3 (2.2)	0
Seizures or fits				
True ^[2]	66 (97.1) [89.8-99.6]	114 (97.4) [92.7-99.5]	138 (99.3) [96.1-100.0]	21 (100.0) [83.9-100.0]
False	0	0	1 (0.7)	0
Don't know	2 (2.9)	3 (2.6)	0	0

Source: Appendix B: Table 4.6

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 4.7 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by gender - Completed surveys

Question	Gender		
	Male (N=241) n (%) [95% CI] ^[1]	Female (N=102) n (%) [95% CI] ^[1]	Prefer not to answer (N=2) n (%) [95% CI] ^[1]
Question 18: Which of the following MAY be a cause of Erectile Dysfunction (ED) and should be considered when assessing a patient for suitability for Viagra Connect. Please select True/False/Don't Know.			
Undiagnosed depression			
True ^[2]	211 (87.6) [82.7-91.4]	95 (93.1) [86.4-97.2]	2 (100.0) [15.8-100.0]
False	23 (9.5)	4 (3.9)	0
Don't know	7 (2.9)	3 (2.9)	0
Anxiety			
True ^[2]	224 (92.9) [88.9-95.8]	98 (96.1) [90.3-98.9]	2 (100.0) [15.8-100.0]
False	12 (5.0)	1 (1.0)	0
Don't know	5 (2.1)	3 (2.9)	0
Excessive alcohol use			
True ^[2]	232 (96.3) [93.0-98.3]	101 (99.0) [94.7-100.0]	2 (100.0) [15.8-100.0]
False	8 (3.3)	0	0
Don't know	1 (0.4)	1 (1.0)	0
Hypertension			
True ^[2]	173 (71.8) [65.6-77.4]	67 (65.7) [55.6-74.8]	2 (100.0) [15.8-100.0]
False	53 (22.0)	30 (29.4)	0
Don't know	15 (6.2)	5 (4.9)	0
Diabetes mellitus			
True ^[2]	227 (94.2) [90.4-96.8]	93 (91.2) [83.9-95.9]	2 (100.0) [15.8-100.0]
False	8 (3.3)	7 (6.9)	0
Don't know	6 (2.5)	2 (2.0)	0
Hypercholesterolemia			

Table 4.7 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by gender - Completed surveys

Question	Gender		
	Male (N=241) n (%) [95% CI] ^[1]	Female (N=102) n (%) [95% CI] ^[1]	Prefer not to answer (N=2) n (%) [95% CI] ^[1]
True ^[2]	140 (58.1) [51.6-64.4]	55 (53.9) [43.8-63.8]	1 (50.0) [1.3-98.7]
False	73 (30.3)	35 (34.3)	1 (50.0)
Don't know	28 (11.6)	12 (11.8)	0
Cardiovascular disease			
True ^[2]	220 (91.3) [87.0-94.5]	89 (87.3) [79.2-93.0]	2 (100.0) [15.8-100.0]
False	17 (7.1)	11 (10.8)	0
Don't know	4 (1.7)	2 (2.0)	0
Osteoarthritis			
True	15 (6.2)	5 (4.9)	0
False ^[2]	199 (82.6) [77.2-87.1]	89 (87.3) [79.2-93.0]	2 (100.0) [15.8-100.0]
Don't know	27 (11.2)	8 (7.8)	0
Question 19: If a patient requests Viagra Connect but shows evidence of undiagnosed depression, anxiety or excessive alcohol use, which action should you take? Please select True/False/Don't Know.			
Provide lifestyle advice			
True ^[2]	234 (97.1) [94.1-98.8]	100 (98.0) [93.1-99.8]	2 (100.0) [15.8-100.0]
False	7 (2.9)	2 (2.0)	0
Don't know	0	0	0
Recommend follow up with his doctor			
True ^[2]	237 (98.3) [95.8-99.5]	101 (99.0) [94.7-100.0]	2 (100.0) [15.8-100.0]
False	3 (1.2)	1 (1.0)	0
Don't know	1 (0.4)	0	0
Question 20: Please select True/False/Don't Know for the following statements.			
Pharmacists should provide lifestyle advice to all men with Erectile Dysfunction (ED) who request Viagra Connect.			

Table 4.7 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by gender - Completed surveys

Question	Gender		
	Male (N=241) n (%) [95% CI] ^[1]	Female (N=102) n (%) [95% CI] ^[1]	Prefer not to answer (N=2) n (%) [95% CI] ^[1]
True ^[2]	207 (85.9) [80.8-90.0]	90 (88.2) [80.4-93.8]	2 (100.0) [15.8-100.0]
False	28 (11.6)	8 (7.8)	0
Don't know	6 (2.5)	4 (3.9)	0
Lifestyle advice includes losing weight, stopping smoking, cutting back on alcohol and recreational drugs, exercising regularly and reducing stress.			
True ^[2]	240 (99.6) [97.7-100.0]	102 (100.0) [96.4-100.0]	2 (100.0) [15.8-100.0]
False	1 (0.4)	0	0
Don't know	0	0	0
All patients supplied with Viagra Connect should be advised to consult their doctor within 6 months from the first supply.			
True ^[2]	204 (84.6) [79.5-89.0]	95 (93.1) [86.4-97.2]	2 (100.0) [15.8-100.0]
False	27 (11.2)	5 (4.9)	0
Don't know	10 (4.1)	2 (2.0)	0
All patients who are refused Viagra Connect should be advised to contact their doctor.			
True ^[2]	213 (88.4) [83.6-92.1]	97 (95.1) [88.9-98.4]	2 (100.0) [15.8-100.0]
False	25 (10.4)	5 (4.9)	0
Don't know	3 (1.2)	0	0
Question 21: Complete True/False/Don't know for the following statement: Patients should be advised to STOP TAKING Viagra Connect and seek medical attention immediately if they experience the following symptoms.			
Chest pains			
True ^[2]	240 (99.6) [97.7-100.0]	102 (100.0) [96.4-100.0]	2 (100.0) [15.8-100.0]
False	0	0	0
Don't know	1 (0.4)	0	0

Table 4.7 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by gender - Completed surveys

Question	Gender		
	Male (N=241) n (%) [95% CI] ^[1]	Female (N=102) n (%) [95% CI] ^[1]	Prefer not to answer (N=2) n (%) [95% CI] ^[1]
Persistent and sometimes painful erection lasting longer than 4 hours			
True ^[2]	236 (97.9) [95.2-99.3]	102 (100.0) [96.4-100.0]	2 (100.0) [15.8-100.0]
False	1 (0.4)	0	0
Don't know	4 (1.7)	0	0
Dyspepsia			
True	29 (12.0)	14 (13.7)	0
False ^[2]	205 (85.1) [79.9-89.3]	84 (82.4) [73.6-89.2]	2 (100.0) [15.8-100.0]
Don't know	7 (2.9)	4 (3.9)	0
Sudden decrease or loss of vision			
True ^[2]	240 (99.6) [97.7-100.0]	102 (100.0) [96.4-100.0]	2 (100.0) [15.8-100.0]
False	0	0	0
Don't know	1 (0.4)	0	0
Headache			
True	47 (19.5)	24 (23.5)	1 (50.0)
False ^[2]	186 (77.2) [71.4-82.3]	76 (74.5) [64.9-82.6]	1 (50.0) [1.3-98.7]
Don't know	8 (3.3)	2 (2.0)	0
Allergic reaction (with symptoms of wheeziness, difficulty breathing or dizziness)			
True ^[2]	241 (100.0) [98.5-100.0]	102 (100.0) [96.4-100.0]	2 (100.0) [15.8-100.0]
False	0	0	0
Don't know	0	0	0
Nausea			
True	37 (15.4)	16 (15.7)	0

Table 4.7 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by gender - Completed surveys

Question	Gender		
	Male (N=241) n (%) [95% CI] ^[1]	Female (N=102) n (%) [95% CI] ^[1]	Prefer not to answer (N=2) n (%) [95% CI] ^[1]
False ^[2]	192 (79.7) [74.0-84.6]	80 (78.4) [69.2-86.0]	2 (100.0) [15.8-100.0]
Don't know	12 (5.0)	6 (5.9)	0
Serious skin reactions (eg, Stevens-Johnson Syndrome (SJS))			
True ^[2]	236 (97.9) [95.2-99.3]	102 (100.0) [96.4-100.0]	2 (100.0) [15.8-100.0]
False	2 (0.8)	0	0
Don't know	3 (1.2)	0	0
Seizures or fits			
True ^[2]	237 (98.3) [95.8-99.5]	100 (98.0) [93.1-99.8]	2 (100.0) [15.8-100.0]
False	1 (0.4)	0	0
Don't know	3 (1.2)	2 (2.0)	0

Source: Appendix B: Table 4.7

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 4.8 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists" - Completed surveys

Question	Reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists"	
	Yes (N=334) n (%) [95% CI] ^[1]	No (N=11) n (%) [95% CI] ^[1]
Question 18: Which of the following MAY be a cause of Erectile Dysfunction (ED) and should be considered when assessing a patient for suitability for Viagra Connect. Please select True/False/Don't Know.		
Undiagnosed depression		
True ^[2]	298 (89.2) [85.4-92.3]	10 (90.9) [58.7-99.8]
False	26 (7.8)	1 (9.1)
Don't know	10 (3.0)	0
Anxiety		
True ^[2]	314 (94.0) [90.9-96.3]	10 (90.9) [58.7-99.8]
False	12 (3.6)	1 (9.1)
Don't know	8 (2.4)	0
Excessive alcohol use		
True ^[2]	324 (97.0) [94.6-98.6]	11 (100.0) [71.5-100.0]
False	8 (2.4)	0
Don't know	2 (0.6)	0
Hypertension		
True ^[2]	234 (70.1) [64.8-74.9]	8 (72.7) [39.0-94.0]
False	81 (24.3)	2 (18.2)
Don't know	19 (5.7)	1 (9.1)
Diabetes mellitus		
True ^[2]	311 (93.1) [89.8-95.6]	11 (100.0) [71.5-100.0]
False	15 (4.5)	0

Table 4.8 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists" - Completed surveys

Question	Reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists"	
	Yes (N=334) n (%) [95% CI] ^[1]	No (N=11) n (%) [95% CI] ^[1]
Don't know	8 (2.4)	0
Hypercholesterolemia		
True ^[2]	191 (57.2) [51.7-62.6]	5 (45.5) [16.7-76.6]
False	106 (31.7)	3 (27.3)
Don't know	37 (11.1)	3 (27.3)
Cardiovascular disease		
True ^[2]	301 (90.1) [86.4-93.1]	10 (90.9) [58.7-99.8]
False	27 (8.1)	1 (9.1)
Don't know	6 (1.8)	0
Osteoarthritis		
True	19 (5.7)	1 (9.1)
False ^[2]	283 (84.7) [80.4-88.4]	7 (63.6) [30.8-89.1]
Don't know	32 (9.6)	3 (27.3)
Question 19: If a patient requests Viagra Connect but shows evidence of undiagnosed depression, anxiety or excessive alcohol use, which action should you take? Please select True/False/Don't Know.		
Provide lifestyle advice		
True ^[2]	325 (97.3) [94.9-98.8]	11 (100.0) [71.5-100.0]
False	9 (2.7)	0
Don't know	0	0
Recommend follow up with his doctor		
True ^[2]	329 (98.5) [96.5-99.5]	11 (100.0) [71.5-100.0]

Table 4.8 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists" - Completed surveys

Question	Reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists"	
	Yes (N=334) n (%) [95% CI] ^[1]	No (N=11) n (%) [95% CI] ^[1]
False	4 (1.2)	0
Don't know	1 (0.3)	0
Question 20: Please select True/False/Don't Know for the following statements.		
Pharmacists should provide lifestyle advice to all men with Erectile Dysfunction (ED) who request Viagra Connect.		
True ^[2]	290 (86.8) [82.7-90.3]	9 (81.8) [48.2-97.7]
False	35 (10.5)	1 (9.1)
Don't know	9 (2.7)	1 (9.1)
Lifestyle advice includes losing weight, stopping smoking, cutting back on alcohol and recreational drugs, exercising regularly and reducing stress.		
True ^[2]	333 (99.7) [98.3-100.0]	11 (100.0) [71.5-100.0]
False	1 (0.3)	0
Don't know	0	0
All patients supplied with Viagra Connect should be advised to consult their doctor within 6 months from the first supply.		
True ^[2]	291 (87.1) [83.1-90.5]	10 (90.9) [58.7-99.8]
False	31 (9.3)	1 (9.1)
Don't know	12 (3.6)	0
All patients who are refused Viagra Connect should be advised to contact their doctor.		
True ^[2]	301 (90.1) [86.4-93.1]	11 (100.0) [71.5-100.0]
False	30 (9.0)	0
Don't know	3 (0.9)	0

Table 4.8 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists" - Completed surveys

Question	Reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists"	
	Yes (N=334) n (%) [95% CI] ^[1]	No (N=11) n (%) [95% CI] ^[1]
Question 21: Complete True/False/Don't know for the following statement: Patients should be advised to STOP TAKING Viagra Connect and seek medical attention immediately if they experience the following symptoms.		
Chest pains		
True ^[2]	333 (99.7) [98.3-100.0]	11 (100.0) [71.5-100.0]
False	0	0
Don't know	1 (0.3)	0
Persistent and sometimes painful erection lasting longer than 4 hours		
True ^[2]	330 (98.8) [97.0-99.7]	10 (90.9) [58.7-99.8]
False	1 (0.3)	0
Don't know	3 (0.9)	1 (9.1)
Dyspepsia		
True	40 (12.0)	3 (27.3)
False ^[2]	284 (85.0) [80.7-88.7]	7 (63.6) [30.8-89.1]
Don't know	10 (3.0)	1 (9.1)
Sudden decrease or loss of vision		
True ^[2]	333 (99.7) [98.3-100.0]	11 (100.0) [71.5-100.0]
False	0	0
Don't know	1 (0.3)	0
Headache		
True	68 (20.4)	4 (36.4)
False ^[2]	256 (76.6) [71.7-81.1]	7 (63.6) [30.8-89.1]

Table 4.8 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists" - Completed surveys

Question	Reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists"	
	Yes (N=334) n (%) [95% CI] ^[1]	No (N=11) n (%) [95% CI] ^[1]
Don't know	10 (3.0)	0
Allergic reaction (with symptoms of wheeziness, difficulty breathing or dizziness)		
True ^[2]	334 (100.0) [98.9-100.0]	11 (100.0) [71.5-100.0]
False	0	0
Don't know	0	0
Nausea		
True	49 (14.7)	4 (36.4)
False ^[2]	267 (79.9) [75.2-84.1]	7 (63.6) [30.8-89.1]
Don't know	18 (5.4)	0
Serious skin reactions (eg, Stevens-Johnson Syndrome (SJS))		
True ^[2]	330 (98.8) [97.0-99.7]	10 (90.9) [58.7-99.8]
False	1 (0.3)	1 (9.1)
Don't know	3 (0.9)	0
Seizures or fits		
True ^[2]	329 (98.5) [96.5-99.5]	10 (90.9) [58.7-99.8]
False	0	1 (9.1)
Don't know	5 (1.5)	0

Source: Appendix B: Table 4.8

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 4.9 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by using the optional Viagra Connect Pharmacy Checklist at the point of supply - Completed surveys

Question	Using the Optional Viagra Connect Pharmacy Checklist at the Point of Supply		
	Yes (N=317) n (%) [95% CI] ^[1]	No (N=18) n (%) [95% CI] ^[1]	I do not recall (N=10) n (%) [95% CI] ^[1]
Question 18: Which of the following MAY be a cause of Erectile Dysfunction (ED) and should be considered when assessing a patient for suitability for Viagra Connect. Please select True/False/Don't Know.			
Undiagnosed depression			
True ^[2]	282 (89.0) [85.0-92.2]	17 (94.4) [72.7-99.9]	9 (90.0) [55.5-99.7]
False	25 (7.9)	1 (5.6)	1 (10.0)
Don't know	10 (3.2)	0	0
Anxiety			
True ^[2]	299 (94.3) [91.2-96.6]	18 (100.0) [81.5-100.0]	7 (70.0) [34.8-93.3]
False	12 (3.8)	0	1 (10.0)
Don't know	6 (1.9)	0	2 (20.0)
Excessive alcohol use			
True ^[2]	308 (97.2) [94.7-98.7]	18 (100.0) [81.5-100.0]	9 (90.0) [55.5-99.7]
False	8 (2.5)	0	0
Don't know	1 (0.3)	0	1 (10.0)
Hypertension			
True ^[2]	226 (71.3) [66.0-76.2]	10 (55.6) [30.8-78.5]	6 (60.0) [26.2-87.8]
False	72 (22.7)	7 (38.9)	4 (40.0)
Don't know	19 (6.0)	1 (5.6)	0
Diabetes mellitus			
True ^[2]	296 (93.4) [90.1-95.9]	17 (94.4) [72.7-99.9]	9 (90.0) [55.5-99.7]
False	14 (4.4)	1 (5.6)	0
Don't know	7 (2.2)	0	1 (10.0)

Table 4.9 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by using the optional Viagra Connect Pharmacy Checklist at the point of supply - Completed surveys

Question	Using the Optional Viagra Connect Pharmacy Checklist at the Point of Supply		
	Yes (N=317) n (%) [95% CI] ^[1]	No (N=18) n (%) [95% CI] ^[1]	I do not recall (N=10) n (%) [95% CI] ^[1]
Hypercholesterolemia			
True ^[2]	181 (57.1) [51.4-62.6]	10 (55.6) [30.8-78.5]	5 (50.0) [18.7-81.3]
False	100 (31.5)	6 (33.3)	3 (30.0)
Don't know	36 (11.4)	2 (11.1)	2 (20.0)
Cardiovascular disease			
True ^[2]	286 (90.2) [86.4-93.3]	18 (100.0) [81.5-100.0]	7 (70.0) [34.8-93.3]
False	26 (8.2)	0	2 (20.0)
Don't know	5 (1.6)	0	1 (10.0)
Osteoarthritis			
True	20 (6.3)	0	0
False ^[2]	264 (83.3) [78.7-87.2]	17 (94.4) [72.7-99.9]	9 (90.0) [55.5-99.7]
Don't know	33 (10.4)	1 (5.6)	1 (10.0)
Question 19: If a patient requests Viagra Connect but shows evidence of undiagnosed depression, anxiety or excessive alcohol use, which action should you take? Please select True/False/Don't Know.			
Provide lifestyle advice			
True ^[2]	309 (97.5) [95.1-98.9]	18 (100.0) [81.5-100.0]	9 (90.0) [55.5-99.7]
False	8 (2.5)	0	1 (10.0)
Don't know	0	0	0
Recommend follow up with his doctor			
True ^[2]	312 (98.4) [96.4-99.5]	18 (100.0) [81.5-100.0]	10 (100.0) [69.2-100.0]
False	4 (1.3)	0	0
Don't know	1 (0.3)	0	0
Question 20: Please select True/False/Don't Know for the following statements.			

Table 4.9 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by using the optional Viagra Connect Pharmacy Checklist at the point of supply - Completed surveys

Question	Using the Optional Viagra Connect Pharmacy Checklist at the Point of Supply		
	Yes (N=317) n (%) [95% CI] ^[1]	No (N=18) n (%) [95% CI] ^[1]	I do not recall (N=10) n (%) [95% CI] ^[1]
Pharmacists should provide lifestyle advice to all men with Erectile Dysfunction (ED) who request Viagra Connect.			
True ^[2]	278 (87.7) [83.6-91.1]	14 (77.8) [52.4-93.6]	7 (70.0) [34.8-93.3]
False	30 (9.5)	4 (22.2)	2 (20.0)
Don't know	9 (2.8)	0	1 (10.0)
Lifestyle advice includes losing weight, stopping smoking, cutting back on alcohol and recreational drugs, exercising regularly and reducing stress.			
True ^[2]	317 (100.0) [98.8-100.0]	17 (94.4) [72.7-99.9]	10 (100.0) [69.2-100.0]
False	0	1 (5.6)	0
Don't know	0	0	0
All patients supplied with Viagra Connect should be advised to consult their doctor within 6 months from the first supply.			
True ^[2]	279 (88.0) [83.9-91.4]	15 (83.3) [58.6-96.4]	7 (70.0) [34.8-93.3]
False	27 (8.5)	3 (16.7)	2 (20.0)
Don't know	11 (3.5)	0	1 (10.0)
All patients who are refused Viagra Connect should be advised to contact their doctor.			
True ^[2]	287 (90.5) [86.8-93.5]	17 (94.4) [72.7-99.9]	8 (80.0) [44.4-97.5]
False	28 (8.8)	1 (5.6)	1 (10.0)
Don't know	2 (0.6)	0	1 (10.0)
Question 21: Complete True/False/Don't know for the following statement: Patients should be advised to STOP TAKING Viagra Connect and seek medical attention immediately if they experience the following symptoms.			
Chest pains			
True ^[2]	316 (99.7) [98.3-100.0]	18 (100.0) [81.5-100.0]	10 (100.0) [69.2-100.0]

Table 4.9 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by using the optional Viagra Connect Pharmacy Checklist at the point of supply - Completed surveys

Question	Using the Optional Viagra Connect Pharmacy Checklist at the Point of Supply		
	Yes (N=317) n (%) [95% CI] ^[1]	No (N=18) n (%) [95% CI] ^[1]	I do not recall (N=10) n (%) [95% CI] ^[1]
False	0	0	0
Don't know	1 (0.3)	0	0
Persistent and sometimes painful erection lasting longer than 4 hours			
True ^[2]	313 (98.7) [96.8-99.7]	17 (94.4) [72.7-99.9]	10 (100.0) [69.2-100.0]
False	1 (0.3)	0	0
Don't know	3 (0.9)	1 (5.6)	0
Dyspepsia			
True	41 (12.9)	2 (11.1)	0
False ^[2]	265 (83.6) [79.1-87.5]	16 (88.9) [65.3-98.6]	10 (100.0) [69.2-100.0]
Don't know	11 (3.5)	0	0
Sudden decrease or loss of vision			
True ^[2]	316 (99.7) [98.3-100.0]	18 (100.0) [81.5-100.0]	10 (100.0) [69.2-100.0]
False	0	0	0
Don't know	1 (0.3)	0	0
Headache			
True	66 (20.8)	4 (22.2)	2 (20.0)
False ^[2]	242 (76.3) [71.3-80.9]	14 (77.8) [52.4-93.6]	7 (70.0) [34.8-93.3]
Don't know	9 (2.8)	0	1 (10.0)
Allergic reaction (with symptoms of wheeziness, difficulty breathing or dizziness)			
True ^[2]	317 (100.0) [98.8-100.0]	18 (100.0) [81.5-100.0]	10 (100.0) [69.2-100.0]
False	0	0	0
Don't know	0	0	0

Table 4.9 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by using the optional Viagra Connect Pharmacy Checklist at the point of supply - Completed surveys

Question	Using the Optional Viagra Connect Pharmacy Checklist at the Point of Supply		
	Yes (N=317) n (%) [95% CI] ^[1]	No (N=18) n (%) [95% CI] ^[1]	I do not recall (N=10) n (%) [95% CI] ^[1]
Nausea			
True	50 (15.8)	3 (16.7)	0
False ^[2]	249 (78.5) [73.6-82.9]	15 (83.3) [58.6-96.4]	10 (100.0) [69.2-100.0]
Don't know	18 (5.7)	0	0
Serious skin reactions (eg, Stevens-Johnson Syndrome (SJS))			
True ^[2]	314 (99.1) [97.3-99.8]	18 (100.0) [81.5-100.0]	8 (80.0) [44.4-97.5]
False	1 (0.3)	0	1 (10.0)
Don't know	2 (0.6)	0	1 (10.0)
Seizures or fits			
True ^[2]	313 (98.7) [96.8-99.7]	17 (94.4) [72.7-99.9]	9 (90.0) [55.5-99.7]
False	0	0	1 (10.0)
Don't know	4 (1.3)	1 (5.6)	0

Source: Appendix B: Table 4.9

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 4.10 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
Question 18: Which of the following MAY be a cause of Erectile Dysfunction (ED) and should be considered when assessing a patient for suitability for Viagra Connect. Please select True/False/Don't Know.					
Undiagnosed depression					
True ^[2]	47 (87.0) [75.1-94.6]	254 (90.1) [86.0-93.3]	6 (75.0) [34.9-96.8]	1 (100.0) [2.5-100.0]	0
False	4 (7.4)	21 (7.4)	2 (25.0)	0	0
Don't know	3 (5.6)	7 (2.5)	0	0	0
Anxiety					
True ^[2]	50 (92.6) [82.1-97.9]	266 (94.3) [90.9-96.7]	7 (87.5) [47.3-99.7]	1 (100.0) [2.5-100.0]	0
False	1 (1.9)	11 (3.9)	1 (12.5)	0	0
Don't know	3 (5.6)	5 (1.8)	0	0	0
Excessive alcohol use					
True ^[2]	53 (98.1) [90.1-100.0]	274 (97.2) [94.5-98.8]	7 (87.5) [47.3-99.7]	1 (100.0) [2.5-100.0]	0
False	1 (1.9)	6 (2.1)	1 (12.5)	0	0

Table 4.10 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
Don't know	0	2 (0.7)	0	0	0
Hypertension					
True ^[2]	39 (72.2) [58.4-83.5]	195 (69.1) [63.4-74.5]	7 (87.5) [47.3-99.7]	1 (100.0) [2.5-100.0]	0
False	13 (24.1)	70 (24.8)	0	0	0
Don't know	2 (3.7)	17 (6.0)	1 (12.5)	0	0
Diabetes mellitus					
True ^[2]	52 (96.3) [87.3-99.5]	261 (92.6) [88.8-95.3]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
False	1 (1.9)	14 (5.0)	0	0	0
Don't know	1 (1.9)	7 (2.5)	0	0	0
Hypercholesterolemia					
True ^[2]	32 (59.3) [45.0-72.4]	158 (56.0) [50.0-61.9]	5 (62.5) [24.5-91.5]	1 (100.0) [2.5-100.0]	0
False	17 (31.5)	90 (31.9)	2 (25.0)	0	0

Table 4.10 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
Don't know	5 (9.3)	34 (12.1)	1 (12.5)	0	0
Cardiovascular disease					
True ^[2]	49 (90.7) [79.7-96.9]	253 (89.7) [85.6-93.0]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
False	5 (9.3)	23 (8.2)	0	0	0
Don't know	0	6 (2.1)	0	0	0
Osteoarthritis					
True	3 (5.6)	16 (5.7)	1 (12.5)	0	0
False ^[2]	46 (85.2) [72.9-93.4]	237 (84.0) [79.2-88.1]	6 (75.0) [34.9-96.8]	1 (100.0) [2.5-100.0]	0
Don't know	5 (9.3)	29 (10.3)	1 (12.5)	0	0
Question 19: If a patient requests Viagra Connect but shows evidence of undiagnosed depression, anxiety or excessive alcohol use, which action should you take? Please select True/False/Don't Know.					
Provide lifestyle advice					
True ^[2]	52 (96.3) [87.3-99.5]	275 (97.5) [95.0-99.0]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0

Table 4.10 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
False	2 (3.7)	7 (2.5)	0	0	0
Don't know	0	0	0	0	0
Recommend follow up with his doctor					
True ^[2]	54 (100.0) [93.4-100.0]	278 (98.6) [96.4-99.6]	7 (87.5) [47.3-99.7]	1 (100.0) [2.5-100.0]	0
False	0	3 (1.1)	1 (12.5)	0	0
Don't know	0	1 (0.4)	0	0	0
Question 20: Please select True/False/Don't Know for the following statements.					
Pharmacists should provide lifestyle advice to all men with Erectile Dysfunction (ED) who request Viagra Connect.					
True ^[2]	46 (85.2) [72.9-93.4]	244 (86.5) [82.0-90.3]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
False	6 (11.1)	30 (10.6)	0	0	0
Don't know	2 (3.7)	8 (2.8)	0	0	0
Lifestyle advice includes losing weight, stopping smoking, cutting back on alcohol and recreational drugs, exercising regularly and reducing stress.					

Table 4.10 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
True ^[2]	54 (100.0) [93.4-100.0]	281 (99.6) [98.0-100.0]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
False	0	1 (0.4)	0	0	0
Don't know	0	0	0	0	0
All patients supplied with Viagra Connect should be advised to consult their doctor within 6 months from the first supply.					
True ^[2]	47 (87.0) [75.1-94.6]	246 (87.2) [82.8-90.9]	8 (100.0) [63.1-100.0]	0 [0.0-97.5]	0
False	6 (11.1)	25 (8.9)	0	1 (100.0)	0
Don't know	1 (1.9)	11 (3.9)	0	0	0
All patients who are refused Viagra Connect should be advised to contact their doctor.					
True ^[2]	47 (87.0) [75.1-94.6]	257 (91.1) [87.2-94.2]	7 (87.5) [47.3-99.7]	1 (100.0) [2.5-100.0]	0
False	6 (11.1)	23 (8.2)	1 (12.5)	0	0
Don't know	1 (1.9)	2 (0.7)	0	0	0
Question 21: Complete True/False/Don't know for the following statement: Patients should be advised to STOP TAKING Viagra Connect and seek medical attention immediately if they experience the following symptoms.					

Table 4.10 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
Chest pains					
True ^[2]	54 (100.0) [93.4-100.0]	281 (99.6) [98.0-100.0]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
False	0	0	0	0	0
Don't know	0	1 (0.4)	0	0	0
Persistent and sometimes painful erection lasting longer than 4 hours					
True ^[2]	54 (100.0) [93.4-100.0]	277 (98.2) [95.9-99.4]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
False	0	1 (0.4)	0	0	0
Don't know	0	4 (1.4)	0	0	0
Dyspepsia					
True	8 (14.8)	33 (11.7)	2 (25.0)	0	0
False ^[2]	45 (83.3) [70.7-92.1]	239 (84.8) [80.0-88.7]	6 (75.0) [34.9-96.8]	1 (100.0) [2.5-100.0]	0
Don't know	1 (1.9)	10 (3.5)	0	0	0

Table 4.10 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
Sudden decrease or loss of vision					
True ^[2]	54 (100.0) [93.4-100.0]	281 (99.6) [98.0-100.0]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
False	0	0	0	0	0
Don't know	0	1 (0.4)	0	0	0
Headache					
True	19 (35.2)	52 (18.4)	1 (12.5)	0	0
False ^[2]	33 (61.1) [46.9-74.1]	222 (78.7) [73.5-83.4]	7 (87.5) [47.3-99.7]	1 (100.0) [2.5-100.0]	0
Don't know	2 (3.7)	8 (2.8)	0	0	0
Allergic reaction (with symptoms of wheeziness, difficulty breathing or dizziness)					
True ^[2]	54 (100.0) [93.4-100.0]	282 (100.0) [98.7-100.0]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
False	0	0	0	0	0
Don't know	0	0	0	0	0

Table 4.10 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
Nausea					
True	11 (20.4)	40 (14.2)	2 (25.0)	0	0
False ^[2]	39 (72.2) [58.4-83.5]	228 (80.9) [75.8-85.3]	6 (75.0) [34.9-96.8]	1 (100.0) [2.5-100.0]	0
Don't know	4 (7.4)	14 (5.0)	0	0	0
Serious skin reactions (eg, Stevens-Johnson Syndrome (SJS))					
True ^[2]	52 (96.3) [87.3-99.5]	279 (98.9) [96.9-99.8]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
False	1 (1.9)	1 (0.4)	0	0	0
Don't know	1 (1.9)	2 (0.7)	0	0	0
Seizures or fits					
True ^[2]	51 (94.4) [84.6-98.8]	279 (98.9) [96.9-99.8]	8 (100.0) [63.1-100.0]	1 (100.0) [2.5-100.0]	0
False	1 (1.9)	0	0	0	0

Table 4.10 Responses to all Questions about pharmacist knowledge of part II other important key messages for pharmacists to consider during consultation by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%) [95% CI] ^[1]	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%) [95% CI] ^[1]	Medication reference (BNF) (N=8) n (%) [95% CI] ^[1]	Pharmacy Journals/ Colleagues (N=1) n (%) [95% CI] ^[1]	Other (N=0) n (%) [95% CI] ^[1]
Don't know	2 (3.7)	3 (1.1)	0	0	0

Source: Appendix B: Table 4.10

CI = Confidence interval

^[1] 95% exact two-sided confidence intervals are calculated using the Clopper-Pearson method.

^[2] Correct response.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 5 Responses to all questions regarding the source of pharmacist knowledge of key risk messages pertaining to Viagra Connect and other OTC products - Completed surveys

Question	Pharmacists (N=345) n (%)
Question 22: Which of the following sources is your main reference about the safe dispensing practices of Viagra Connect? Please select ONE only.	
The Viagra Connect Summary of Product Characteristics (SmPC)	52 (15.1)
The Viagra Connect Box Label	2 (0.6)
The Viagra Connect Pharmacist Training "essential information for the supply of Viagra Connect"	161 (46.7)
The Viagra Connect Pharmacist Checklist	115 (33.3)
My pharmacy's medication reference e.g. British National Formulary (BNF)	8 (2.3)
Viagra Connect website	5 (1.4)
Pharmacy journals (e.g. The Pharmaceutical Journal, Pharmacy, The Clinical Pharmacist)	1 (0.3)
Colleagues	0
Pfizer sales professional	1 (0.3)
Other	0

Source: Appendix B: Table 5
OTC = Over the counter

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 6 Responses to all questions about pharmacist experience toward patient counseling - Completed surveys

Question	Pharmacists (N=345) n (%)
Question 23: Regarding the counselling of patients seeking to purchase Viagra Connect:	
I am comfortable counselling the patient each time they request Viagra Connect	
Yes	315 (91.3)
No	30 (8.7)
My experience is that patients are interested in learning and open to discussing their health	
Yes	249 (72.2)
No	96 (27.8)
Patients often tell me that they do not want to go through counselling	
Yes	98 (28.4)
No	247 (71.6)
If I have covered some of the issues with the patient during a previous purchase I am less likely to discuss it again	
Yes	233 (67.5)
No	112 (32.5)
I think that these discussions (ie, Viagra Connect supply counselling) make some patients uncomfortable and unwilling to divulge information	
Yes	183 (53.0)
No	162 (47.0)
The counselling about Viagra Connect makes me uncomfortable	
Yes	18 (5.2)
No	327 (94.8)
It is difficult to counsel patients because there is no private space to do so in my pharmacy	
Yes	14 (4.1)
No	331 (95.9)
Patients have expressed dissatisfaction with counselling	
Yes	35 (10.1)
No	310 (89.9)

Source: Appendix B: Table 6

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 7 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing - Completed surveys

Question	Pharmacists (N=345) n (%)
Question 24: Do you use the optional Viagra Connect Pharmacy Checklist at the point of supply?	
Yes	317 (91.9)
No	18 (5.2)
I do not recall	10 (2.9)
Question 25: From the list below please select reason(s) for NOT utilizing the optional Viagra Connect Pharmacy Checklist. Select ALL that apply:^{[1],[2]}	
I was not aware of the checklist	6 (21.4)
I used it for a while after the training but did not think I needed to continue to use it as it was no longer required as a prompt.	8 (28.6)
I am PGD (pharmacy group direction)-trained (or equivalent) for PDE-5i's	4 (14.3)
I am familiar with the information and I do not think I need the checklist to consult the patient	10 (35.7)
I use it only with new patients but not with returning patients	10 (35.7)
Other	1 (3.6)
N/A (Answered "Yes" to Question 24)	317
Question 26: How frequently do you use the optional Viagra Connect Pharmacy Checklist?	
For new requests for Viagra Connect^[1]	
All the time for all customers presenting	308 (97.2)
Only used after first trained and no longer required as a prompt	8 (2.5)
Never	1 (0.3)
N/A (Answered "No" or "I do not recall" to Question 24)	28
For patients returning for repeat supplies of Viagra Connect^[1]	
All the time for all customers presenting	111 (35.0)
Only used after first trained and no longer required as a prompt	122 (38.5)
Never	84 (26.5)
N/A (Answered "No" or "I do not recall" to Question 24)	28
Question 27: How frequently do you provide the patient with the tear off slip contained on the bottom of the checklist?	
If I have supplied Viagra Connect	

Table 7 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing - Completed surveys

Question	Pharmacists (N=345) n (%)
Always	315 (91.3)
Sometimes	23 (6.7)
Never	7 (2.0)
If I have denied the patient's request for Viagra Connect	
Always	219 (63.5)
Sometimes	59 (17.1)
Never	67 (19.4)
Question 32: Before today, were you aware of the <u>Viagra Connect Pharmacy Checklist</u>?	
Yes	341 (98.8)
No	4 (1.2)

Source: Appendix B: Table 7

^[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

^[2] More than one response can be selected, so percentages may not sum up to 100%.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 7.1 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by participation in the Viagra Connect pharmacist training - Completed surveys

Question	Participation in the Viagra Connect Pharmacist Training		
	Yes (N=238) n (%)	No (N=60) n (%)	Don't recall (N=47) n (%)
Question 24: Do you use the optional Viagra Connect Pharmacy Checklist at the point of supply?			
Yes	219 (92.0)	55 (91.7)	43 (91.5)
No	13 (5.5)	4 (6.7)	1 (2.1)
I do not recall	6 (2.5)	1 (1.7)	3 (6.4)
Question 25: From the list below please select reason(s) for NOT utilizing the optional Viagra Connect Pharmacy Checklist. Select ALL that apply:^{[1],[2]}			
I was not aware of the checklist	3 (15.8)	2 (40.0)	1 (25.0)
I used it for a while after the training but did not think I needed to continue to use it as it was no longer required as a prompt.	6 (31.6)	2 (40.0)	0
I am PGD (pharmacy group direction)-trained (or equivalent) for PDE-5i's	2 (10.5)	2 (40.0)	0
I am familiar with the information and I do not think I need the checklist to consult the patient	7 (36.8)	2 (40.0)	1 (25.0)
I use it only with new patients but not with returning patients	9 (47.4)	0	1 (25.0)
Other	0	0	1 (25.0)
N/A (Answered "Yes" to Question 24)	219	55	43
Question 26: How frequently do you use the optional Viagra Connect Pharmacy Checklist?			
For new requests for Viagra Connect^[1]			
All the time for all customers presenting	214 (97.7)	52 (94.5)	42 (97.7)
Only used after first trained and no longer required as a prompt	5 (2.3)	2 (3.6)	1 (2.3)
Never	0	1 (1.8)	0
N/A (Answered "No" or "I do not recall" to Question 24)	19	5	4
For patients returning for repeat supplies of Viagra Connect^[1]			
All the time for all customers presenting	71 (32.4)	23 (41.8)	17 (39.5)

Table 7.1 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by participation in the Viagra Connect pharmacist training - Completed surveys

Question	Participation in the Viagra Connect Pharmacist Training		
	Yes (N=238) n (%)	No (N=60) n (%)	Don't recall (N=47) n (%)
Only used after first trained and no longer required as a prompt	83 (37.9)	20 (36.4)	19 (44.2)
Never	65 (29.7)	12 (21.8)	7 (16.3)
N/A (Answered "No" or "I do not recall" to Question 24)	19	5	4
Question 27: How frequently do you provide the patient with the tear off slip contained on the bottom of the checklist?			
If I have supplied Viagra Connect			
Always	225 (94.5)	48 (80.0)	42 (89.4)
Sometimes	10 (4.2)	8 (13.3)	5 (10.6)
Never	3 (1.3)	4 (6.7)	0
If I have denied the patient's request for Viagra Connect			
Always	159 (66.8)	32 (53.3)	28 (59.6)
Sometimes	36 (15.1)	14 (23.3)	9 (19.1)
Never	43 (18.1)	14 (23.3)	10 (21.3)
Question 32: Before today, were you aware of the <u>Viagra Connect Pharmacy Checklist</u>?			
Yes	236 (99.2)	59 (98.3)	46 (97.9)
No	2 (0.8)	1 (1.7)	1 (2.1)

Source: Appendix B: Table 7.1

^[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

^[2] More than one response can be selected, so percentages may not sum up to 100%.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 7.2 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys

Question	Number of Patients Requested to Purchase Viagra Connect in the Last 6 months			
	1-10 (N=170) n (%)	11-30 (N=117) n (%)	More than 30 (N=58) n (%)	I don't know (N=0) n (%)
Question 24: Do you use the optional Viagra Connect Pharmacy Checklist at the point of supply?				
Yes	163 (95.9)	104 (88.9)	50 (86.2)	0
No	4 (2.4)	7 (6.0)	7 (12.1)	0
I do not recall	3 (1.8)	6 (5.1)	1 (1.7)	0
Question 25: From the list below please select reason(s) for NOT utilizing the optional Viagra Connect Pharmacy Checklist. Select ALL that apply:^{[1], [2]}				
I was not aware of the checklist	2 (28.6)	2 (15.4)	2 (25.0)	0
I used it for a while after the training but did not think I needed to continue to use it as it was no longer required as a prompt.	1 (14.3)	3 (23.1)	4 (50.0)	0
I am PGD (pharmacy group direction)-trained (or equivalent) for PDE-5i's	0	1 (7.7)	3 (37.5)	0
I am familiar with the information and I do not think I need the checklist to consult the patient	2 (28.6)	4 (30.8)	4 (50.0)	0
I use it only with new patients but not with returning patients	3 (42.9)	6 (46.2)	1 (12.5)	0
Other	0	0	1 (12.5)	0
N/A (Answered "Yes" to Question 24)	163	104	50	0
Question 26: How frequently do you use the optional Viagra Connect Pharmacy Checklist?				
For new requests for Viagra Connect^[1]				
All the time for all customers presenting	161 (98.8)	100 (96.2)	47 (94.0)	0
Only used after first trained and no longer required as a prompt	2 (1.2)	3 (2.9)	3 (6.0)	0
Never	0	1 (1.0)	0	0

Table 7.2 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys

Question	Number of Patients Requested to Purchase Viagra Connect in the Last 6 months			
	1-10 (N=170) n (%)	11-30 (N=117) n (%)	More than 30 (N=58) n (%)	I don't know (N=0) n (%)
N/A (Answered "No" or "I do not recall" to Question 24)	7	13	8	0
For patients returning for repeat supplies of Viagra Connect^[1]				
All the time for all customers presenting	65 (39.9)	36 (34.6)	10 (20.0)	0
Only used after first trained and no longer required as a prompt	58 (35.6)	39 (37.5)	25 (50.0)	0
Never	40 (24.5)	29 (27.9)	15 (30.0)	0
N/A (Answered "No" or "I do not recall" to Question 24)	7	13	8	0
Question 27: How frequently do you provide the patient with the tear off slip contained on the bottom of the checklist?				
If I have supplied Viagra Connect				
Always	160 (94.1)	104 (88.9)	51 (87.9)	0
Sometimes	7 (4.1)	11 (9.4)	5 (8.6)	0
Never	3 (1.8)	2 (1.7)	2 (3.4)	0
If I have denied the patient's request for Viagra Connect				
Always	109 (64.1)	73 (62.4)	37 (63.8)	0
Sometimes	21 (12.4)	24 (20.5)	14 (24.1)	0
Never	40 (23.5)	20 (17.1)	7 (12.1)	0
Question 32: Before today, were you aware of the <u>Viagra Connect Pharmacy Checklist</u>?				
Yes	168 (98.8)	115 (98.3)	58 (100.0)	0
No	2 (1.2)	2 (1.7)	0	0

Source: Appendix B: Table 7.2

^[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

^[2] More than one response can be selected, so percentages may not sum up to 100%.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 7.3 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by place of pharmacy - Completed surveys

Question	Place of Pharmacy	
	Urban (N=255) n (%)	Rural (N=90) n (%)
Question 24: Do you use the optional Viagra Connect Pharmacy Checklist at the point of supply?		
Yes	236 (92.5)	81 (90.0)
No	13 (5.1)	5 (5.6)
I do not recall	6 (2.4)	4 (4.4)
Question 25: From the list below please select reason(s) for NOT utilizing the optional Viagra Connect Pharmacy Checklist. Select ALL that apply:^{[1],[2]}		
I was not aware of the checklist	3 (15.8)	3 (33.3)
I used it for a while after the training but did not think I needed to continue to use it as it was no longer required as a prompt.	6 (31.6)	2 (22.2)
I am PGD (pharmacy group direction)-trained (or equivalent) for PDE-5i's	4 (21.1)	0
I am familiar with the information and I do not think I need the checklist to consult the patient	8 (42.1)	2 (22.2)
I use it only with new patients but not with returning patients	6 (31.6)	4 (44.4)
Other	1 (5.3)	0
N/A (Answered "Yes" to Question 24)	236	81
Question 26: How frequently do you use the optional Viagra Connect Pharmacy Checklist?		
For new requests for Viagra Connect^[1]		
All the time for all customers presenting	228 (96.6)	80 (98.8)
Only used after first trained and no longer required as a prompt	7 (3.0)	1 (1.2)
Never	1 (0.4)	0
N/A (Answered "No" or "I do not recall" to Question 24)	19	9
For patients returning for repeat supplies of Viagra Connect^[1]		
All the time for all customers presenting	82 (34.7)	29 (35.8)
Only used after first trained and no longer required as a prompt	91 (38.6)	31 (38.3)

Table 7.3 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by place of pharmacy - Completed surveys

Question	Place of Pharmacy	
	Urban (N=255) n (%)	Rural (N=90) n (%)
Never	63 (26.7)	21 (25.9)
N/A (Answered "No" or "I do not recall" to Question 24)	19	9
Question 27: How frequently do you provide the patient with the tear off slip contained on the bottom of the checklist?		
If I have supplied Viagra Connect		
Always	234 (91.8)	81 (90.0)
Sometimes	17 (6.7)	6 (6.7)
Never	4 (1.6)	3 (3.3)
If I have denied the patient's request for Viagra Connect		
Always	160 (62.7)	59 (65.6)
Sometimes	47 (18.4)	12 (13.3)
Never	48 (18.8)	19 (21.1)
Question 32: Before today, were you aware of the <u>Viagra Connect Pharmacy Checklist</u>?		
Yes	254 (99.6)	87 (96.7)
No	1 (0.4)	3 (3.3)

Source: Appendix B: Table 7.3

^[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

^[2] More than one response can be selected, so percentages may not sum up to 100%.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 7.4 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by type of pharmacy - Completed surveys

Question	Type of Pharmacy		
	Large Multiple Pharmacy Chain (more than 100 stores) (N=157) n (%)	Small Multiple Pharmacy Chain (6 to 99 stores) (N=61) n (%)	Independent Pharmacy (1 to 5 stores) (N=127) n (%)
Question 24: Do you use the optional Viagra Connect Pharmacy Checklist at the point of supply?			
Yes	143 (91.1)	60 (98.4)	114 (89.8)
No	10 (6.4)	1 (1.6)	7 (5.5)
I do not recall	4 (2.5)	0	6 (4.7)
Question 25: From the list below please select reason(s) for NOT utilizing the optional Viagra Connect Pharmacy Checklist. Select ALL that apply:^{[1], [2]}			
I was not aware of the checklist	3 (21.4)	1 (100.0)	2 (15.4)
I used it for a while after the training but did not think I needed to continue to use it as it was no longer required as a prompt.	6 (42.9)	0	2 (15.4)
I am PGD (pharmacy group direction)-trained (or equivalent) for PDE-5i's	3 (21.4)	0	1 (7.7)
I am familiar with the information and I do not think I need the checklist to consult the patient	5 (35.7)	0	5 (38.5)
I use it only with new patients but not with returning patients	4 (28.6)	0	6 (46.2)
Other	1 (7.1)	0	0
N/A (Answered "Yes" to Question 24)	143	60	114
Question 26: How frequently do you use the optional Viagra Connect Pharmacy Checklist?			
For new requests for Viagra Connect^[1]			
All the time for all customers presenting	139 (97.2)	57 (95.0)	112 (98.2)
Only used after first trained and no longer required as a prompt	3 (2.1)	3 (5.0)	2 (1.8)
Never	1 (0.7)	0	0
N/A (Answered "No" or "I do not recall" to Question 24)	14	1	13

Table 7.4 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by type of pharmacy - Completed surveys

Question	Type of Pharmacy		
	Large Multiple Pharmacy Chain (more than 100 stores) (N=157) n (%)	Small Multiple Pharmacy Chain (6 to 99 stores) (N=61) n (%)	Independent Pharmacy (1 to 5 stores) (N=127) n (%)
For patients returning for repeat supplies of Viagra Connect^[1]			
All the time for all customers presenting	35 (24.5)	21 (35.0)	55 (48.2)
Only used after first trained and no longer required as a prompt	53 (37.1)	27 (45.0)	42 (36.8)
Never	55 (38.5)	12 (20.0)	17 (14.9)
N/A (Answered "No" or "I do not recall" to Question 24)	14	1	13
Question 27: How frequently do you provide the patient with the tear off slip contained on the bottom of the checklist?			
If I have supplied Viagra Connect			
Always	153 (97.5)	57 (93.4)	105 (82.7)
Sometimes	3 (1.9)	3 (4.9)	17 (13.4)
Never	1 (0.6)	1 (1.6)	5 (3.9)
If I have denied the patient's request for Viagra Connect			
Always	106 (67.5)	38 (62.3)	75 (59.1)
Sometimes	24 (15.3)	11 (18.0)	24 (18.9)
Never	27 (17.2)	12 (19.7)	28 (22.0)
Question 32: Before today, were you aware of the <u>Viagra Connect Pharmacy Checklist</u>?			
Yes	154 (98.1)	61 (100.0)	126 (99.2)
No	3 (1.9)	0	1 (0.8)

Source: Appendix B: Table 7.4

^[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

^[2] More than one response can be selected, so percentages may not sum up to 100%.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 7.5 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%)	2-5 years (N=39) n (%)	6-10 years (N=64) n (%)	11-20 years (N=99) n (%)	Greater than 20 years (N=119) n (%)
Question 24: Do you use the optional Viagra Connect Pharmacy Checklist at the point of supply?					
Yes	21 (87.5)	34 (87.2)	61 (95.3)	88 (88.9)	113 (95.0)
No	3 (12.5)	3 (7.7)	1 (1.6)	6 (6.1)	5 (4.2)
I do not recall	0	2 (5.1)	2 (3.1)	5 (5.1)	1 (0.8)
Question 25: From the list below please select reason(s) for NOT utilizing the optional Viagra Connect Pharmacy Checklist. Select ALL that apply:^{[1], [2]}					
I was not aware of the checklist	2 (66.7)	1 (20.0)	0	3 (27.3)	0
I used it for a while after the training but did not think I needed to continue to use it as it was no longer required as a prompt.	1 (33.3)	3 (60.0)	1 (33.3)	2 (18.2)	1 (16.7)
I am PGD (pharmacy group direction)-trained (or equivalent) for PDE-5i's	0	1 (20.0)	2 (66.7)	1 (9.1)	0
I am familiar with the information and I do not think I need the checklist to consult the patient	1 (33.3)	3 (60.0)	1 (33.3)	4 (36.4)	1 (16.7)
I use it only with new patients but not with returning patients	0	1 (20.0)	1 (33.3)	4 (36.4)	4 (66.7)
Other	0	0	0	1 (9.1)	0

Table 7.5 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%)	2-5 years (N=39) n (%)	6-10 years (N=64) n (%)	11-20 years (N=99) n (%)	Greater than 20 years (N=119) n (%)
N/A (Answered "Yes" to Question 24)	21	34	61	88	113
Question 26: How frequently do you use the optional Viagra Connect Pharmacy Checklist?					
For new requests for Viagra Connect^[1]					
All the time for all customers presenting	19 (90.5)	34 (100.0)	61 (100.0)	86 (97.7)	108 (95.6)
Only used after first trained and no longer required as a prompt	1 (4.8)	0	0	2 (2.3)	5 (4.4)
Never	1 (4.8)	0	0	0	0
N/A (Answered "No" or "I do not recall" to Question 24)	3	5	3	11	6
For patients returning for repeat supplies of Viagra Connect^[1]					
All the time for all customers presenting	5 (23.8)	10 (29.4)	26 (42.6)	27 (30.7)	43 (38.1)
Only used after first trained and no longer required as a prompt	9 (42.9)	14 (41.2)	22 (36.1)	33 (37.5)	44 (38.9)
Never	7 (33.3)	10 (29.4)	13 (21.3)	28 (31.8)	26 (23.0)
N/A (Answered "No" or "I do not recall" to Question 24)	3	5	3	11	6
Question 27: How frequently do you provide the patient with the tear off slip contained on the bottom of the checklist?					
If I have supplied Viagra Connect					

Table 7.5 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%)	2-5 years (N=39) n (%)	6-10 years (N=64) n (%)	11-20 years (N=99) n (%)	Greater than 20 years (N=119) n (%)
Always	20 (83.3)	35 (89.7)	58 (90.6)	90 (90.9)	112 (94.1)
Sometimes	2 (8.3)	3 (7.7)	4 (6.3)	8 (8.1)	6 (5.0)
Never	2 (8.3)	1 (2.6)	2 (3.1)	1 (1.0)	1 (0.8)
If I have denied the patient's request for Viagra Connect					
Always	16 (66.7)	22 (56.4)	41 (64.1)	60 (60.6)	80 (67.2)
Sometimes	4 (16.7)	7 (17.9)	11 (17.2)	19 (19.2)	18 (15.1)
Never	4 (16.7)	10 (25.6)	12 (18.8)	20 (20.2)	21 (17.6)
Question 32: Before today, were you aware of the <u>Viagra Connect Pharmacy Checklist</u>?					
Yes	23 (95.8)	38 (97.4)	64 (100.0)	98 (99.0)	118 (99.2)
No	1 (4.2)	1 (2.6)	0	1 (1.0)	1 (0.8)

Source: Appendix B: Table 7.5

[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

[2] More than one response can be selected, so percentages may not sum up to 100%.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 7.6 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by age group - Completed surveys

Question	Age Group			
	22-30 years (N=68) n (%)	31-40 years (N=117) n (%)	41-60 years (N=139) n (%)	Greater than 61 years (N=21) n (%)
Question 24: Do you use the optional Viagra Connect Pharmacy Checklist at the point of supply?				
Yes	61 (89.7)	104 (88.9)	132 (95.0)	20 (95.2)
No	5 (7.4)	8 (6.8)	4 (2.9)	1 (4.8)
I do not recall	2 (2.9)	5 (4.3)	3 (2.2)	0
Question 25: From the list below please select reason(s) for NOT utilizing the optional Viagra Connect Pharmacy Checklist. Select ALL that apply:^{[1], [2]}				
I was not aware of the checklist	2 (28.6)	4 (30.8)	0	0
I used it for a while after the training but did not think I needed to continue to use it as it was no longer required as a prompt.	4 (57.1)	3 (23.1)	1 (14.3)	0
I am PGD (pharmacy group direction)-trained (or equivalent) for PDE-5i's	1 (14.3)	3 (23.1)	0	0
I am familiar with the information and I do not think I need the checklist to consult the patient	4 (57.1)	4 (30.8)	2 (28.6)	0
I use it only with new patients but not with returning patients	1 (14.3)	3 (23.1)	5 (71.4)	1 (100.0)
Other	0	1 (7.7)	0	0
N/A (Answered "Yes" to Question 24)	61	104	132	20
Question 26: How frequently do you use the optional Viagra Connect Pharmacy Checklist?				
For new requests for Viagra Connect^[1]				
All the time for all customers presenting	59 (96.7)	103 (99.0)	128 (97.0)	18 (90.0)
Only used after first trained and no longer required as a prompt	1 (1.6)	1 (1.0)	4 (3.0)	2 (10.0)
Never	1 (1.6)	0	0	0

Table 7.6 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by age group - Completed surveys

Question	Age Group			
	22-30 years (N=68) n (%)	31-40 years (N=117) n (%)	41-60 years (N=139) n (%)	Greater than 61 years (N=21) n (%)
N/A (Answered "No" or "I do not recall" to Question 24)	7	13	7	1
For patients returning for repeat supplies of Viagra Connect^[1]				
All the time for all customers presenting	15 (24.6)	39 (37.5)	47 (35.6)	10 (50.0)
Only used after first trained and no longer required as a prompt	27 (44.3)	38 (36.5)	50 (37.9)	7 (35.0)
Never	19 (31.1)	27 (26.0)	35 (26.5)	3 (15.0)
N/A (Answered "No" or "I do not recall" to Question 24)	7	13	7	1
Question 27: How frequently do you provide the patient with the tear off slip contained on the bottom of the checklist?				
If I have supplied Viagra Connect				
Always	58 (85.3)	107 (91.5)	131 (94.2)	19 (90.5)
Sometimes	6 (8.8)	8 (6.8)	7 (5.0)	2 (9.5)
Never	4 (5.9)	2 (1.7)	1 (0.7)	0
If I have denied the patient's request for Viagra Connect				
Always	39 (57.4)	74 (63.2)	91 (65.5)	15 (71.4)
Sometimes	13 (19.1)	22 (18.8)	22 (15.8)	2 (9.5)
Never	16 (23.5)	21 (17.9)	26 (18.7)	4 (19.0)
Question 32: Before today, were you aware of the <u>Viagra Connect Pharmacy Checklist</u>?				
Yes	67 (98.5)	115 (98.3)	138 (99.3)	21 (100.0)
No	1 (1.5)	2 (1.7)	1 (0.7)	0

Source: Appendix B: Table 7.6

^[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

^[2] More than one response can be selected, so percentages may not sum up to 100%.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 7.7 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by gender - Completed surveys

Question	Gender		
	Male (N=241) n (%)	Female (N=102) n (%)	Prefer not to answer (N=2) n (%)
Question 24: Do you use the optional Viagra Connect Pharmacy Checklist at the point of supply?			
Yes	220 (91.3)	95 (93.1)	2 (100.0)
No	14 (5.8)	4 (3.9)	0
I do not recall	7 (2.9)	3 (2.9)	0
Question 25: From the list below please select reason(s) for NOT utilizing the optional Viagra Connect Pharmacy Checklist. Select ALL that apply:^{[1], [2]}			
I was not aware of the checklist	3 (14.3)	3 (42.9)	0
I used it for a while after the training but did not think I needed to continue to use it as it was no longer required as a prompt.	6 (28.6)	2 (28.6)	0
I am PGD (pharmacy group direction)-trained (or equivalent) for PDE-5i's	3 (14.3)	1 (14.3)	0
I am familiar with the information and I do not think I need the checklist to consult the patient	8 (38.1)	2 (28.6)	0
I use it only with new patients but not with returning patients	8 (38.1)	2 (28.6)	0
Other	1 (4.8)	0	0
N/A (Answered "Yes" to Question 24)	220	95	2
Question 26: How frequently do you use the optional Viagra Connect Pharmacy Checklist?			
For new requests for Viagra Connect^[1]			
All the time for all customers presenting	213 (96.8)	93 (97.9)	2 (100.0)
Only used after first trained and no longer required as a prompt	6 (2.7)	2 (2.1)	0
Never	1 (0.5)	0	0
N/A (Answered "No" or "I do not recall" to Question 24)	21	7	0
For patients returning for repeat supplies of Viagra Connect^[1]			
All the time for all customers presenting	80 (36.4)	31 (32.6)	0

Table 7.7 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by gender - Completed surveys

Question	Gender		
	Male (N=241) n (%)	Female (N=102) n (%)	Prefer not to answer (N=2) n (%)
Only used after first trained and no longer required as a prompt	84 (38.2)	36 (37.9)	2 (100.0)
Never	56 (25.5)	28 (29.5)	0
N/A (Answered "No" or "I do not recall" to Question 24)	21	7	0
Question 27: How frequently do you provide the patient with the tear off slip contained on the bottom of the checklist?			
If I have supplied Viagra Connect			
Always	214 (88.8)	99 (97.1)	2 (100.0)
Sometimes	21 (8.7)	2 (2.0)	0
Never	6 (2.5)	1 (1.0)	0
If I have denied the patient's request for Viagra Connect			
Always	148 (61.4)	70 (68.6)	1 (50.0)
Sometimes	42 (17.4)	16 (15.7)	1 (50.0)
Never	51 (21.2)	16 (15.7)	0
Question 32: Before today, were you aware of the <u>Viagra Connect Pharmacy Checklist</u>?			
Yes	240 (99.6)	99 (97.1)	2 (100.0)
No	1 (0.4)	3 (2.9)	0

Source: Appendix B: Table 7.7

^[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

^[2] More than one response can be selected, so percentages may not sum up to 100%.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 7.8 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists" - Completed surveys

Question	Reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists"	
	Yes (N=334) n (%)	No (N=11) n (%)
Question 24: Do you use the optional Viagra Connect Pharmacy Checklist at the point of supply?		
Yes	308 (92.2)	9 (81.8)
No	18 (5.4)	0
I do not recall	8 (2.4)	2 (18.2)
Question 25: From the list below please select reason(s) for NOT utilizing the optional Viagra Connect Pharmacy Checklist. Select ALL that apply:^{[1],[2]}		
I was not aware of the checklist	5 (19.2)	1 (50.0)
I used it for a while after the training but did not think I needed to continue to use it as it was no longer required as a prompt.	8 (30.8)	0
I am PGD (pharmacy group direction)-trained (or equivalent) for PDE-5i's	4 (15.4)	0
I am familiar with the information and I do not think I need the checklist to consult the patient	9 (34.6)	1 (50.0)
I use it only with new patients but not with returning patients	9 (34.6)	1 (50.0)
Other	1 (3.8)	0
N/A (Answered "Yes" to Question 24)	308	9
Question 26: How frequently do you use the optional Viagra Connect Pharmacy Checklist?		
For new requests for Viagra Connect^[1]		
All the time for all customers presenting	300 (97.4)	8 (88.9)
Only used after first trained and no longer required as a prompt	7 (2.3)	1 (11.1)
Never	1 (0.3)	0
N/A (Answered "No" or "I do not recall" to Question 24)	26	2
For patients returning for repeat supplies of Viagra Connect^[1]		
All the time for all customers presenting	108 (35.1)	3 (33.3)

Table 7.8 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists" - Completed surveys

Question	Reading the "Essential Information For the Supply of Viagra Connect guide for pharmacists"	
	Yes (N=334) n (%)	No (N=11) n (%)
Only used after first trained and no longer required as a prompt	118 (38.3)	4 (44.4)
Never	82 (26.6)	2 (22.2)
N/A (Answered "No" or "I do not recall" to Question 24)	26	2
Question 27: How frequently do you provide the patient with the tear off slip contained on the bottom of the checklist?		
If I have supplied Viagra Connect		
Always	305 (91.3)	10 (90.9)
Sometimes	22 (6.6)	1 (9.1)
Never	7 (2.1)	0
If I have denied the patient's request for Viagra Connect		
Always	214 (64.1)	5 (45.5)
Sometimes	56 (16.8)	3 (27.3)
Never	64 (19.2)	3 (27.3)
Question 32: Before today, were you aware of the <u>Viagra Connect Pharmacy Checklist</u>?		
Yes	331 (99.1)	10 (90.9)
No	3 (0.9)	1 (9.1)

Source: Appendix B: Table 7.8

[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

[2] More than one response can be selected, so percentages may not sum up to 100%.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 7.9 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%)	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%)	Medication reference (BNF) (N=8) n (%)	Pharmacy Journals/ Colleagues (N=1) n (%)	Other (N=0) n (%)
Question 24: Do you use the optional Viagra Connect Pharmacy Checklist at the point of supply?					
Yes	45 (83.3)	263 (93.3)	8 (100.0)	1 (100.0)	0
No	6 (11.1)	12 (4.3)	0	0	0
I do not recall	3 (5.6)	7 (2.5)	0	0	0
Question 25: From the list below please select reason(s) for NOT utilizing the optional Viagra Connect Pharmacy Checklist. Select ALL that apply:^{[1], [2]}					
I was not aware of the checklist	1 (11.1)	5 (26.3)	0	0	0
I used it for a while after the training but did not think I needed to continue to use it as it was no longer required as a prompt.	4 (44.4)	4 (21.1)	0	0	0
I am PGD (pharmacy group direction)-trained (or equivalent) for PDE-5i's	3 (33.3)	1 (5.3)	0	0	0
I am familiar with the information and I do not think I need the checklist to consult the patient	6 (66.7)	4 (21.1)	0	0	0

Table 7.9 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%)	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%)	Medication reference (BNF) (N=8) n (%)	Pharmacy Journals/ Colleagues (N=1) n (%)	Other (N=0) n (%)
I use it only with new patients but not with returning patients	2 (22.2)	8 (42.1)	0	0	0
Other	0	1 (5.3)	0	0	0
N/A (Answered "Yes" to Question 24)	45	263	8	1	0
Question 26: How frequently do you use the optional Viagra Connect Pharmacy Checklist?					
For new requests for Viagra Connect^[1]					
All the time for all customers presenting	43 (95.6)	257 (97.7)	7 (87.5)	1 (100.0)	0
Only used after first trained and no longer required as a prompt	1 (2.2)	6 (2.3)	1 (12.5)	0	0
Never	1 (2.2)	0	0	0	0
N/A (Answered "No" or "I do not recall" to Question 24)	9	19	0	0	0
For patients returning for repeat supplies of Viagra Connect^[1]					
All the time for all customers presenting	21 (46.7)	88 (33.5)	2 (25.0)	0	0
Only used after first trained and no longer required as a prompt	16 (35.6)	103 (39.2)	2 (25.0)	1 (100.0)	0

Table 7.9 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%)	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%)	Medication reference (BNF) (N=8) n (%)	Pharmacy Journals/ Colleagues (N=1) n (%)	Other (N=0) n (%)
Never	8 (17.8)	72 (27.4)	4 (50.0)	0	0
N/A (Answered "No" or "I do not recall" to Question 24)	9	19	0	0	0
Question 27: How frequently do you provide the patient with the tear off slip contained on the bottom of the checklist?					
If I have supplied Viagra Connect					
Always	44 (81.5)	262 (92.9)	8 (100.0)	1 (100.0)	0
Sometimes	8 (14.8)	15 (5.3)	0	0	0
Never	2 (3.7)	5 (1.8)	0	0	0
If I have denied the patient's request for Viagra Connect					
Always	33 (61.1)	180 (63.8)	5 (62.5)	1 (100.0)	0
Sometimes	13 (24.1)	45 (16.0)	1 (12.5)	0	0
Never	8 (14.8)	57 (20.2)	2 (25.0)	0	0
Question 32: Before today, were you aware of the <u>Viagra Connect Pharmacy Checklist</u>?					
Yes	53 (98.1)	279 (98.9)	8 (100.0)	1 (100.0)	0

Table 7.9 Responses to all questions about the pharmacist awareness and utilization of the Viagra Connect pharmacist checklist and tear off slip at the point of dispensing by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%)	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%)	Medication reference (BNF) (N=8) n (%)	Pharmacy Journals/ Colleagues (N=1) n (%)	Other (N=0) n (%)
No	1 (1.9)	3 (1.1)	0	0	0

Source: Appendix B: Table 7.9

^[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

^[2] More than one response can be selected, so percentages may not sum up to 100%.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 8 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training - Completed surveys

Question	Pharmacists (N=345) n (%)
Question 28: Did you participate in the Viagra Connect pharmacist training?	
Yes	238 (69.0)
No	60 (17.4)
I don't recall	47 (13.6)
Question 29: What was your main reason for NOT accessing the training? Select ONE only.^[1]	
I did not know about it	35 (32.7)
I have not had time	19 (17.8)
I had difficulty accessing the materials electronically	6 (5.6)
I am PGD (pharmacy group direction)-trained (or equivalent) for phosphodiesterase type 5 inhibitors (PDE-5i's)	21 (19.6)
Other	26 (24.3)
N/A (Answered "Yes" to Question 28)	238
Question 30: What format of the Viagra Connect pharmacist training did you participate in? Select ALL that apply.^{[1], [2]}	
Online training through a website for pharmacists accredited by the Royal Pharmaceutical Society (RPS)	40 (16.8)
During a regional pharmacist meeting	53 (22.3)
Online training via the Viagra Connect Website	67 (28.2)
Online training provided by company eg, Boots own training	86 (36.1)
I received printed training materials in the mail	129 (54.2)
During a face-to-face training in my pharmacy	44 (18.5)
Other	4 (1.7)
N/A (Answered "No" or "I don't recall" to Question 28)	107

Source: Appendix B: Table 8

^[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

^[2] More than one response can be selected, so percentages may not sum up to 100%.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 8.1 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys

Question	Number of Patients Requested to Purchase Viagra Connect in the Last 6 months			
	1-10 (N=170) n (%)	11-30 (N=117) n (%)	More than 30 (N=58) n (%)	I don't know (N=0) n (%)
Question 28: Did you participate in the Viagra Connect pharmacist training?				
Yes	113 (66.5)	82 (70.1)	43 (74.1)	0
No	29 (17.1)	23 (19.7)	8 (13.8)	0
I don't recall	28 (16.5)	12 (10.3)	7 (12.1)	0
Question 29: What was your main reason for NOT accessing the training? Select ONE only.^[1]				
I did not know about it	23 (40.4)	7 (20.0)	5 (33.3)	0
I have not had time	6 (10.5)	10 (28.6)	3 (20.0)	0
I had difficulty accessing the materials electronically	3 (5.3)	3 (8.6)	0	0
I am PGD (pharmacy group direction)-trained (or equivalent) for phosphodiesterase type 5 inhibitors (PDE-5i's)	7 (12.3)	11 (31.4)	3 (20.0)	0
Other	18 (31.6)	4 (11.4)	4 (26.7)	0
N/A (Answered "Yes" to Question 28)	113	82	43	0
Question 30: What format of the Viagra Connect pharmacist training did you participate in? Select ALL that apply.^{[1], [2]}				
Online training through a website for pharmacists accredited by the Royal Pharmaceutical Society (RPS)	22 (19.5)	13 (15.9)	5 (11.6)	0
During a regional pharmacist meeting	28 (24.8)	12 (14.6)	13 (30.2)	0
Online training via the Viagra Connect Website	37 (32.7)	26 (31.7)	4 (9.3)	0
Online training provided by company eg, Boots own training	35 (31.0)	31 (37.8)	20 (46.5)	0
I received printed training materials in the mail	67 (59.3)	36 (43.9)	26 (60.5)	0

Table 8.1 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys

Question	Number of Patients Requested to Purchase Viagra Connect in the Last 6 months			
	1-10 (N=170) n (%)	11-30 (N=117) n (%)	More than 30 (N=58) n (%)	I don't know (N=0) n (%)
During a face-to-face training in my pharmacy	15 (13.3)	21 (25.6)	8 (18.6)	0
Other	2 (1.8)	2 (2.4)	0	0
N/A (Answered "No" or "I don't recall" to Question 28)	57	35	15	0

Source: Appendix B: Table 8.1

^[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

^[2] More than one response can be selected, so percentages may not sum up to 100%.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 8.2 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by place of pharmacy - Completed surveys

Question	Place of Pharmacy	
	Urban (N=255) n (%)	Rural (N=90) n (%)
Question 28: Did you participate in the Viagra Connect pharmacist training?		
Yes	170 (66.7)	68 (75.6)
No	45 (17.6)	15 (16.7)
I don't recall	40 (15.7)	7 (7.8)
Question 29: What was your main reason for NOT accessing the training? Select ONE only.^[1]		
I did not know about it	28 (32.9)	7 (31.8)
I have not had time	14 (16.5)	5 (22.7)
I had difficulty accessing the materials electronically	5 (5.9)	1 (4.5)
I am PGD (pharmacy group direction)-trained (or equivalent) for phosphodiesterase type 5 inhibitors (PDE-5i's)	18 (21.2)	3 (13.6)
Other	20 (23.5)	6 (27.3)
N/A (Answered "Yes" to Question 28)	170	68
Question 30: What format of the Viagra Connect pharmacist training did you participate in? Select ALL that apply.^{[1], [2]}		
Online training through a website for pharmacists accredited by the Royal Pharmaceutical Society (RPS)	28 (16.5)	12 (17.6)
During a regional pharmacist meeting	40 (23.5)	13 (19.1)
Online training via the Viagra Connect Website	47 (27.6)	20 (29.4)
Online training provided by company eg, Boots own training	58 (34.1)	28 (41.2)
I received printed training materials in the mail	97 (57.1)	32 (47.1)
During a face-to-face training in my pharmacy	35 (20.6)	9 (13.2)
Other	4 (2.4)	0
N/A (Answered "No" or "I don't recall" to Question 28)	85	22

Source: Appendix B: Table 8.2

^[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

^[2] More than one response can be selected, so percentages may not sum up to 100%.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 8.3 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by type of pharmacy - Completed surveys

Question	Type of Pharmacy		
	Large Multiple Pharmacy Chain (more than 100 stores) (N=157) n (%)	Small Multiple Pharmacy Chain (6 to 99 stores) (N=61) n (%)	Independent Pharmacy (1 to 5 stores) (N=127) n (%)
Question 28: Did you participate in the Viagra Connect pharmacist training?			
Yes	127 (80.9)	41 (67.2)	70 (55.1)
No	17 (10.8)	10 (16.4)	33 (26.0)
I don't recall	13 (8.3)	10 (16.4)	24 (18.9)
Question 29: What was your main reason for NOT accessing the training? Select ONE only.^[1]			
I did not know about it	11 (36.7)	5 (25.0)	19 (33.3)
I have not had time	5 (16.7)	5 (25.0)	9 (15.8)
I had difficulty accessing the materials electronically	0	2 (10.0)	4 (7.0)
I am PGD (pharmacy group direction)-trained (or equivalent) for phosphodiesterase type 5 inhibitors (PDE-5i's)	4 (13.3)	3 (15.0)	14 (24.6)
Other	10 (33.3)	5 (25.0)	11 (19.3)
N/A (Answered "Yes" to Question 28)	127	41	70
Question 30: What format of the Viagra Connect pharmacist training did you participate in? Select ALL that apply.^{[1], [2]}			
Online training through a website for pharmacists accredited by the Royal Pharmaceutical Society (RPS)	20 (15.7)	5 (12.2)	15 (21.4)
During a regional pharmacist meeting	27 (21.3)	7 (17.1)	19 (27.1)
Online training via the Viagra Connect Website	39 (30.7)	15 (36.6)	13 (18.6)
Online training provided by company eg, Boots own training	81 (63.8)	1 (2.4)	4 (5.7)
I received printed training materials in the mail	59 (46.5)	27 (65.9)	43 (61.4)
During a face-to-face training in my pharmacy	16 (12.6)	8 (19.5)	20 (28.6)

Table 8.3 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by type of pharmacy - Completed surveys

Question	Type of Pharmacy		
	Large Multiple Pharmacy Chain (more than 100 stores) (N=157) n (%)	Small Multiple Pharmacy Chain (6 to 99 stores) (N=61) n (%)	Independent Pharmacy (1 to 5 stores) (N=127) n (%)
Other	1 (0.8)	1 (2.4)	2 (2.9)
N/A (Answered "No" or "I don't recall" to Question 28)	30	20	57

Source: Appendix B: Table 8.3

^[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

^[2] More than one response can be selected, so percentages may not sum up to 100%.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 8.4 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%)	2-5 years (N=39) n (%)	6-10 years (N=64) n (%)	11-20 years (N=99) n (%)	Greater than 20 years (N=119) n (%)
Question 28: Did you participate in the Viagra Connect pharmacist training?					
Yes	16 (66.7)	26 (66.7)	37 (57.8)	75 (75.8)	84 (70.6)
No	6 (25.0)	7 (17.9)	15 (23.4)	11 (11.1)	21 (17.6)
I don't recall	2 (8.3)	6 (15.4)	12 (18.8)	13 (13.1)	14 (11.8)
Question 29: What was your main reason for NOT accessing the training? Select ONE only.^[1]					
I did not know about it	3 (37.5)	6 (46.2)	13 (48.1)	7 (29.2)	6 (17.1)
I have not had time	1 (12.5)	2 (15.4)	5 (18.5)	3 (12.5)	8 (22.9)
I had difficulty accessing the materials electronically	0	0	0	0	6 (17.1)
I am PGD (pharmacy group direction)-trained (or equivalent) for phosphodiesterase type 5 inhibitors (PDE-5i's)	0	2 (15.4)	4 (14.8)	5 (20.8)	10 (28.6)
Other	4 (50.0)	3 (23.1)	5 (18.5)	9 (37.5)	5 (14.3)
N/A (Answered "Yes" to Question 28)	16	26	37	75	84
Question 30: What format of the Viagra Connect pharmacist training did you participate in? Select ALL that apply.^{[1], [2]}					

Table 8.4 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%)	2-5 years (N=39) n (%)	6-10 years (N=64) n (%)	11-20 years (N=99) n (%)	Greater than 20 years (N=119) n (%)
Online training through a website for pharmacists accredited by the Royal Pharmaceutical Society (RPS)	0	6 (23.1)	6 (16.2)	10 (13.3)	18 (21.4)
During a regional pharmacist meeting	0	4 (15.4)	8 (21.6)	21 (28.0)	20 (23.8)
Online training via the Viagra Connect Website	1 (6.3)	9 (34.6)	11 (29.7)	19 (25.3)	27 (32.1)
Online training provided by company eg, Boots own training	11 (68.8)	16 (61.5)	14 (37.8)	23 (30.7)	22 (26.2)
I received printed training materials in the mail	6 (37.5)	11 (42.3)	24 (64.9)	35 (46.7)	53 (63.1)
During a face-to-face training in my pharmacy	4 (25.0)	8 (30.8)	7 (18.9)	9 (12.0)	16 (19.0)
Other	1 (6.3)	0	1 (2.7)	1 (1.3)	1 (1.2)
N/A (Answered "No" or "I don't recall" to Question 28)	8	13	27	24	35

Source: Appendix B: Table 8.4

[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

[2] More than one response can be selected, so percentages may not sum up to 100%.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 8.5 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by age group - Completed surveys

Question	Age Group			
	22-30 years (N=68) n (%)	31-40 years (N=117) n (%)	41-60 years (N=139) n (%)	Greater than 61 years (N=21) n (%)
Question 28: Did you participate in the Viagra Connect pharmacist training?				
Yes	43 (63.2)	81 (69.2)	101 (72.7)	13 (61.9)
No	14 (20.6)	20 (17.1)	21 (15.1)	5 (23.8)
I don't recall	11 (16.2)	16 (13.7)	17 (12.2)	3 (14.3)
Question 29: What was your main reason for NOT accessing the training? Select ONE only.^[1]				
I did not know about it	11 (44.0)	17 (47.2)	6 (15.8)	1 (12.5)
I have not had time	5 (20.0)	4 (11.1)	9 (23.7)	1 (12.5)
I had difficulty accessing the materials electronically	0	0	3 (7.9)	3 (37.5)
I am PGD (pharmacy group direction)-trained (or equivalent) for phosphodiesterase type 5 inhibitors (PDE-5i's)	2 (8.0)	5 (13.9)	13 (34.2)	1 (12.5)
Other	7 (28.0)	10 (27.8)	7 (18.4)	2 (25.0)
N/A (Answered "Yes" to Question 28)	43	81	101	13
Question 30: What format of the Viagra Connect pharmacist training did you participate in? Select ALL that apply.^{[1], [2]}				
Online training through a website for pharmacists accredited by the Royal Pharmaceutical Society (RPS)	6 (14.0)	10 (12.3)	19 (18.8)	5 (38.5)
During a regional pharmacist meeting	5 (11.6)	22 (27.2)	21 (20.8)	5 (38.5)
Online training via the Viagra Connect Website	13 (30.2)	22 (27.2)	28 (27.7)	4 (30.8)
Online training provided by company eg, Boots own training	28 (65.1)	27 (33.3)	30 (29.7)	1 (7.7)
I received printed training materials in the mail	18 (41.9)	41 (50.6)	63 (62.4)	7 (53.8)

Table 8.5 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by age group - Completed surveys

Question	Age Group			
	22-30 years (N=68) n (%)	31-40 years (N=117) n (%)	41-60 years (N=139) n (%)	Greater than 61 years (N=21) n (%)
During a face-to-face training in my pharmacy	11 (25.6)	11 (13.6)	18 (17.8)	4 (30.8)
Other	1 (2.3)	1 (1.2)	1 (1.0)	1 (7.7)
N/A (Answered "No" or "I don't recall" to Question 28)	25	36	38	8

Source: Appendix B: Table 8.5

^[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

^[2] More than one response can be selected, so percentages may not sum up to 100%.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 8.6 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by gender - Completed surveys

Question	Gender		
	Male (N=241) n (%)	Female (N=102) n (%)	Prefer not to answer (N=2) n (%)
Question 28: Did you participate in the Viagra Connect pharmacist training?			
Yes	161 (66.8)	75 (73.5)	2 (100.0)
No	47 (19.5)	13 (12.7)	0
I don't recall	33 (13.7)	14 (13.7)	0
Question 29: What was your main reason for NOT accessing the training? Select ONE only.^[1]			
I did not know about it	29 (36.3)	6 (22.2)	0
I have not had time	15 (18.8)	4 (14.8)	0
I had difficulty accessing the materials electronically	5 (6.3)	1 (3.7)	0
I am PGD (pharmacy group direction)-trained (or equivalent) for phosphodiesterase type 5 inhibitors (PDE-5i's)	16 (20.0)	5 (18.5)	0
Other	15 (18.8)	11 (40.7)	0
N/A (Answered "Yes" to Question 28)	161	75	2
Question 30: What format of the Viagra Connect pharmacist training did you participate in? Select ALL that apply.^{[1], [2]}			
Online training through a website for pharmacists accredited by the Royal Pharmaceutical Society (RPS)	33 (20.5)	7 (9.3)	0
During a regional pharmacist meeting	38 (23.6)	15 (20.0)	0
Online training via the Viagra Connect Website	47 (29.2)	20 (26.7)	0
Online training provided by company eg, Boots own training	52 (32.3)	32 (42.7)	2 (100.0)
I received printed training materials in the mail	85 (52.8)	43 (57.3)	1 (50.0)
During a face-to-face training in my pharmacy	30 (18.6)	14 (18.7)	0
Other	3 (1.9)	1 (1.3)	0

Table 8.6 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by gender - Completed surveys

Question	Gender		
	Male (N=241) n (%)	Female (N=102) n (%)	Prefer not to answer (N=2) n (%)
N/A (Answered "No" or "I don't recall" to Question 28)	80	27	0

Source: Appendix B: Table 8.6

^[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

^[2] More than one response can be selected, so percentages may not sum up to 100%.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 8.7 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%)	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%)	Medication reference (BNF) (N=8) n (%)	Pharmacy Journals/ Colleagues (N=1) n (%)	Other (N=0) n (%)
Question 28: Did you participate in the Viagra Connect pharmacist training?					
Yes	37 (68.5)	194 (68.8)	6 (75.0)	1 (100.0)	0
No	13 (24.1)	46 (16.3)	1 (12.5)	0	0
I don't recall	4 (7.4)	42 (14.9)	1 (12.5)	0	0
Question 29: What was your main reason for NOT accessing the training? Select ONE only.^[1]					
I did not know about it	4 (23.5)	30 (34.1)	1 (50.0)	0	0
I have not had time	3 (17.6)	16 (18.2)	0	0	0
I had difficulty accessing the materials electronically	1 (5.9)	5 (5.7)	0	0	0
I am PGD (pharmacy group direction)-trained (or equivalent) for phosphodiesterase type 5 inhibitors (PDE-5i's)	5 (29.4)	16 (18.2)	0	0	0
Other	4 (23.5)	21 (23.9)	1 (50.0)	0	0
N/A (Answered "Yes" to Question 28)	37	194	6	1	0
Question 30: What format of the Viagra Connect pharmacist training did you participate in? Select ALL that apply.^{[1],[2]}					

Table 8.7 Responses to all questions about pharmacists participating in Viagra Connect pharmacist training by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%)	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%)	Medication reference (BNF) (N=8) n (%)	Pharmacy Journals/ Colleagues (N=1) n (%)	Other (N=0) n (%)
Online training through a website for pharmacists accredited by the Royal Pharmaceutical Society (RPS)	7 (18.9)	33 (17.0)	0	0	0
During a regional pharmacist meeting	12 (32.4)	39 (20.1)	2 (33.3)	0	0
Online training via the Viagra Connect Website	14 (37.8)	52 (26.8)	1 (16.7)	0	0
Online training provided by company eg, Boots own training	13 (35.1)	71 (36.6)	2 (33.3)	0	0
I received printed training materials in the mail	18 (48.6)	108 (55.7)	2 (33.3)	1 (100.0)	0
During a face-to-face training in my pharmacy	6 (16.2)	35 (18.0)	3 (50.0)	0	0
Other	0	4 (2.1)	0	0	0
N/A (Answered "No" or "I don't recall" to Question 28)	17	88	2	0	0

Source: Appendix B: Table 8.7

^[1] Percentages are calculated based on the sample presented with this question because of skip logic in the survey.

^[2] More than one response can be selected, so percentages may not sum up to 100%.

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 9 Responses to all questions about pharmacist utilization/reading of the "Essential Information For The Supply of Viagra Connect" guide for pharmacists - Completed surveys

Question	Pharmacists (N=345) n (%)
Question 31: Did you read the “<u>Essential Information For The Supply of Viagra Connect</u>” guide for pharmacists?	
Yes	334 (96.8)
No	11 (3.2)

Source: Appendix B: Table 9

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 9.1 Responses to all questions about pharmacist utilization/reading of the "Essential Information For The Supply of Viagra Connect" guide for pharmacists by participation in the Viagra Connect pharmacist training - Completed surveys

Question	Participation in the Viagra Connect Pharmacist Training		
	Yes (N=238) n (%)	No (N=60) n (%)	Don't recall (N=47) n (%)
Question 31: Did you read the "<u>Essential Information For The Supply of Viagra Connect</u>" guide for pharmacists?			
Yes	232 (97.5)	58 (96.7)	44 (93.6)
No	6 (2.5)	2 (3.3)	3 (6.4)

Source: Appendix B: Table 9.1

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 9.2 Responses to all questions about pharmacist utilization/reading of the "Essential Information For The Supply of Viagra Connect" guide for pharmacists by number of patients requested to purchase Viagra Connect in the last 6 months - Completed surveys

Question	Number of Patients Requested to Purchase Viagra Connect in the Last 6 months			
	1-10 (N=170) n (%)	11-30 (N=117) n (%)	More than 30 (N=58) n (%)	I don't know (N=0) n (%)
Question 31: Did you read the "Essential Information For The Supply of Viagra Connect" guide for pharmacists?				
Yes	167 (98.2)	112 (95.7)	55 (94.8)	0
No	3 (1.8)	5 (4.3)	3 (5.2)	0

Source: Appendix B: Table 9.2

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 9.3 Responses to all questions about pharmacist utilization/reading of the "Essential Information For The Supply of Viagra Connect" guide for pharmacists by place of pharmacy - Completed surveys

Question	Place of Pharmacy	
	Urban (N=255) n (%)	Rural (N=90) n (%)
Question 31: Did you read the "<u>Essential Information For The Supply of Viagra Connect</u>" guide for pharmacists?		
Yes	245 (96.1)	89 (98.9)
No	10 (3.9)	1 (1.1)

Source: Appendix B: Table 9.3

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 9.4 Responses to all questions about pharmacist utilization/reading of the "Essential Information For The Supply of Viagra Connect" guide for pharmacists by type of pharmacy - Completed surveys

Question	Type of Pharmacy		
	Large Multiple Pharmacy Chain (more than 100 stores) (N=157) n (%)	Small Multiple Pharmacy Chain (6 to 99 stores) (N=61) n (%)	Independent Pharmacy (1 to 5 stores) (N=127) n (%)
Question 31: Did you read the "Essential Information For The Supply of Viagra Connect" guide for pharmacists?			
Yes	153 (97.5)	60 (98.4)	121 (95.3)
No	4 (2.5)	1 (1.6)	6 (4.7)

Source: Appendix B: Table 9.4

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 9.5 Responses to all questions about pharmacist utilization/reading of the "Essential Information For The Supply of Viagra Connect" guide for pharmacists by time dispensing medications as pharmacist - Completed surveys

Question	Time Dispensing Medications as Pharmacist				
	Less than 2 years (N=24) n (%)	2-5 years (N=39) n (%)	6-10 years (N=64) n (%)	11-20 years (N=99) n (%)	Greater than 20 years (N=119) n (%)
Question 31: Did you read the “<u>Essential Information For The Supply of Viagra Connect</u>” guide for pharmacists?					
Yes	24 (100.0)	37 (94.9)	62 (96.9)	96 (97.0)	115 (96.6)
No	0	2 (5.1)	2 (3.1)	3 (3.0)	4 (3.4)

Source: Appendix B: Table 9.5

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 9.6 Responses to all questions about pharmacist utilization/reading of the "Essential Information For The Supply of Viagra Connect" guide for pharmacists by age group - Completed surveys

Question	Age Group			
	22-30 years (N=68) n (%)	31-40 years (N=117) n (%)	41-60 years (N=139) n (%)	Greater than 61 years (N=21) n (%)
Question 31: Did you read the "Essential Information For The Supply of Viagra Connect" guide for pharmacists?				
Yes	66 (97.1)	115 (98.3)	132 (95.0)	21 (100.0)
No	2 (2.9)	2 (1.7)	7 (5.0)	0

Source: Appendix B: Table 9.6

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 9.7 Responses to all questions about pharmacist utilization/reading of the "Essential Information For The Supply of Viagra Connect" guide for pharmacists by gender - Completed surveys

Question	Gender		
	Male (N=241) n (%)	Female (N=102) n (%)	Prefer not to answer (N=2) n (%)
Question 31: Did you read the "<u>Essential Information For The Supply of Viagra Connect</u>" guide for pharmacists?			
Yes	233 (96.7)	99 (97.1)	2 (100.0)
No	8 (3.3)	3 (2.9)	0

Source: Appendix B: Table 9.7

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 9.8 Responses to all questions about pharmacist utilization/reading of the "Essential Information For The Supply of Viagra Connect" guide for pharmacists by main sources referenced about safe dispensing practices of Viagra Connect - Completed surveys

Question	Main Sources Referenced about Safe Dispensing practices of Viagra Connect				
	Viagra Connect SmPC/Box Label (N=54) n (%)	Viagra Connect Training/aRMM tools/Pfizer sales professional (N=282) n (%)	Medication reference (BNF) (N=8) n (%)	Pharmacy Journals/ Colleagues (N=1) n (%)	Other (N=0) n (%)
Question 31: Did you read the “Essential Information For The Supply of Viagra Connect” guide for pharmacists?					
Yes	53 (98.1)	274 (97.2)	6 (75.0)	1 (100.0)	0
No	1 (1.9)	8 (2.8)	2 (25.0)	0	0

Source: Appendix B: Table 9.8

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Table 10 Responses to all questions about the pharmacist attitude toward Viagra Connect pharmacist training and patient counselling - Completed surveys

Question	Pharmacists (N=345) n (%)
Question 33: Did you find the Viagra Connect pharmacist training/reference tools to be of use in your practice? Please select only ONE response for each tool listed below:	
Viagra Connect Training Guide to Pharmacists	
Not useful	2 (0.6)
Somewhat useful	10 (2.9)
No opinion/not sure	13 (3.8)
Very useful	106 (30.7)
Extremely useful	205 (59.4)
Not applicable	9 (2.6)
Viagra Connect Pharmacist Checklist	
Not useful	2 (0.6)
Somewhat useful	5 (1.4)
No opinion/not sure	0
Very useful	70 (20.3)
Extremely useful	264 (76.5)
Not applicable	4 (1.2)
Tear-off slip at the bottom of the pharmacist checklist	
Not useful	8 (2.3)
Somewhat useful	34 (9.9)
No opinion/not sure	13 (3.8)
Very useful	110 (31.9)
Extremely useful	176 (51.0)
Not applicable	4 (1.2)

Source: Appendix B: Table 10

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Listing 1 Last question answered and time spend on the survey for eligible respondents who did not complete the survey

Last answered question	Time spent on the survey (minutes)
Question 9	152
Question 12	4
Question 12	1
Question 12	8
Question 12	2
Question 14	4
Question 15	2
Question 15	3
Question 18	4
Question 20	6
Question 20	14
Question 21	26

Source: Appendix B: Listing 1

090177e19187789e\Final\Final On: 23-Jul-2019 07:33 (GMT)

Document Approval Record

Document Name:	Viagra Connect Pharmacist KAB-Report Body
Document Title:	A1481334

Signed By:	Date(GMT)	Signing Capacity
Campbell, Ulka	24-Jul-2019 18:12:59	Final Approval
De Bernardi, Barbara	24-Jul-2019 18:42:55	EUQPPV Approval